Cartilage response to in vitro models of injury in combination with growth factor and antioxidant treatments by Wheeler, Cameron, 1978-
CARTILAGE RESPONSE TO IN VITRO MODELS OF INJURY IN COMBINATION WITH
GROWTH FACTOR AND ANTIOXIDANT TREATMENTS
Cameron A Wheeler
S.B. Mechanical Engineering, MIT, 2003
S.M. Biological Engineering, MIT, 2007
Submitted to the Department of Biological Engineering
in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy in Biological Engineering
at the
Massachusetts Institute of Technology
December 2007
© 2007 Massachusetts Institute of Technology
All Right Reserved
The author hereby grants MIT permission to reproduce and to distribute publicly paper and
electronic copies of this thesis document in whole or in part.
Signature of Author ,_,
/ -- /1 " ~( - -  Cameron A Wheeler
/?/7 Department of Biological Engineering
Certified by
~4 an J/Grodzinsky, Thesis Advisor
Professor of Mechanica, Electric, and Biological Engineering
Accepted by ,
Ram Sasisekharan, Graduate Program Co-Chairman
Professor of Biological Engineering
MAS- HUET. t4T.T
MASSACHUS-TTS IN, 1011
OF TEOHNOLOGY
7RCHNES
V I
JAN L2 U•
LIBRARIES
Thesis Committee:
Alan J. Grodzinsky .................Professor of Biological, Electrical, and Mechanical Engineering
Massachusetts Institute of Technology
Roger D. Kamm .................................. Professor of Biological and Mechanical Engineering
Massachusetts Institute of Technology
Christopher Evans ................... .................. Professor of Orthopedic Surgery
Brigham and Women's Hospital, Harvard Medical School
Abstract
Approximately one in five Americans is affected by arthritis, making it one of the most
prevalent diseases and the leading cause of disability in the United States. Post-traumatic
arthritis occurs after joint injury (e.g., ACL rupture or intraarticular fracture) and makes up a
substantial proportion of the population with arthritis. In previous clinical studies, patients
suffering from a traumatic joint injury have shown an increased risk in osteoarthritis (OA),
independent of surgical intervention to stabilize the joint. Thus, the early events post-injury have
an important effect on tissue within the joint in the long term. To understand the processes
involved in the onset of OA and factors leading to OA post-traumatic injury, in vitro models
have been developed to isolate components of the complex processes occurring in vivo. While in
vitro models do not mimic true physiologic conditions in vivo, by isolating the effects of
mechanical compression, cytokine treatment, and cartilage co-cultured with adjacent tissue, in
vitro models can give insight into key biological and mechanical pathways occurring in vivo.
This study focuses on changes in cartilage gene and protein expression and associated
cartilage matrix degradation in response to static or injurious compression of the tissue in the
presence or absence of cytokines including TNF-a and IL-6. In addition, normal or injuriously
compressed cartilage explants were co-cultured with injured (excised) joint capsule tissue,
another in vitro model of post-traumatic cellular behavior. Both young bovine cartilage and
human cartilage from a wide range of ages were used. The growth factors insulin-like growth
factor-1 (IGF-1) and Osteogenic protein-i (OP-1), as well as the antioxidant, superoxide
dismutase mimetic (SODm), were tested to examine if they had the capability to abrogate the
negative effects of these injury models. Taking a systems approach, the effects of these stimuli
on expression of over 48 genes (in cartilage as well as joint capsule) were quantified, along with
measures of chondrocyte viability, biosynthesis, protein expression, and GAG loss.
Chondrocyte gene expression was differentially regulated by 50% static compression or
IGF- 1 treatment or the combination of compression and IGF- 1. Results showed that IGF- 1
stimulated aggrecan biosynthesis in a transcriptionally regulated manner, whereas compression
inhibited aggrecan synthesis in a manner not regulated by transcriptional activity. The injury
plus co-culture model was examined in detail, and OP-1 and IGF-1 were unable to rescue
changes in transcriptional expressions due to injury. However, these growth factors were able to
rescue cells from apoptosis, and slightly increase biosynthesis rates. Human tissue was used to
further validate the model of mechanical injury (INJ) combined with co-culture (Co).
Immunohistochemical analysis of human cartilage explants after INJ+Co treatment revealed
changes in versican and aggrecan protein expression, as well as changes in surface tissue
morphology, that mimicked certain changes observed in human osteochondral plugs taken from
patients at the time of notchplasty surgery (post ACL reconstruction) at 1, 3, or 57 months post-
ACL rupture.
The oxidative stress involved in a cytokine plus injury model showed that SODm had no
ability to selectively diminish protease transcriptional activity. Cartilage treated with this
antioxidant showed significant increases in GAG loss to the medium, but diminished levels of
chondrocyte apoptosis. Taken together, this work supports further investigation of the
mechanisms of action of OP-1, IGF-1, and SODm in order to elucidate their possible therapeutic
value, and demonstrates the usefulness of these complementary in vitro models of cartilage
injury.
Acknowledgements
I want to thank my advisor, Alan Grodzinsky for all the help he has given me in editing
and guiding my research. His open personality and approach to research has given me an
opportunity to explore my ideas and concentrate on my scientific interests. My thesis committee,
Roger and Chris, have given me useful suggestions as well as important question that have
shaped my work. I am extremely grateful for the open environment which exists in Al's group
and the interactions I've been able to have with amazing members of the lab. In particular, Jon
Fitzgerald, Mike DiMicco, and Jenny Lee guided my thinking and training, and were always
available for all my questions. They gave me directly or indirectly a framework for thinking
about research which enabled me to develop my own ideas and understand the tools and
techniques to explore those ideas. Jon particularly was always patient in the teaching process
which was invaluable. I also would like to thank the current members of the group, Sangwon,
Bobae, Rachel, Diana, Shuodan, Paul, Detlef, Eric, Yi, and Sui-Yi for their contribution to
wonderful working environment. A special thank you is also in order for the constants in the lab
equation, Han-Hwa, Linda, and Elliot. All I have relied on to accomplish things I could not do
myself, and am grateful for their approachability. Lastly, I want to thank my family, who have
always supported me these past four years, and who are my biggest fans. I cherish those
relationships and am grateful that they will always be with me. The past four years have been an
amazing time for my own development both personally and scientifically, and I am humbled and
grateful for those opportunities.
Table of Contents
CHAPTER 1 MECHANOBIOLOGY: INTRODUCTION, BACKGROUND, AND
SIG NIFICAN CE ............................................. ....................................................................... 14
1.1 PURPOSE OF THE CHAPTER .......... ....................................................................... 15
1.2 INTRODUCTION ............................... .. ................................................. 16
1.3 SYSTEMS FOR STUDYING CHONDROCYTE MECHANOTRANSDUCTION .............................. 16
1.4 CHONDROCYTE BIOSYNTHESIS AND GENE EXPRESSION ............................................... .. 17
1.5 U PSTREAM SIGNALING ................................................................................................. 19
1.6 PRO-INFLAMMATORY PATHWAYS IN NORMAL AND INJURIOUS COMPRESSION .................. 22
1.7 SYSTEMS BIOLOGY APPROACHES ................................ ............................ 25
1.8 C O NCLU SIO N ........................................................... .... ............................................... 27
1.9 REFERENCES AND RECOMMENDED READING ......... .............................. 28
CHAPTER 2 CURRENT IN VITRO INJURY MODELS ................................................ 35
2 .1 IN TR O D U C TIO N ................................................................... ................................................ 36
2.2 M ODELS OF M ECHANICAL INJURY.............................................................................. 37
2.3 CYTOKINE TREATMENT MODELS OF INJURY ........................................ .......... 39
2.4 SYNOVIUM-JOINT CAPSULE CO-CULTURE MODELS OF INJURY ...................................... 40
2.5 COMBINATION MODELS OF INJURY .............................................................. 41
2.6 CONCLUSION . .............................................. ....... ........................ 43
2.7 REFERENCES ..................... ................... ......................... 44
CHAPTER 3 TRANSCRIPTIONAL EFFECTS OF COMBINED MECHANICAL
COMPRESSION AND IGF-1 STIMULATION ON BOVINE CARTILAGE EXPLANTS
....................................................... 49
3.1 A BSTR ACT ............................... ................................................... ...... ..................... 50
3.2 INTRO DU CTIO N ............................ ................... ............. ................... ........................... 52
3 .3 M ETH O D S ............................................................................................................................ 5 5
3.4 RESULTS .................. ...................... ... ................................................... 59
3 .5 D ISC U SSIO N ................................ .. .. ..................................... ....... ............................. 6 7
3.6 CONCLUSION. ............................................................................ ........ 74
3.7 R EFEREN CES ............................ ...................................... .......................... 76
3.8 A PPEN D IX ..................... ................. ...................................................................... 79
Appendix 3.8.1- Gene Expression relative to Control .............................................. 79
Appendix 3.8.2- The Effects of IGF-1 on Gene Expression......................................... 81
CHAPTER 4 INFLUENCE OF OP-1 AND IGF-1 ON CARTILAGE SUBJECTED TO
COMBINED MECHANICAL INJURY AND CO-CULTURE WITH JOINT CAPSULE 83
4.1 INTRODUCTION ............................................................................... ............................ 84
4.2 M ATERIALS AND M ETHODS. .................................... ......... ..... .... ......................... ....... 87
4.3 RESULTS .................... .  ... ... ...... . ..... .......... ... ............................ 93
4.4 DISCUSSION .......... ...................... .......... . ............ .................................... 119
4.5 CONCLUSION ...................................... ........ ..... . ....................... 127
4.6 R EFERENCES ..................................................................................................................... 129
4.7 A PPENDIX OF FIGURES .......................................... ...................................................... 136
4. 7.1 Short Term Gene Expression ...................................... 136
4.7.2 Effects of GF Treatment- Short Term Gene Expression ........................................ 141
4.7.3 Joint Capsule Gene Expression ........................................................... .................. 147
4.7.4 Longer Term Gene Expression ..................................... 151
4.7.5 Effects of GF Treatment- Longer Term Gene Expression ...................................... 157
CHAPTER 5 HUMAN TISSUE RESPONSE TO MECHANICAL INJURY AND CO-
CULTURE WITH EXCISED JOINT CAPSULE .............................................................. 163
5.1 INTRO D U CTIO N .................................................................................................................. 164
5.2 MATERIALS AND METHODS.................................. 165
5 .3 R ESU LT S ............................................................................................................................ 17 1
5.4 D ISCUSSION ...................................... 177
5.5 CONCLUSION ................................................. 181
5.6 R EFERENCES ..................................................................................................................... 182
5.7 A PPEND IX ................. ........................................................................................... 185
5.7.1 Biosynthesis Data- Radiolabel incorporation ..................................... 185
5.7.2 GAG Loss to the medium ........................................ 188
CHAPTER 6 THE EFFECTS OF SODM ON CARTILAGE SUBJECTED TO
CYTOKINE TREATMENT COMBINED WITH MECHANICAL INJURY ................ 190
6 .1 IN TRO D U CTIO N .................................................................................................................. 19 1
6.2 MATERIALS AND METHODS.................................. 193
6.3 RESULTS ........................................................................................................ ....... 199
6.4 DISCUSSION........................................................................ 206
6.5 CONCLUSION ................................................ 210
6.6 R EFERENCES ..................................................................................................................... 2 11
6 .7 A P PEND IX ......................................................................................................................... 2 15
Appendix 6.7.1 SODm Dose Response ..................................... 215
Appendix 6.7.2 H 202 Positive Control............................................................................... 217
Appendix 6.7.3 Gene Expression 35 Cartilage Relevant Genes............................... 219
Appendix 6.7.4 The Effects of SODm on Gene Expression.......................... 223
CHAPTER 7 SUMMARY AND CONCLUSION ..................................... 228
APPENDIX A: EXPERIMENTAL PROTOCOLS ......... ......................... 233
A. 1 RNA EXTRACTION PROTOCOL- BOVINE ........................................ 233
A.2 RNA EXTRACTION PROTOCOL- HUMAN TISSUE ........................................................... 236
A.3 EXTRACTED RNA MEASUREMENTS ........................................ 239
A.4 REVERSE TRANSCRIPTION OF RNA TO CDNA ..................................... 240
A.5 STANDARD CURVE MEASUREMENTS FOR QPCR PRIMERS ..................................... 241
A.6 FINDING/DESIGNING PRIMERS FOR QPCR ....................................... 242
A .7 PRIM ER INVENTORY .......................................... ......................................................... 243
A.8 BOVINE DNA STANDARD AND ASSAY USING HOECHST 33258 DYE............................. 244
A.9 GAG STANDARD AND THE GAG ASSAY WITH MAXY MACHINE .................................. 246
A. 10 HUMAN DNA STANDARD AND ASSAY USING CYQUANT DYE .................................. 248
A. 11 RADIOLABEL SCINTILLATION COUNTING USING MICROBETA PLATE READER ............. 250
APPENDIX B: NITRIC OXIDE PROJECT........... ......................................... 252
INTRODUCTION ......................... ... ........... .... ........ ..................... 254
M E T H O D S ....................................... ....................................................................................... 2 5 6
R E SU L T S ........................................................... ............ .. .. .. ........... .................................... 2 6 0
R EFERENCES ....................... ...................... .. ...................... .......................... 269
List of Figures
Figure 1.1: Schematic of physical forces and flows occurring during mechanical loading of
cartilage in vivo, that can be stimulated in vitro by means of (a) static compression, (b) dynamic
compression, and (c) dynamic tissue shear .................................................. 18
Figure 1.2 : Loading of cartilage explants (a), or direct mechanical stimulation of cells (b) can
produce mechanical stimuli that may be sensed by the cell and its pericellular microenvironment
(b). These mechanical stimuli may alter the rate of synthesis as well as the molecular structure of
ECM molecules such as aggrecan (c) which, in turn, could ultimately affect tissue-level
biomechanical properties in a feedback fashion (a). New cell-level and molecular-level
measurement techniques, such as those based on atomic force microscopy, are being used to
quantify the molecular mechanical properties of ECM macromolecules (d) as well as cellular
m echanical properties (b)..................................... . . ................. ............. ........................ 25
Figure 3.1. A schematic of the four conditions measured. 5 plugs were punched for each time
point and matched for time. IGF-1 treatment and static compression were applied at time 0, and
plugs were flash frozen at 2, 8, 24, 32, and 48 hours............................ .... ................ 56
Figure 3.2. Gene expression of proteinases, growth factors, and ECM molecules. 8 cartilage
disks were pooled for each time point for each experiment. All genes were normalized to 18s
and plotted relative to 0% compression 0 IGF-1. Significance was measured by the Wilcoxon
sign ranked test compared to 0% compression 0 IGF-1 (* p-value <0.07). Mean ± SE (n=4) ... 60
Figure 3.3. Effects of IGF-1. Gene expression was plotted normalized to like loading condition
in order to elucidate the effects of IGF-1 under compression or non-compression. Aggrecan (A)
and Link (C) respond to IGF-1 in a compression dependent manner, while TIMP-3 (D) and
Collagen II (F) respond to IGF-1 in a compression independent manner. Significance was
measured by the Wilcoxon sign ranked test compared to like compression 0 IGF-1. (* p-value
<0.07). M ean + SE (n=4) ..................................................................................................... 63
Figure 3.4 Standardized gene expression visualized in principle component space. Principle
component 1, 2, and 3 represent 80% of the variance in the data. Genes were allocated to one of
five distinct groups by way of k-means clustering. Large solid black circles denote the centroid
of the corresponding group. .................................................. ...................... ............................ 65
Figure 3.5 Five expression profiles represent the combination of 0% compression 300 ng/ml of
IGF-1, 50% compression 0 ng/ml of IGF-1, and 50% compression 300 ng/ml of IGF-1. Centroid
profiles were calculated through the average projection coordinates of genes in each group, and
transformed from principle component space through use of the calculated principle components.
Mean ± SE (n varies based on group component number) ..................... ....... 67
Figure 3.6 Aggrecan Protein Synthesis compared to Aggrecan Gene Expression. (A) Aggrecan
protein synthesis as measured by 35S radiolabel incorporation normalized to 0% compression 0
IGF-1 adapted from Bonassar et al [5]. Mean plotted. (B) Aggrecan gene expression
normalized to 18s and plotted relative to 0% compression 0 IGF-1. Significance was measured
by the Wilcoxon sign ranked test compared to like compression 0 IGF-1. (* p-value <0.07) .... 73
Figure 4.1 Aggrecan and Collagen type IX short-term gene expression. Data was plotted
relative to FS conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean ± SEM. Time points: m 2 Hrs, m 8 Hrs, 0 24 Hrs, O 48 Hrs, !f
72 Hrs ..................................................................... 93
Figure 4.2 MMP-9 and TIMP-1 short-term gene expression. Data was plotted relative to FS
conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean ± SEM. Time points: m 2 Hrs, U 8 Hrs, E 24 Hrs, OI 48 Hrs, Ei
7 2 H rs ............................................................................................................................................ 9 5
Figure 4.3 ADAMTS-1 and iNOS short-term gene expression. Data was plotted relative to FS
conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean ± SEM. Time points: m 2 Hrs, m 8 Hrs, D 24 Hrs, O 48 Hrs, 1
72 H rs ............................................................................................................................  9 6
Figure 4.4 LIF and Caspase-3 short-term gene expression. Data was plotted relative to FS
conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean ± SEM. Time points: m 2 Hrs, 1 8 Hrs, E 24 Hrs, ElO 48 Hrs, I
72 H rs .................................................. 99
Figure 4.5 Standardized gene expression visualized in principle component space. Principle
components 1, 2, and 3 represent 80% of the variance in the data. Genes were allocated to one of
five distinct groups by way of k-means clustering. Large solid black circles denote the centroid
of the corresponding group. ........................................................................................................ 100
Figure 4.6 Five expression profiles represent the combination of conditions and treatments.
Centroid profiles were calculated through the average projection coordinates of genes in each
group and transformed from principle component space through use of the calculated principle
components. Mean ± SEM (n varies based on group component number). Time points: m 2 Hrs,
m 8 Hrs, E 24 Hrs, O 48 Hrs, E3 72 Hrs ...................................... 102
Figure 4.7 Basal levels of gene expression for joint capsule and cartilage relative to the least
abundant gene. Proteinases are colored in red; ECM molecules are colored in blue. ............. 103
Figure 4.8 Aggrecan and Fibronectin longer-term gene expression. Data was plotted relative to
FS conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean ± SEM. Time points: I Day 2, U Day 4, 0 Day 8, O Day 16
..................................................................................................................................................... 10 5
Figure 4.9 MMP-3 and MMP-9 longer-term gene expression. Data was plotted relative to FS
conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean ± SEM. Time points: I Day 2, N Day 4, 0 Day 8, OE Day 16
.................................................................................................................................................... 10 7
Figure 4.10 TIMP-1 and c-Fos longer-term gene expression. Data was plotted relative to FS
conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean ± SEM. Time points: U Day 2, M Day 4, O Day 8, Ol Day 16
.................................  ....................................................................................... 10 9
Figure 4.11 Standardized gene expression visualized in principle component space. Principle
components 1, 2, and 3 represent 70% of the variance in the data. Genes were allocated to one of
five distinct groups by way of k-means clustering. Large solid black circles denote the centroid
of the corresponding group ............................................................ 113
Figure 4.12 Five expression profiles represent the combination of conditions and treatments.
Centroid profiles were calculated through the average projection coordinates of genes in each
group and transformed from principle component space through use of the calculated principle
components. Mean ± SEM (n varies based on group component number). Time points: U Day
2, 0 Day 4, O Day 8, O Day 16..... ...................................... 114
Figure 4.13 Sulfate incorporation measured over 16 days. Data was plotted relative to FS
conditions (A) and relative to the corresponding treatment (B). Stars indicate significance (p-
values < 0.05) between condition and corresponding FS (A) or treatment (B) value. Mean ±
SEM. Time points: N Day 2, M Day 4, U Day 8, O Day 12, 9 Day 16................................. 116
Figure 4.14 Proline incorporation measured over 16 days. Data was plotted relative to FS
conditions (A) and relative to the corresponding treatment (B). Stars indicate significance (p-
values < 0.05) between condition and corresponding FS (A) or treatment (B) value. Mean ±
SEM. Time points: N Day 2, M Day 4, U Day 8, O Day 12, Q Day 16........................... 117
Figure 4.15 Levels of apoptosis 8 days after loading. Percentage apoptotic cells represent the
amount of apoptotic cells divided by the total number of cells. Stars indicate significance (p-
values < 0.05) between condition and FS. Bar indicates statistical difference (p-values < 0.05)
between the two end points. Mean ± SEM. ..................................... 118
Figure 4.16 Levels of apoptosis 16 days after loading. Percentage apoptotic cells represent the
amount of apoptotic cells divided by the total number of cells. Stars indicate significance (p-
values < 0.05) between condition and FS. Mean ± SEM ....... ................ ......... 119
Figure 5.1 Schematic of knee joint where orange circles denote location of joint capsule excision
and white ovals denote areas of cartilage harvest ..................................... ............................ 167
Figure 5.2 Biosynthesis rates of [35S]-Sulfate and [3H]-Proline 1st mm knee tissue in Human 2
(19 years). Stars represent significant difference compared to FS conditions (p-values <0.05).
................................................................................................. . . .. . .. . .... .... .... .... .... .... . 1 7 1
Figure 5.3 Biosynthesis rates of [35S]-Sulfate and [3H]-Proline ankle tissue in Human 3 (19
years) . ............................................................. ...... .......... 172
Figure 5.4 Biosynthesis rates of [35S]-Sulfate and [3H]-Proline ankle tissue in Human 5 (74
years). Bars represent statistical significance between ends (p-value < 0.05)....................... 172
Figure 5.5 GAG loss to the medium in 1st mm Knee, 2nd mm Knee, and Ankle from Human 2
(19 years old). Percentage GAG loss was determined by GAG lost to the medium divided by
total GAG measured (GAG lost to medium + GAG in plug). Stars represent statistical
significance compared to FS conditions (p-value < 0.05). .................................... 174
Figure 5.6 IHC samples stained with Anti-DPE targeting Versican expression from 1st mm and
2nd mm knee cartilage from Human 2 (19 years old). Plugs were placed in 10% formalin after 2,
6, and 16 days of treatment post treatment/injury......................... 176
Figure 5.7 IHC samples stained with Anti-CDAG targeting aggrecan expression from 1st mm
and 2nd mm knee cartilage from Human 2 (19 years old). Plugs were placed in 10% formalin
after 2, 6, and 16 days of treatment post treatment/injury. ........................................ 177
Figure 5.8 IHC samples stained with Anti-DPE targeting versican expression from human
cartilage tissue taken from notchplasty experiment post-ACL reconstructive surgery. Tissue was
examined 0, 1, 3, and 57 months post-surgery. ..................................... 178
Figure 5.9 IHC samples stained with Anti-CDAG targeting aggrecan expression from human
cartilage tissue taken from notchplasty experiment post-ACL reconstructive surgery. Tissue was
examined 0, 1, 3, and 57 months post-surgery. ..................................... 179
Figure 6.1 Superoxide dismutase mimetic structure, Manganese(III)tetrakis (1-methyl-4-pyridyl)
porphyrin pentachloride. ..................... .. ...... ... .... .............................. ............................ 192
Figure 6.2 Aggrecan and collagen type II gene expression at 2, 8, 24, 48, and 72 hours after
treatment. Data was plotted relative to FS conditions, and stars indicate significance (p-values <
0.05) between condition and corresponding FS value. Mean ± SEM. ................................... 199
Figure 6.3 Caspase-3 and MMP-9 gene expression at 2, 8, 24, 48, and 72 hours after treatment.
Data was plotted relative to FS conditions, and stars indicate significance (p-values < 0.05)
between condition and corresponding FS value. Mean ± SEM..................................... 200
Figure 6.4 Effects of SODm treatment on aggrecan and collagen type II gene expression at 2, 8,
24, 48, and 72 hours after treatment. Data was plotted relative to corresponding loading
conditions (FS or INJ), and stars indicate significance (p-values < 0.05) between SODm
treatment and corresponding loading value. Mean ± SEM.......................... 201
Figure 6.5 Standardized gene expression visualized in principle component space. Principle
components 1, 2, and 3 represent 79% of the variance in the data. Genes were allocated to one of
five distinct groups by way of k-means clustering. Large solid black circles denote the centroid
of the corresponding group. ........................................................................................................ 203
Figure 6.6 Five expression profiles represent the combination of FS + 2.5 gM SODm, INJ, and
INJ + 2.5 gM SODm. Centroid profiles were calculated through the average projection
coordinates of genes in each group, and transformed from principle component space through
use of the calculated principle components. Mean ± SE (n varies based on group component
num ber) .................................................. 205
Figure 6.7 sGAG loss to the medium in free swell (FS), mechanical injury (INJ), TNF-a
treatment (TNF), and mechanical injury with TNF-a treatment (INJ+TNF) and all conditions +
2.5 gM SODm plotted relative to FS conditions. Stars indicate significance (p-values < 0.05)
between condition and FS, and bar indicates significance between two conditions. Mean ± SEM.
..................................................................................................................................................... 2 0 6
List of Tables
Table 3.1 24 Cartilage Relevant Genes. Primers were designed Primer3 software
(www.genome.wi.mit.edu/cgi-bin/primer/primer3www.cgi). Standard dilutions were used to
calculate relative mRNA copy number ................................................................. ..................... 57
Table 3.2 P-value of Centroid Profile Separation. P-values were obtained through student T-
test, comparing centroid to centroid Euclidean distance. Degrees of freedom were taken as the
num ber of genes in each group. ................................................ .......... 64
Table 3.3 Gene clustering groupings. Resulted gene sorting according to extent and kinetics of
expression. Specific gene allocation and centroid coordinates when all data are clustered (A),
0% compression 300 ng/ml IGF-1 data clustered (B), 50% compression 0 IGF-1 data clustered
(C), and 50% compression 300 ng/ml IGF-1 data clustered (D). .......... ........................................ 69
Table 4.1 List of 48 cartilage relevant genes measured by qPCR. Primer3 and Primer Express
were used to design primers. Standard dilutions were used to calculate relative mRNA copy
num b er . ....................................................................................................................... . . ..... 90
Table 4.2 P-value of Centroid Profile Separation. P-values were obtained through student T-
test, comparing centroid to centroid Euclidean distance. Degrees of freedom were taken as the
number of genes in each group.. .... ...................................... 122
Table 4.3 P-value of Centroid Profile Separation. P-values were obtained through student T-
test, comparing centroid to centroid Euclidean distance. Degrees of freedom were taken as the
num ber of genes in each group. ........................................ ........................... ......................... 125
Table 5.1 List of human donor information and tissue provided by Gift of Hope Organ and
T issue D onor N etw ork .................................... ..... ............................................................. 166
Table 6.1 List of 36 cartilage relevant genes measured by qPCR. Primer3 and Primer Express
were used to design primers. Standard dilutions were used to calculate relative mRNA copy
number . ....................................................................... 196
Table 6.2 P-value of Centroid Profile Separation. P-values were obtained through student T-
test, comparing centroid to centroid Euclidean distance. Degrees of freedom were taken as the
num ber of genes in each group. ................................................................................................. 208
Chapter 1
Mechanobiology: Introduction, Background, and
Significance
* This chapter has appeared as a review paper in Current Opinions in Orthopaedics (Wheeler,
Cameron A; Fitzgerald, Jonathan B; Grodzinsky, Alan Cartilage mechanobiology: the
response of chondrocytes to mechanical force. Current Opinion in Orthopedics. 16(5):346-
353, October 2005.)
1.1 Purpose of the Chapter
A comprehensive understanding of chondrocyte mechanobiology is critically important
for a clear understanding of the etiopathology and treatment of osteoarthritis (OA) as well as for
the long-term survival of tissue engineered implants for cartilage repair.
Recent Findings
A large body of evidence has emerged documenting the effects of various mechanical
loading modalities on chondrocyte biosynthesis and gene expression. Many physical forces and
flows occur in cartilage during loading in vivo. For example, dynamic compression of cartilage
results in deformation of cells and the extracellular matrix, hydrostatic pressurization of the
tissue fluid, pressure gradients and the accompanying flow of fluid within the tissue, and
streaming potentials and currents induced by fluid convection of counter-ions through the
negatively charged extracellular matrix (ECM). In addition, local changes in tissue volume
caused by compression also lead to alterations in matrix water content, ECM fixed charge
density, mobile ion concentrations, and osmotic pressure. Any of these mechanical and
physicochemical phenomena in the micro-environment of chondrocytes may affect cellular
metabolism. While specific components of certain mechanotransduction pathways have been
identified, the exact mechanisms by which mechanical forces influence the biological activity of
chondrocytes are not yet fully understood. New genomic and proteomic technologies and
methodologies including systems biological analyses are being applied to better understand
cellular mechanotransduction.
Summary
Investigators have focused on mechano-regulation of upstream signaling and responses at
the level of gene transcription, protein translation and post-translational modifications.
Intracellular pathways including those involving integrin signaling, mitogen activated protein
kinases (MAPKs), and release of intracellular calcium have been confirmed in several
laboratories.
1.2 Introduction
Articular cartilage is an avascular, aneural, alymphatic tissue that provides a low friction
weight bearing surface for joint locomotion. During joint loading in vivo, cartilage is subjected to
mechanical stresses and strains that span a wide range of amplitudes and frequencies [1, 2]. Peak
stresses can reach 10-20 MPa (100-200 atm) during activities such as stair climbing [3]. While
compressive strains of 15% - 40% may occur in response to long-term or "static" loads within
the physiological range [1], compressions of only a few percent occur during normal ambulation
(e.g., the "dynamic" strains that occur at walking frequencies of -1 Hz). Chondrocytes occupy
3% to 5% of tissue volume in adult human cartilage [1]. These cells maintain a mechanically
functional extra-cellular matrix (ECM) by mediating the synthesis, assembly, and degradation of
proteoglycans (PGs), collagens, glycoproteins, and other matrix molecules. It is well known that
chondrocytes can sense and respond to their mechanical environment; however, the
mechanotransduction pathways by which mechanical forces influence the biological activity of
chondrocytes are not fully understood.
1.3 Systems for Studying Chondrocyte Mechanotransduction
Since mechanotransduction mechanisms are difficult to quantify in vivo, model systems
such as cartilage explant organ culture and three dimensional chondrocyte/gel culture have been
used. Cartilage explants preserve native tissue structure and cell-matrix interactions and thereby
enable quantitative correlations between mechanical loading parameters and biological responses
such as gene expression and biosynthesis. Muir [4] emphasized the important but complex role
of the native ECM and chondrocyte-ECM interactions in chondrocyte response to load; thus,
investigators [4] have cautioned that the use of isolated, plated chondrocytes that are depleted of
ECM must be approached with care regarding the potential for chondrocyte dedifferentiation and
the interpretation of the results in relation to the behavior of cartilage. In native tissue, however,
the coupling between mechanical, chemical, and electrical forces and flows within the ECM can
complicate the identification of specific physical stimuli, necessitating specialized experimental
and theoretical modeling approaches. Therefore, three-dimensional agarose [5], alginate [6], and
other scaffold culture systems have also been used to study chondrocyte response to mechanical
compression[7-9], hydrostatic pressure [10], stretch [ 11], physicochemical stimuli (pH and
osmolarity [12], and electrical currents [13]). Finally, a variety of specialized, incubator-housed
instruments have been developed to mimic mechanical stimuli found in vivo and apply
components of compression, shear, stretching, hydrostatic or osmotic pressure to explants,
isolated cells, or cell-encapsulated gel constructs in vitro [14-17], shown schematically in Fig.
1.1.
1.4 Chondrocyte biosynthesis and gene expression
Static compression (Fig. 1.1a) of animal and human cartilage explants [18, 19] as well as
high hydrostatic pressure applied to chondrocyte monolayers [20] can cause a dose-dependent
decrease in the biosynthesis of proteoglycans, collagens, and other ECM proteins as quickly as
one hour after application of compression. Complete recovery of biosynthesis can occur after
release of compression, but at different rates for different ECM macromolecules [21], strongly
suggesting that specific transduction pathways are involved. In contrast, dynamic compression
and shear (Fig 1.1b,c) [18, 22, 23] and cyclic hydrostatic compression [20, 24] can markedly
upregulate ECM biosynthesis in a manner dependent on compression amplitude and frequency
[20, 22], as well as the developmental stage and the depth from the articular surface of the
cartilage sample [14, 25, 26]. Tissue-level and cell-level quantitative autoradiography have been
used to visualize the spatial distribution of newly-synthesized ECM molecules in response to
compression and shear [23, 27, 28], and to compare with the theoretically predicted profiles of
physical stimuli, highlighting the roles of ECM and cell deformation as well as intratissue fluid
flow (shown schematically in Fig. 1.1).
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Figure 1.1: Schematic of physical forces and flows occurring during mechanical loading of
cartilage in vivo, that can be stimulated in vitro by means of (a) static compression, (b) dynamic
compression, and (c) dynamic tissue shear.
Mechanical forces can also influence aggrecan gene expression [29-33] and the
transcription of many matrix proteins and proteases in chondrocytes and other connective tissue
cells [33-36]. Investigators have also found thatfluid shear flow [37-40] can alter aggrecan
synthesis and the expression of aggrecan, TIMP-1, IL-6 and MMP-9. The induction of MMP-9
gene expression appeared to be mediated via the JNK signaling pathway [38], and the aggrecan
promoter via the ERK pathway [39]. While the fluid velocities in these experiments were much
higher than physiological for cartilage, the resulting shear stresses may be relevant. When
isolated bovine and human chondrocytes were cyclically stretched on flexible membranes,
aggrecan and type II collagen mRNA expression were increased [40], consistent with a role for
cell deformation and membrane perturbation. Cyclic (1 Hz square wave) uniaxial stretch (5%
elongation) of embryonic chick sternal chondrocytes seeded into a 3D collagen sponge induced
expression of Indian hedgehog (Ihh) and also upregulated bone morphogenic proteins 2 and 4
downstream of Ihh which, in combination, stimulated cell proliferation [11 ]. Interestingly,
mechanical induction of Ihh mRNA was abolished by blocking stretch activated channels [11].
1.5 Upstream Signaling
Investigators have been trying to map the sequential intracellular signaling pathways through
which mechanical forces can modify the gene expression of specific molecules. Major roles have
been identified for certain classical signaling pathways including those involving integrins,
mitogen activated protein kinases (MAPKs), and release of intracellular calcium.
Integrin signaling pathways
Evidence suggests that integrins can convert extracellular mechanical stimuli into
intracellular signals in a variety of cell types [41]. In chondrocytes, the alpha a5pl fibronectin-
binding integrins have been implicated as part of a mechanotransduction complex that involves
tyrosine protein kinases, cytoskeletal proteins, ion channels, and second-messenger signaling
cascades [42, 43]. Researchers have also shown that the a5pl integrin complex is present in OA
chondrocytes, but results in different downstream effects when activated or blocked compared to
normal chondrocytes [44]. Application of hydrostatic pressure to chondrocyte monolayers in a
manner that induced strain on the culture dish and plated cells caused interleukin-4 (IL-4)
secretion via x51I1 integrin and subsequent intracellular calcium release followed by cell
hyperpolarization [42, 45]. One possible connecting link is the N-methyl-D-aspartate (NMDA)
receptor, since integrin signaling has been shown to influence the activity of this receptor in
other cells [46]. NMDA is phosphorylated by protein kinases including protein kinase C (PKC)
and phosphotidylinositol 3-kinase (PI3K) [47]. Salter el al. observed that the NMDA receptor
induced depolarization in OA chondrocytes and hyperpolarization in normal chondrocytes,
suggesting a possible alteration in chondrocytic mechanotransduction as a consequence of the
function of the NMDA receptor during OA [48].
Mitogen activated protein kinase pathways
Investigators have been trying to map the sequential intracellular signaling pathways
through which mechanical forces may modify chondrocyte gene expression of specific
molecules. Several recent studies have demonstrated a role for mitogen activated protein kinases
(MAPKs) [49, 50] which can alter matrix gene expression and changes in matrix production by
chondrocytes within compressed cartilage and in chondrocyte monolayers [51]. This family of
ubiquitous signaling molecules includes extracellular-signal regulated protein kinases (ERK1/2),
c-Jun N-terminal kinase (JNK) and p38. Activated MAP kinases are thought to translocate to the
nucleus, where they may induce phosphorylation of transcriptional factors and eventual
upregulation of various genes.
Fanning et al. [52] examined the effects of slow ramp-and-hold compression of cartilage explants
to final static strains up to 50% that were held for a range of compression durations; these
compression conditions were found previously to inhibit chondrocyte biosynthesis but not to
affect cell viability. Mechanical compression caused (1) a rapid induction of ERK1/2
phosphorylation at 10 min followed by a rapid decay, as well as a sustained level of ERK2
phosphorylation that persisted for at least 24 hrs; (2) phosphorylation of p38 in strictly a transient
fashion, with maximal phosphorylation occurring at 10 min; and (3) stimulation of SEKI
phosphorylation with a maximum at the relatively delayed time point of 1hr and with a higher
amplitude than ERK1/2 and p38 phosphorylation. (SEKiis an immediate upstream specific
activator of JNKs 1,2 and 3 [53], and the JNK and p38 kinases together constitute the SAPK sub-
family of MAPKs [54]). Fanning et al. [50] proposed that the rapid activation of ERK1/2 and
p38 may be due to the cell deformation, fluid flow and pressurization, while the SEK1 pathway
was activated only under static compression without fluid flow or pressurization [50]. Thus, it
was suggested that the initial transient ERK1/2 response was due to the dynamic components of
static compression, consistent with the results of Li et al. [49], who found a significant
upregulation of ERK1/2 activation in response to dynamic compression.
ATP and Ca2+
Ion channels have been identified as another important factor in mechanotransduction, including
effects of cell stretching on chondrocyte hyperpolarization and depolarization [55]. ATP has
been shown to be involved in signaling in many cell types. Under compressive conditions,
bovine chondrocytes can release ATP [56, 57] which, in the extracellular space, can then bind to
membrane receptors and initiate a signaling cascade including stimulation of proteoglycan
synthesis [58]. While ATP can induce anabolic signaling in normal chondrocytes, OA
chondrocytes do not show upregulation of matrix production. Mechanical stimulation can also
increase the concentration of intracellular calcium ions, derived either from intracellular stores or
from the extracellular space and transported into the cell via stretch activated ion channels.
While hyperosmotic stress can initiate intracellular Ca2+ signaling in chondrocytes [59],
Erickson et al. demonstrated that the stretch activated ion channels were not necessarily
responsible for Ca2+ transients under these conditions. Cell volume was also shown to decrease
under hyperosmotic stress and, hence, the stretch effect was explained by an inhomogeneity in
the cell surface [59]. The role of intracellular calcium in native cartilage explants was studied by
Vahlmu and Raia [60]; using blockers of intracellular Ca2+ and protein kinase C, they
demonstrated that regulation of aggrecan mRNA levels under creep compression involved
Ca2+/calmodulin and myo-inositol 1,4,5-triphosphate signaling processes. Fitzgerald et al. also
found that compression of cartilage explants induces multiple time-dependent gene expression
patterns that involve intracellular calcium and cyclic AMP [61].
1.6 Pro-inflammatory pathways in normal and injurious
compression
Acute traumatic joint injury increases the risk for subsequent development of OA [62].
In order to quantify the events following cartilage and joint injury, investigators have turned to a
variety of in vitro and animal models. Studies have shown that threshold levels of compressive
strain, strain rate, and peak stress can cause cartilage matrix disruption, tissue swelling, cell
necrosis and apoptosis, and increased loss of matrix macromolecules [63-70]. As a baseline
control for changes in gene expression in bovine calf cartilage explants, mRNA levels measured
in non-injured free swelling tissue was found to vary over five orders of magnitude, with matrix
molecules being the most highly expressed of the genes tested and cytokines, matrix
metalloproteinases (MMPs), aggrecanases (ADAMTSs), and transcription factors showing lower
levels of expression [71]. While the matrix molecules showed little change in expression after
injurious compression, MMP-3 increased -250-fold, ADAMTS-5 increased -40-fold, and
TIMP-1 increased -12-fold over free swelling levels [66]. In addition, injurious compression
results in a decrease in biosynthetic rates in the remaining viable cells, and these viable cells no
longer respond to the stimulatory effects of moderate dynamic compression seen in normal
cartilage [70]. Taken together, these studies suggest that mechanical overload can cause long-
term cell mediated changes in matrix quality and turnover.
Deschner et al. recently summarized the interaction between loading and inflammatory pathways
[72], which may be activated by excessive loads and inhibited by moderate cyclical loading [42,
45, 73]. Thus, these interactions appear to depend on the magnitude and loading rate (frequency).
Mechanical forces can influence production of NO [16, 74, 75], PGE2 [37], and IL-6 [76].
Interestingly, cross-talk between NO and PGE2 pro-inflammatory pathways, and between NOS2
and COX2 (upstream of NO and PGE2), can be regulated by mechanical stimuli [77]. These
pathways have been traditionally associated with inflammatory cytokines such as IL-1, an
initiator of cartilage degradation [42, 45, 73, 78-80]. Dynamic compression (15% strain
amplitude, 1Hz, 48 hr) could inhibit NO synthesis by equine chondrocytes in agarose gel
constructs [81] ,and could inhibit NO and PGE2 release by superficial zone equine chondrocytes
stimulated by IL-103 [82].
Cell microenvironment and organelle morphology
Loading of cartilage (Fig. 1.2a) produces cellular deformation [83, 84] in proportion to the local
deformation of the ECM, and in a manner consistent with the depth-dependent compressive
properties of the bulk tissue [85]. Deformations within the pericellular matrix (Fig. 1.2b) also
affect the physicochemical microenvironment of the chondrocyte [28, 86] and may, in turn,
signal the cell to modulate its biosynthetic response. Deformation-induced fluid flow in the
pericellular region enhances transport of soluble factors to cell receptors, and alters the local
concentration of mobile ions leading to electrochemical changes such as shifts in pH[87]. Cell-
surface connections to the ECM enable pericellular deformations to be transmitted through the
cell membrane to intracellular organelles via cytoskeletal elements such as actin microfilaments,
microtubules, and intermediate filaments[20, 83, 88]. Compression can also dramatically affect
the morphology of intracellular organelles that regulate cell biosynthesis and metabolism by
altering gene transcription, intracellular transport and trafficking, and protein translation and
post-translational processing. Using chemical fixation, high-pressure freezing, and electron
microscopy, Szafranski et al. [89] observed that compression of bovine cartilage explants caused
a concomitant reduction in the volume of the extracellular matrix, chondrocyte, nucleus, rough
endoplasmic reticulum, and mitochondria. Interestingly, however, the Golgi apparatus was able
to resist loss of intraorganelle water and retain a portion of its volume relative to the remainder
of the cell. These combined results suggested the hypothesis that organelle volume changes
were driven mainly by osmotic interactions while shape changes were mediated by structural
factors, such as cytoskeletal interactions that may be linked to extracellular matrix deformations.
The observed volume and shape changes of the chondrocyte organelles and the differential
behavior between organelles during tissue compression provides evidence for an important
mechanotransduction pathway linking translational and post-translational events. For example,
since the Golgi is the site of post-translational modifications of aggrecan (e.g., glycosylation and
sulfation) [89, 90], changes in Golgi morphology and function with compression may play a
critical role in the known changes in GAG chain length and sulfation caused by compression
[21]. Such changes in GAG and aggrecan structure, which also occur naturally with age (Fig.
1.2c) may profoundly influence aggrecan function. Such functional mechanical changes can now
be measured directly using atomic force microscopy methodologies [91, 92] (Fig. 1.2d).
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Figure 1.2 : Loading of cartilage explants (a), or direct mechanical stimulation of cells (b) can
produce mechanical stimuli that may be sensed by the cell and its pericellular microenvironment
(b). These mechanical stimuli may alter the rate of synthesis as well as the molecular structure of
ECM molecules such as aggrecan (c) which, in turn, could ultimately affect tissue-level
biomechanical properties in a feedback fashion (a). New cell-level and molecular-level
measurement techniques, such as those based on atomic force microscopy, are being used to
quantify the molecular mechanical properties of ECM macromolecules (d) as well as cellular
mechanical properties (b).
1.7 Systems biology approaches
Real time PCR and gene clustering analyses have been used to study intermediate-size
gene sets (20-48 genes) thought to be involved with cartilage mechanotransduction. Fitzgerald et
al. [33] examined the kinetics of mechano-regulation of gene transcription in response to static
compression of bovine calf cartilage explants for periods between 1-24 hours in the presence or
absence of an intracellular calcium chelator or an inhibitor of cyclic AMP activated protein
kinase A. Cluster analysis of the data revealed four main expression patterns: two groups that
contained either transiently upregulated or duration-enhanced expression profiles could each be
(b)
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subdivided into genes that did or did not require intracellular calcium release and cyclic AMP
activated protein kinase A for their mechano-regulation. Transcription levels for aggrecan, type
II collagen, and link protein were upregulated approximately 2 to 3-fold during the first 8 hrs of
50% compression and subsequently down-regulated to levels below that of free-swelling controls
by 24hrs. Transcription levels of matrix metalloproteinases-3,9,13, aggrecanase- 1 and the matrix
protease regulator cyclooxygenase-2 increased with the duration of 50% compression 2 to 16-
fold up to by 24 hrs. Thus, transcription of proteins involved in matrix remodeling and
catabolism dominated over anabolic matrix proteins as the duration of static compression
increased. These approaches are also being used to study responses to dynamic compression and
tissue shear of cartilage explants.
Researchers have begun to integrate genomic and proteomic approaches with the
computational tools of systems biology for applications in musculoskeletal research, including
medical diagnostics, and drug discovery [93]. DNA microarray technology is being used to
explore the complex feedback loops in transcription factors and layered signaling pathways
underlying the mechanotransduction as well as the pathobiology of osteoarthritis. Aigner et al.
[94-96] examined transcript levels of matrix components and matrix degrading proteinases using
DNA arrays. By comparing normal chondrocytes with early and late stage OA chondrocytes,
they examined expression trends involving up and down regulation of MMPs, TIMPS,
proteoglycans, and collagens [96]. Such approaches can be directly applied to the study of
mechanotransduction. While DNA arrays can sample large numbers of genes, they are limited in
their sensitivity and they do not measure posttranscriptional regulation or modifications [94].
While recognizing these limitations, the potential of such profiling approaches is clear [95, 97],
since the results can be used to formulate hypotheses about specific molecules and mechanisms
in ways that are complementary to the traditional one-gene or one-protein hypothesis-testing
approach.
1.8 Conclusion
Chondrocytes can sense and respond to mechanical forces in an extraordinarily sensitive
and robust manner. These cells can distinguish between compression, tension and shear
deformation of the surrounding ECM, and respond in a manner that varies with the rate
(frequency) of loading. Recent studies have identified several intracellular signaling pathways
that are involved in chondrocyte mechanotransduction and the regulation of cartilage and exhibit
levels of overlap or crosstalk in their signaling. These complex signals are responsible for
activation of ECM molecules proteinases, inflammatory factors, and regulatory proteins which
govern tissue homeostasis. Significant technical advances have enabled the study of transduction
mechanisms by chondrocytes within their native, dense ECM. Advanced genomic and proteomic
technologies should lead to a further rapid increase understanding the fundamental link between
chondrocyte mechanobiology, physiology, and tissue homeostatis in health and disease, with
direct application to cartilage repair and tissue engineering.
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Chapter 2
Current in vitro Injury Models
2.1 Introduction
Approximately one in five Americans is affected by arthritis, making it one of the most
prevalent diseases and the leading cause of disability in the United States [1]. Post-traumatic
arthritis occurs after a traumatic joint injury (ACL rupture [2, 3] or intraarticular fracture [4, 5])
and makes up a significant proportion of the population with arthritis [6]. In previous clinical
studies, patients suffering from a traumatic joint injury have shown an increased risk in
osteoarthritis (OA), independent of surgical intervention to stabilize the joint [7-11]. Thus, the
early events post-injury have an important effect on tissue within the joint in the long term.
Studies have shown a dramatic increase in concentration of inflammatory cytokines IL-113 and
TNF-a in the synovial fluid within twenty-four hours post injury [12] and have shown them to
remain at high levels in the synovial fluid for longer periods of times (months to years) [4, 13,
14]. The interplay between mechanical forces and cellular response to these forces are thought
to play a crucial role in understanding the onset of OA [15, 16]. Aggrecan molecules and
collagen matrix play an essential role in cartilage homeostasis, and the degradation of this matrix
and loss of aggrecan from cartilage is a crucial event in osteoarthritis [17, 18].
To understand the processes involved in the onset of OA and factors leading to OA post-
traumatic injury, in vitro models have been developed to isolate components of the complex
processes occurring in vivo. While in vitro models do not mimic true physiologic conditions in
vivo, by isolating the effects of mechanical compression, cytokine treatment, and cartilage co-
cultured with adjacent tissue (to name a few models), in vitro models can give insight into key
biological and mechanical processes occurring in vivo.
The aim of this chapter is to review and analyze the current in vitro models of injury.
While many in vivo animal models exist mimicking the injury process [19-21], this chapter will
focus on experiment models which isolate the components of such in vivo models.
2.2 Models of Mechanical Injury
In vitro mechanical injury has been shown to increase hydraulic permeability [22] and
water content [23-25], decrease stiffness [24, 26], increase collagen lost to the medium[22], and
increase glycosaminoglycan (GAG) lost to the medium [24, 27-29]. Cells subject to this
mechanical injury have been shown to decrease biosynthesis rates [24], undergo apoptosis and
necrosis[23, 24, 30, 31], and have elevated levels of protease transcript activity within the first 3
hours post-injury [32] and within the first 24 hours post-injury [33].
There exist significant differences between loading of articular cartilage in vivo and
mechanically loading explants. In vivo, articular cartilage is prone to experience different stress
concentrations throughout the tissue due to the rigid topography of the osteochondral cartilage
interface. Stress concentration in vivo probably corresponds to irregularities in subchondral
bone, or to a local variation in cartilage composition [34]. While explant loading may have
different stress profiles than in vivo loading, the advantage of in vitro mechanical loading is the
specific and accurate measure of the load applied to the explant and the resulting peak stress,
strain, and strain rate. Under these controlled conditions, the strain, strain rate, and peak stress
can be measured with precision, and since the three are interdependent, one or two of these
factors can be controlled for as the dependent variables, while the remaining variables are
considered the independent variables.
The application of these loads are applied in various different manners, including impact
loading (drop tower-type devices [35], material testing machines[36], and free flight masses
[37]) and injurious compression [38]. Researchers have suggested that there may be a threshold
level of peak stress that separates injurious compression from non-injurious compression [23, 39,
40]. Injurious compression techniques tend to explore the stress-strain response of articular
cartilage and how it and other tissues attenuate impact load. Studies have shown that when
applied compression reaches 50% strain, chondrocyte viability decreases [24, 26, 40-42] and
cartilage surfaces become physically disrupted, with generation of fissures [42]. A recent study
investigated the effect of indentation probing used as a diagnostic tool during or after surgical
procedures and its effect on chondrocyte viability [43]. This study reported that 30% strain
performed in arthroscopy decreased cell viability. The effect of strain rates has been investigated
by varying speed of impact and has been shown to be an important parameter in defining
mechanical injury [24, 44]. Articular cartilage generally behaves as a visco- or poro-elastic
fibre-composite material, and as such, its material properties depend on the rate of loading [45].
For example, at high rates, cartilage acts as a quasi-elastic material provided the stress is not too
high. Studies have found that fissuring and cell death occurred in the superficial zone with a
higher release of glycosaminoglycan (GAGs) when the strain rate was increased [42] and
apoptosis was increased as peak stress increased [26]. Alternatively, loads can be applied in a
load-rate dependent manner. A high load-rate of 600 MPa/sec caused concentrated cell death in
the superficial zone of articular cartilage, and a lower load-rate (30 MPa/sec) showed a more
diffuse pattern of cell death [23, 42, 46]. In a separate experiment, load-rates of 900 MPa/sec
and 40 MPa/sec were applied to cartilage explants. Matrix damage increased at the high load-
rate and caused substantial cell death around fissures and fractures while cell death was diffuse
throughout the explants at the low rates, as seen before [47]. Recently, peak stress has been
shown to not be an important cause of GAG loss from human cartilage in a model of 65% total
strain at a relatively high strain rate of 400%/sec [48].
Mechanical injury has also been shown to stimulate chondrocytes to produce harmful
reactive oxygen species (ROS) which depolymerize hyaluronic acid and kill chondrocytes [30,
49, 50]. After mechanical injury, cell death was abrogated by blocking NO synthesis, and since
NO synthesis is unlikely in itself to cause cell death, it is likely that the high levels of NO in
combination with ROS react to form toxic compounds like peroxynitrite [50-52].
2.3 Cytokine treatment Models of Injury
Interleukin-1 (IL-1), a pro-inflammatory cytokine considered to play a pivotal role in OA,
is used often as a catabolic stimulant in in vitro studies [53, 54]. Studies have shown that IL-i
increases expression of matrix metalloproteinases (MMPs) and aggrecanases involved in
cartilage matrix catabolism [32, 55] and mediates matrix degradation [56]. Treatment with IL-la
at concentrations of 10 ng/ml and TNF-a at 100 ng/ml had a significant increase in GAG loss
compared to free swell conditions for immature bovine cartilage [27]. In both adult human knee
and ankle, IL-la had no affect on GAG loss after three days in culture. TNF-a also showed no
significant difference in GAG loss of human knee cartilage three days or seven days post TNF-a
treatment [27].
Interleukin-6 (IL-6) is a cytokine involved in the regulation of inflammatory and
immunological responses and has been shown to be produced by human chondrocytes [57]. The
known inflammatory and destructive cytokines, IL-1 and TNF-a, have been shown to stimulate
IL-6 production, which acts in an autocrine fashion to increase production of interleukin-6
receptor (IL-6R) [58]. Initially IL-6 and IL-6R were proposed as critical mediators in
controlling the catabolic effects of pro-inflammatory cytokines like IL-I and TNF-c [59].
Recently IL-6 and IL-6R have been shown to synergistically increase cartilage breakdown and
collagenase production in combination with IL-la [60], and have been shown to be upregulated
in the synovial fluid in patients who have undergone anterior cruciate ligament injuries (32
weeks post-surgery) [61].
2.4 Synovium-Joint Capsule co-culture models of Injury
Co-culturing un-injured cartilage with damaged joint capsule (JC) in vitro has resulted in
a decrease in cartilage biosynthesis rates [62, 63], as well as a loss of proteoglycan and collagen,
as seen through histology staining [64]. GAG release from cartilage co-cultured with synovial or
capsular tissue was not decreased with the inhibition of IL-10, TNF-a, and ACITIC [65]. Under
the same conditions of cartilage co-cultured with joint capsule, GAG loss was blocked by
treatment with EDTA [65]. Interestingly, studies have shown that the presence of dead joint
capsule as well as joint capsule with viable cells produce similar degradation effects. This
suggests that the factors contributed from the joint capsule need not be actively produced by cells
within the joint capsule and may reside in the extracellular space or ECM of the tissue [66].
While the effects of JC co-culture appear to accelerate degradation, studies have also shown that
synoviocytes from joint capsule tissue provide chondrocytes with protection against reactive
oxygen species, which are known to induce membrane damage and lipid peroxidation [67].
Synovial cells from normal bovine or osteoarthritic human tissue have been shown to
produce aggrecanase-2 (ADAMTS-5). Yet interestingly, aggrecanase activity or expression
were not induced by IL-la or retinoic acid [65, 68], two mediators that are known to induce
aggrecanase expression in cartilage [69, 70]. The specific factor or factors from joint capsule
and/or synovial cells responsible for increased cartilage degradation still remain to be
determined.
2.5 Combination Models of Injury
An in vitro model of injury has been established in our lab incorporating the effects of a
mechanical injury and injured joint capsule (JC) tissue [62, 66]. Mechanical injury of cartilage
explants followed by co-culture with excised joint capsule results in further reduction of
biosynthesis found after injury or co-culture alone [62]. Initial studies have also been performed
on gene expression up to 24 hours post-injury [66]. These studies found there were significant
changes in gene expression of key enzymes measured in response to joint capsule co-cultured
with un-injured cartilage and mechanically-injured cartilage and co-culture with joint capsule.
Chapters 4 and 5 explore this model of injury in greater depth. Chapter 4 introduces a
combination of growth factors and measures their effect on the combination of injury and co-
culture. Chapter 5 applies this model to human tissue.
Recent studies showed treatment with cytokines (e.g., IL-1, TNF-a, IL-6 [27, 71])
following injurious compression in vitro increased GAG loss and decreased biosynthesis greater
than either mechanical injury or cytokine treatment alone. Both bovine and human tissue
exhibited a synergistic increase in proteoglycan loss in response to TNF-a or IL- la treatment
combined mechanical injury [27, 72]. Also, new findings have shown that with the addition of
an anti-IL-6 Fab fragment, an inhibitor of IL-6, GAG loss was decreased when both mechanical
injury and TNF-a were present [71]. This result supports the idea that IL-6 is either
endogenously present in cartilage tissue and/or is produced by the chondrocytes in reaction to
injury and/or TNF-a treatment. Recent data has shown that IL-6 is produced in response to
TNF-a treatment in cartilage, supporting previously reported results [58, 72]. The combinatorial
injury model of TNF-a, IL-6, IL-6R, and mechanical compression is further explored on a
transcriptional level in Chapter 6.
Whether the combination of these factors and mechanical injury is simply a result of
increased ability for factors to diffuse through the cartilage due to the micro-damage within the
tissue associated with injurious load or is a result of the synergistic effect of a biological stimulus
combined with a mechanical stimulus acting on the chondrocyte itself remains to be seen.
2.6 Conclusion
In vitro cartilage injury models have provided important insights into the basic
understanding of the acute effects of injury and the development of posttraumatic OA in vivo.
These models are the principle avenue for investigating specific components of in vivo joint
trauma and allow the complex model of joint injury to be understood through compartmentalized
studies. While many joint injury models exist, the four models discussed here are mechanical
injury of cartilage, cytokine treatment, co-culture models that incubate adjacent tissue and cell
types with cartilage, and combination models composed of the combination of mechanical
injury, cytokine treatment, and co-culture. An understanding of how cartilage responds to
complex models of injury (such as co-culture of mechanically injured cartilage with excised
joint capsule) along with the characterization of cell and tissue mechanics and mechanisms of
cartilage degradation will, aid clinicians and researchers in treating posttraumatic osteoarthritis.
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Chapter 3
Transcriptional Effects of Combined Mechanical
Compression and IGF-1 Stimulation on Bovine Cartilage
Explants
* This chapter is in preparation for submission to the Journal of Orthopaedics Research
(Wheeler, Cameron A and Grodzinsky, Alan J.)
3.1 Abstract
Introduction: Insulin-like growth factor-i (IGF- 1) is a potent anabolic factor capable of
endocrine and paracrine/autocrine signaling. Numerous studies have shown that chondrocytes
produce this important growth factor, and that IGF-1 can stimulate ECM biosynthesis by
chondrocytes in native cartilage and tissue engineered constructs. Previous studies have
demonstrated that mechanical compression can regulate the action of IGF-1 on chondrocyte
biosynthesis in intact tissue; when applied simultaneously, these stimuli act by distinct cell
activation pathways. Our objectives were to elucidate the extent and kinetics of the chondrocyte
transcriptional response to combined IGF-1 and static compression in cartilage explants.
Methods: Cartilage explants were harvested as performed previously in our lab. Cartilage plugs
were placed in 50% compression and 0% compression with or without 300 ng/ml of IGF-1.
RNA was obtained and measured by real-time PCR for 2, 8, 24, 32, 48 hours after treatment and
compression.
Results and Discussion: Transcript levels in response to compression alone agreed with
previously published data. Key matrix molecules, aggrecan and collagen II, responded
positively to the addition of IGF- 1 without compression, but this effect was abrogated when
compression was applied in combination with IGF-1 treatment. Clustering analysis revealed five
distinct groups. TIMP-3 and ADAMTS-5, MMP-1 and IGF-2, and IGF-1 and Collagen II, were
all robustly co-expressed under all conditions tested. These co-expressed molecules suggest
inherent regulation and positive feedback in chondrocyte gene expression. In comparing gene
expression levels to previously measured aggrecan biosynthesis levels, aggrecan synthesis is
shown to be transcriptionally regulated by IGF-1, whereas inhibition of aggrecan synthesis by
compression is not transcriptionally regulated.
Conclusion: Many genes measured are responsive the effects of IGF-1 under 0% compression
and 50% compression. Clustering analysis revealed strong co-expressed gene pairings. IGF-1
stimulates aggrecan biosynthesis in a transcriptionally regulated manner, whereas compression
inhibits aggrecan synthesis in a manner not regulated by transcriptional activity.
3.2 Introduction
Insulin-like growth factor-1 (IGF-1) is a 7.6 kDa, 8.5 PI, potent anabolic factor capable of
endocrine and paracrine/autocrine signaling. While IGF-1 is primarily produced in the liver and
transported throughout the body via the blood stream, numerous studies have shown that
chondrocytes produce this important growth factor, and that IGF-1 can stimulate ECM
biosynthesis by chondrocytes in native cartilage and tissue engineered constructs. The use of
growth factors as therapeutics to reverse or inhibit cartilage degradation has been an underlying
focus in cartilage research. The avascular, alymphatic, and aneural nature of cartilage suggests
that the growth factor be administered though means of local delivery. Local delivery is
complicated due to joint motion and cartilage structure which affects special and temporal
diffusion rates.
To investigate the effects of exogenous IGF- 1, many studies have examined how
chondrocytes respond at the protein level as well as the gene transcript level. General protein
levels have been measured using conventional radiolabel incorporation (35S, 3H), and show that
chondrocytes respond in a dose dependent manner to IGF-1 [1-6]. The environment the
chondrocytes are cultured in varies (explants, gels, monolayer), but generally chondrocyte
biosynthesis levels are increased from 150% [4] to 2-6 fold control levels [3, 6-8]. Researchers
have also examined particular proteins using western blot analysis. For example, MMP-13 was
found to be suppressed in response to IGF-1 treatment [9]. When examining the transcript or
gene levels in response to IGF-1, researchers have focused on specific molecules using real-time
PCR and reverse transcription PCR. Type II collagen was shown in multiple studies to be
significantly upregulated by IGF-1 [3, 10-12]. Aggrecan transcripts have shown no significant
increase [3, 4] or slight upregulation [12] with the addition of IGF-1 in the first 48 hours of IGF-
1 treatment, yet were significant upregulation (130%) when treated for 1-3 weeks [10]. IGF-1
transcript levels were shown to peak at 24 hours after IGF-1 treatment, suggesting that IGF-1 has
an autocrine response [1]. Sox-9, a transcription factor was also shown to have no significant
response to IGF-1 [11].
Chondrocytes have been shown to be responsive to mechanical compression on both the
protein and gene transcript levels. Static compression in vitro has been shown to decrease
protein biosynthesis levels of type II collagen and proteoglycans in a dose dependent manner [5,
13]. In alginate and type I collagen gels seeded with chondrocytes, 50% static compression was
shown to decrease radiolabel incorporation by nearly half in comparison to non-compressed
controls [14, 15]. Similar findings have been shown in cartilage explants with proteoglycan and
type II collagen synthesis decreasing within 1-2 hours of loading and remaining suppressed for
the loading period (24 hrs) [16, 17]. When transcript levels were examined in response to static
loading, type II collagen and aggrecan were shown to initially peak anywhere from 1 to 4 hours
after compression, followed by a decrease to unaffected level of gene expression [13, 15, 18, 19].
Fitzgerald et al. have investigated 28 different ECM related molecules including matrix
proteinases, tissue inhibitors of matrix metalloproteinases (TIMPs), growth factors, cytokines,
and structural ECM molecules, under static compression for a 24 hour period and reported 4
distinct patterns associate with gene expression [19].
Bonassar et al. have examined the combination of IGF-1 treatment with static compression at a
protein level and found when cartilage explants were treated with IGF-1 under 0% compression
(cut thickness) a 2-3 fold increase was found over 48 hour [5]. Under static compression
biosynthesis was decrease by 50% compared to non-compressed conditions. When compressed
explants were treated with IGF-1, biosynthesis rates significantly increased, returning to levels
comparable to non-compressed, non-treated explants. Thus compression diminished the effects
of IGF-1, but did not altogether eliminate them. IGF-1 was still able to upregulate or rescues the
synthesis rate of statically compressed cartilage explants.
Chondrocyte gene expression under a combination of IGF-1 treatment and static
compression have not been examined thoroughly. Our objectives were to elucidate the extent
and kinetics of the chondrocyte transcriptional response to combined IGF-1 and static
compression in cartilage explants.
3.3 Methods
Cartilage Harvest, Mechanical Loading, and Growth Factor Treatment: Cartilage-bone
plugs were harvested from the patello-femoral groove of 1-2 week old calves. Cartilage disks
(1mm thick X 3mm diameter) were cored and punch from the middle zone as described
previously [20] and equilibrated for two days under free-swell conditions in the presence of
serum-free feeding medium consisting of high glucose Dulbecco's modified essential medium
supplemented with 10 nM Hepes Buffer, 0.1 mM nonessential amino acids, 20 gg/ml ascorbate,
100 units/ml penicillin, 100 gg/ml streptomycin, and 0.25 tg/ml amphoericin B. Five
anatomically matched disks were separated for each time point (Figure 3.1), and placed in
polysulfone loading chambers. Each time point consisted of four separate experiments. With
cartilage disks matched for time, 8 disks were allocated to 0% compression (i.e., compressed to
1-mm cut thickness from free swelling), 50% compression, 0% compression + 300 ng/ml IGF-1,
and 50% compression + 300 ng/ml IGF- 1, the IGF- 1 concentration found previously to
maximally stimulate similar free-swelling calf cartilage explants [5]. At time zero, all chambers
were slowly compressed to specified strains over a 3 minute period to avoid injurious effects of
high strain rates. These strains were maintained for each of the four conditions for 2, 8, 24, 32,
and 48 hours (Figure 3.1). Upon completion of loading time, disks were promptly removed,
flash frozen in liquid nitrogen, and stored at -80' C.
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Figure 3.1. A schematic of the four conditions measured. 5 plugs were punched for each time
point and matched for time. IGF-1 treatment and static compression were applied at time 0, and
plugs were flash frozen at 2, 8, 24, 32, and 48 hours.
RNA Extraction and Quantization, Primer Design, and Real-Time PCR: 8 disks for each
time point and condition were taken from -80o C freezer and pulverized. In order to prevent
RNA degradation, the pulverizing apparatus was constantly cooled using liquid nitrogen. Once
samples had been pulverized, Trizol (sigma, St. Louis) was added and homogenized to
thoroughly break down the tissue. After chloroform was added, the mixture was transferred to
pre-spun phase gel tubes, and spun at 13,000 rpm for 10 minutes at 40 C. Supernatant was
removed, and RNA was extracted using Qiagen RNAeasy mini kit protocol with recommended
DNase digest (Qiagen). RNA was stored in 50 ýtl of RNase free water under -80o C conditions.
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RNA quality and amount was quantified by using NanoDrop ND-1000 spectrophotometer.
According to RNA measurements, 1tg of RNA was reverse transcribed using Applied
Biosystems reagents as previously described [21]. Forward and reverse primers for 24 relent
genes (Table 3.1) were designed based on bovine genomic sequences and standard curves were
calculated as previously described [19]. Once cDNA was obtained, Real-Time PCR was
performed using MJResearch Opticon2 instrument and SYBR Green Master Mix (SGMM,
Applied Biosystems). SGMM was combined with RNase free water and cDNA and aliquated
into MJResearch 96-well plate. Using a multi-pipette, a premixed solution of forward and
reverse primer for 24 different genes was added to each well. Measured threshold values (Ct)
were converted to RNA copy number according to previously calculated standard curves.
Protease Cytokines Growth Transcription Stress Activated Housekeeping
inhibitors Factors Factors Genes Gene
Type II Collagen MMP1 Timp-1 TNF-a IGF-1 c-Jun HSP90 18s
Aggrecan MMP3 Timp-2 IL-1 IGF-2 c-Fos Txnip
Link Protein MMP13 Timp-3 IL-4 TGF-B Sox-9
Fibronectin ADAMTS-5 IL-6
Table 3.1. 24 Cartilage Relevant Genes. Primers were designed Primer3 software
(www.genome.wi.mit.edu/cgi-bin/primer/primer3www.cgi). Standard dilutions were used to
calculate relative mRNA copy number.
Data Normalization and Statistical Analysis: Under each loading condition and time
point, each gene RNA copy number was normalized to the 18s housekeeping gene from that
same condition and time point [22]. To examine the time course of gene expression, 0%
compression + IGF-1, 50% compression, and 50% compression + IGF-1 were normalized to 0%
compression levels. Thus, if a gene expression value was below or above 1, it represented a
decrease or increase of gene expression respectively compared to 0% compression. Expression
levels due to experimental error were removed. To assign statistical significance to expression
levels, a non-parametric test was used to ensure unbiased results by avoiding the assumption of a
parameter based distribution. The Wilcoxon sign ranked test was used to judge significance
which incorporates the amount of data in the significance statistic. Significance was assigned if
the Wilcoxon sign ranked test statistic produced a p-value less than 0.07. The minimum p-value
using the Wilcoxon sign ranked test is 0.068 due to the fact that there are only four replicates.
Thus, significance of 0.07 was chosen because with this non-parametric test and amount of data,
0.05 cannot be obtained.
Clustering Analysis: In order to understand general transcriptional patterns in the data,
clustering analysis was performed on all normalized conditions (0% compression + IGF-1, 50%
compression, and 50% compression + IGF-1) and time points (2, 8, 24, 32, 48 hours) over 23
genes. This resulted in a 15 x 23 matrix which was standardized by expression amplitude as
described previously [19], in order to accentuate gene expression patterns as appose to
expression magnitudes. The 15 gene expression array vectors were clustered using k-means
clustering. Principle component analysis (PCA) was used to determine the components that
contain the greatest variance in the expression data[23, 24]. Once the 15 principle components
had been calculated, the k-means clustering algorithm was applied to the 15 principle
components and clustered into k groups. The average and variance of each projected coordinate
group was calculated to compose a group centroid. Centroid vectors were formed by combining
the three main principal components weighted by their projected centroid coordinate. The
uniqueness of each Group's expression patterns were evaluated by the Wilcoxon sign ranked
test.
3.4 Results
Effects of static compression: Cartilage disks were subject to 2, 8, 24, 32, and 48 hours
of compression applied in a ramp and hold fashion. The disks experience a peak stress when the
compression is applied, followed by a slow stress relaxation due to the poroelastic properties of
cartilage. The five time points were chosen to capture the kinetics of gene expression in repose to
the changes in stress. Twenty-four different genes were measured at each one of the five time
points and were normalized to 18s, a housekeeping gene, and 0% compression with no added
IGF-1 was used as a control. 8 of the 23 genes measured were up-regulated for 3 or more of the
time points examined. These included ADAM-TS5, MMP-13, MMP-3, TGF-p, c-Fos, c-Jun,
and Sox-9 (Figure 3.2, Appendix 3.8.1). Matrix metalloproteinase- 3 (MMP-3) was significantly
up-regulated at 8, 24, 32, and 48 hours with a peak expression level of 30-fold compared to
control at 32 hours (Figure 3.2A). ADAM-TS5 and MMP-13 displayed a transient increase in
expression levels peaking at 48 hours with >6-fold and >17-fold up-regulation respectively
(Figure 3.2B, Appendix 3.8.1). TGF-3 was consistently up-regulated 2.5-fold from 8 hours to 32
hours (Figure 3.2D). Supporting previously reported data[ 19], c-Fos and c-Jun were
significantly up-regulated in response to 50% static compression at all time points measured
(Appendix 3.8.1). Interestingly, c-Fos, c-Jun and Sox-9 were all maximized at 8 hours (23-fold,
30-fold, and 6.8-fold respectively) (Appendix 3.8.1). Displaying a transient decrease, IGF-1 was
the only gene measured that showed a significant down-regulation in the presence of 50% strain
for at least 3 of the measured time points. IGF-1 was significantly down-regulated by 50% at 24
hours and up to 70% at 48 hours (Appendix 3.8.1).
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Figure 3.2. Gene expression of proteinases, growth factors, and ECM molecules. 8 cartilage
disks were pooled for each time point for each experiment. All genes were normalized to 18s
and plotted relative to 0% compression 0 IGF-1. Significance was measured by the Wilcoxon
sign ranked test compared to 0% compression 0 IGF-1 (* p-value <0.07). Mean ± SE (n=4)
Effects of IGF-1: To examine the effect of IGF-1 on cartilage explants, disks were
incubated for 2, 8, 24, 32, and 48 hours with 300 ng/mL IGF-1 under 0% compression. 10 of the
23 genes were upregulated with the treatment of IGF-1. IGF-1 up-regulated for three or more
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time points, MMP-13, MMP-1, TNF-a, and IL-103, which traditionally are thought to play
catabolic roles in cartilage. MMP-13, TNF-a, and IL- 10 were significantly up-regulated and
peaked at 24 hours to the level of 8-fold, 2.5-fold, and 2.75-fold respectively (Figure 3.2B and
Appendix 3.8.1). MMP-1 and IGF2 were transiently up-regulated to a significant level until a 32
hour peak (4.75-fold and 3-fold respectively), after which expression levels returned to control
(Figure 3.21, 3.2E). Link and Aggrecan were also transiently up-regulated with a peak of 32
hours (4-fold and 2.5-fold respectively), but expression levels at 48 hours were still significantly
above control (Figure 3.2F, 3.2G). As in 50% static compression, Sox-9 was significantly up-
regulated at 8 hours to a comparable level of 6.3-fold (Appendix 3.8.1). TIMP-3 and HSP90
were significantly upregulated at all time points and both displayed an initial peak of expression
(5-fold and 3-fold respectively), followed by a transient decrease of expression over time (Figure
3.2C, Appendix 3.8.1). No genes measured were significantly down-regulated by the treatment
of IGF-1.
Effects of IGF-1 and static compression: Combining the treatment of 300 ng/mL of IGF-
1 and static compression to a level of 50% strain, 11 of the 23 genes were significantly different
than the 0% control for 3 or more time points. MMP-13, MMP-3, TGF-P, c-Fos, c-Jun, TIMP-3,
and HSP90 were significantly up-regulated in at least 3 of the measured time points. MMP-13
and MMP-3 were significantly upregulated 4 out of the 5 time points and had peak values of 28-
fold and 33-fold respectively at 24 hours (Figure 3.2B, 3.2A). TGF-3 and HSP90 were
transiently upregulated to a peak level of 3.8-fold and 2.25-fold respectively, at 32 hours (Figure
3.2D, Appendix 3.8.1). c-Fos and c-Jun were again significantly up-regulated for all time points
with expression peaks at 24 and 8 hours (Appendix 3.8.1). The peak value of c-Fos, 22-fold, was
similar to the expression levels found in 50% static compression alone. Alternatively, the peak
value of c-Jun had decreased from 30-fold under 50% static compression to 16-fold under 50%
static compression with IGF-1. TIMP-3 showed a slow increase of expression which peaked at
24 hours to a level of 19-fold, followed by an up-regulated level of 10-fold (Figure 3.2C). Co12,
IGF-2, TIMP-2, and TXNIP were significantly down-regulated for 3 or more time points
measured. IGF-2 and TXNIP showed a transient decrease of expression over time and bottomed
out at 48 hours decreasing 45% and 52% expression below control (Figure 3.2E, Appendix
3.8.1). Co12 and TIMP-2 were drastically decreased under 50% static compression with IGF-1.
Co12 was transiently down-regulated, decreasing expression levels by 43% at 24 hours, to 62% at
48 hours (Figure 3.2H). TIMP-2 was also transiently down-regulated, decreasing expression
levels by 50% at 24 hours and 92% at 48 hours (Appendix 3.8.1).
Comparing effects of IGF-1 under 0% and 50% compression: To elucidate the different
effects of IGF-1, the effects of IGF-1 were isolated by normalized gene expression to like
loading conditions. 50% static compression with IGF-1 was normalized by 50% static
compression, and 0% static compression with IGF-1 was normalized to 0% static compression.
When examining the effects of IGF-1 under non-loaded conditions (0% static compression), 9 of
the 23 genes were significantly altered for 3 or more time points by the addition of IGF-1. Under
loading conditions (50% static compression), 4 of the 23 genes were significantly altered for 3 or
more time points by the addition of IGF-1 (Appendix 3.8.2). Of the significantly affected genes,
aggrecan, IGF-2, and TIMP-3 were significantly affected by IGF-1 in both loaded and un-loaded
conditions (Figure 3.3). Aggrecan, IGF-2, and Link were all up-regulated when treated with
IGF-1 under un-loaded conditions, and down-regulated when treated with IGF-1 under loaded
conditions (Figure 3.3A, 3.3B, 3.3C). Aggrecan in particular was significantly up-regulated for
all time points by IGF-1 under un-loaded conditions, and significantly down-regulated for all
time points by IGF-1 under loaded conditions (Figure 3.3A). In contrast, TIMP-3 was up-
regulated significantly under both un-loaded and loaded conditions (Figure 3.3D). MMP-1 was
up-regulated significantly with treatment of IGF-1 under un-loaded conditions, but was
unaffected by the treatment of IGF-1 when loading conditions were present (Figure 3.3E).
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Figure 3.3. Effects of IGF-1. Gene expression was plotted normalized to like loading condition
in order to elucidate the effects of IGF-1 under compression or non-compression. Aggrecan (A)
and Link (C) respond to IGF-1 in a compression dependent manner, while TIMP-3 (D) and
Collagen II (F) respond to IGF-1 in a compression independent manner. Significance was
measured by the Wilcoxon sign ranked test compared to like compression 0 IGF-1. (* p-value
<0.07). Mean + SE (n=4)
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Expression Trends and Groupings: After normalization of the data, using principle
component analysis (PCA), the 15 dimensional space was reduced to a three dimensional space,
by calculating three eigenvectors or principle components that represent 80% of the variance in
the data. With three principle components, each standardized gene was projected in to the
principle component space and can be visualized as shown in figure 3.4. All 15 dimensions of
each gene were used in the k-means clustering technique to ensure that smaller gene variations
were represented in the grouping. After dividing the genes into 2 to 8 cluster groups and visually
comparing the distinctness of the groups, 5 groups appeared to be an adequate number of
groupings (Figure 3.4). These 5 groups contained 4 to 7 genes as shown in Table 3.3A. The
mean expression level is represented by a centroid (Figure 3.4) and the mean expression profile
of the 5 groups is shown in Figure 3.5. The centroids were shown to be significantly separated
by taking the euclidean distance between centroids and calculating the gene to centroid
variance[22]. (Table 3.2).
P-value of Centroid Centroid 1 Centroid 2 Centroid 3 Centroid 4Separation
Centroid 2 0.032
Centroid 3 0.017 0.034
Centroid 4 0.007 0.073 0.016
Centroid 5 0.001 0.015 0.006 0.042
Table 3.2. P-value of Centroid Profile Separation. P-values were obtained through student T-
test, comparing centroid to centroid Euclidean distance. Degrees of freedom were taken as the
number of genes in each group.
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Figure 3.4. Standardized gene expression visualized in principle component space. Principle
component 1, 2, and 3 represent 80% of the variance in the data. Genes were allocated to one of
five distinct groups by way of k-means clustering. Large solid black circles denote the centroid
of the corresponding group.
Group 1 was significantly upregulated for all conditions and all time points (Figure
3.5A). Under treatment of IGF-1, a 2-fold increase was observed at 24 hours and under loading
conditions a > 6-fold increase was observed at 24 hours as well. When combining the treatment
of IGF- 1 and compression, it appears the expression levels of IGF- 1 treatment dominate initially
(2 hours). At 24 hours there appears to be an additive effect of compression and IGF-1 treatment
as the combined compression and IGF-1 levels are about 9-fold. (>6 + 2). At 32 and 48 hours,
the effects of compression appear to dominate the effects of IGF-1 treatment. Group 2 under
treatment, compression, and compression with treatment, are initially significantly upregulated,
but return to control expression levels at 48 hours (Figure 3.5B). In both compression and
treatment conditions, group 2 responds strongly by reaching > 3-fold and 2.5-fold respectively.
When IGF-1 treatment and compression are combined, all significantly upregulated time points
(2-32 hours) in treatment and compression are reduced with a peak value of 2-fold. Under
treatment conditions, with a strong significant up-regulated for the first three time points,
(peaked at > 3.5-fold) group 3 appears to be strongly upregulated by IGF-1 (Figure 3.5C). Under
compression, group 3 has no significant initial changes, but at 48 hours in upregulated > 2-fold.
When combining compression and treatment all time points are reduced to control levels, apart
from 24 hours, which is still significantly upregulated, but reduced to 2-fold from > 3.5-fold in
treatment alone. Group 4 under IGF-1 treatment conditions is increasing significantly up-
regulated until 32 hours (2.5-fold) before it returns to near control levels at 48 hours (Figure
3.5D). Under compression conditions, group 4 exhibits a near opposite effect as in the treatment
conditions, by initially being up-regulated ( 3-fold), and decreasing over time to return to control
levels. Previous data has shown that Aggrecan, a member of this group, acts in a similar
expression profile with a initial upregulation with compression followed by a return to control
levels [19]. Combining compression and treatment, no time points are significantly different than
control, but artifacts of the initial peak at 2 hours from compression alone and peak at 32 hours
from IGF-1 treatment alone appear. Group 5 showed very little change under IGF-1 treatment
with a significant upregulation at 32 hours of 1.5-fold (Figure 3.5E). Under compression
conditions, group 5 was upregulated significantly at 2 and 8 hours with a peak of 1.6-fold, but by
24 hours until 48 hours was significantly decreasingly down-regulated to a minimum point at 48
hours, loosing greater than 50% expression compared to control. When combining compression
and IGF-1 treatment, all time points were lower than either compression or IGF-1 treatment
alone, and 24-48 hour were decreasingly down-regulated to a significant level, loosing greater
than 60% expression compared to control at 48 hours.
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Figure 3.5. Five expression profiles represent the combination of 0% compression 300 ng/ml of
IGF-1, 50% compression 0 ng/ml of IGF-1, and 50% compression 300 ng/ml of IGF-1. Centroid
profiles were calculated through the average projection coordinates of genes in each group, and
transformed from principle component space through use of the calculated principle components.
Mean ± SE (n varies based on group component number)
3.5 Discussion
To understand the transcriptional responses under different conditions, the 23 genes
observed were clustered according to IGF-1 treatment alone, 50% static compression alone, and
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the combination of static compression and IGF-1 treatment. Lastly, to understand a more global
view of transcriptional activity, all conditions and time points were clustered together. The
groupings assigned by clustering analysis can be seen in Table 3.3A. Looking at the groupings
under IGF-1 treatment alone, Link, type II collagen, and aggrecan which were significantly
upregulated, were grouped together, while TXNIP, thioredoxin interacting protein, the only
molecule that was significantly down regulated by IGF-1 treatment for multiple time points is
uniquely grouped (Table 3.3B). Groupings of compression alone isolate IL-6, highly non-
responsive to compression over the time course measured, in its own group. Transcription
factors, highly initially upregulated genes, were grouped together while transiently upregulated
proteinases were allocated to a different grouped, both of which support previous findings for
compression (Table 3.3C) [19]. Examining the combination of the treatments, Fibronectin was
partitioned to a unique group for its seemingly non-responsive behavior to compression and IGF-
1 treatment. The majority of proteinases were also grouped together (Table 3.3D). Looking at
all three sets of clusters, of note, MMP- 1 and IGF-2 were grouped together under the three
different conditions, as well as link protein, and the components of the AP-1 complex, c-Fos and
c-Jun. Type II collagen and IGF-1, TIMP-3 and MMP-3, Sox-9 and TIMP-1 were allocated in
the same group for all three conditions. Compiling all conditions observed into an expression
vector, cluster analysis revealed that all cytokines were grouped together, and were significantly
upregulated under IGF-1 treatment alone compared to controls. Under compression alone and
IGF-1 and compression experiments this extensive upregulation was not observed, suggesting
that IGF-1 has a stimulatory effect on cytokines which is mitigated when compression is present.
Also of note, Aggrecan, type II collagen, and link protein were all in separate groupings,
suggesting that there may be different mechanisms involved in the activation of these molecules.
Of the strongly upregulated group, transcription factors, growth factors, protease inhibitors, and
proteinases were grouped together, namely c-Fos, c-Jun, TGF-P, TIMP-3, MMP-3, MMP-13,
and ADAMTS-5.
Centroid Coordinates
Group Genes (PC1, PC2, PC3)
1 TGF-B, c-Fos, c-Jun, Timp-3, ADAMTS-5, MMP13, MMP3 (-2.46, 2.37, -0.33)
2 Sox-9, HSP90, Timp-1, Link (-3.10, 0.95, -0.07)
3 TNF-a, IL-1, IL-4, IL-6 (-2.78, -1.50, -0.94)
4 IGF-2, MMP1, Fibronectin, Aggrecan (-2.71, -0.24, 2.03)
5 IGF-1, Txnip, Timp-2, Collagen II (0.32, 3.21, -0.19)
B
Centroid Coordinates
Group Genes (PC1, PC2, PC3)
1 TGF-B, Sox-9, Timp-2, Timp-1, Fibronectin (-1.81, 0.93, 0.43)
2 Txnip (1.11,0.91, -1.55)
3 IGF-2, IGF-1, c-Jun, c-Fos, ADAMTS-5, MMP1, Link, Collagen II, Aggrecan (-2.05, 0.39, -0.25)
4 TNF-a, IL-6, IL-4, MMP13 (-1.48, -1.58, -0.22)
5 IL-1, HSP90, Timp-3, MMP3 (-2.03, -0.57, -0.05)
C
Centroid Coordinates
Group Genes (PC1, PC2, PC3)
1 IGF-1, Timp-2, Collagen II (0.44, 2.03, -0.13)
2 IGF-2, Txnip, MMP1, Fibronectin, Aggrecan (-1.41, 1.42, -0.48)
3 TNF-a, IL-4, IL-1, Timp-3, ADAMTS-5, MMP13, MMP3 (-1.92, 0.16, 0.56)
4 TGF-B, c-Jun, c-Fos, Sox-9, HSP-90, Timp-1, Link (-1.73, -0.86, -0.37)
5 IL-6 (0.59, -1.18, -1.76)
D
Centroid Coordinates
Group Genes (PC1, PC2, PC3)
IGF-2, MMP1
IL-6, IL-4, IL-1, Timp-3, ADAMTS-5, MMP13, MMP3
TGF-B, TNF-a, c-Jun, c-Fos, Sox-9, HSP90, Timp-1, Link
Fibronectin
IGF-1, Txnip, TIMP-2, Collagen II, Aggrecan
(-0.52, 0.62, -1.65)
(-1.88, -0.49, 0.14)
(-1.88, 0.62, 0.05)
(1.34, -1.62, -0.59)
(1.77, 0.70, 0.14)
Table 3.3. Gene clustering groupings. Resulted gene sorting according to extent and kinetics of
expression. Specific gene allocation and centroid coordinates when all data are clustered (A),
0% compression 300 ng/ml IGF-1 data clustered (B), 50% compression 0 IGF-1 data clustered
(C), and 50% compression 300 ng/ml IGF-1 data clustered (D).
With the 4 different sets of data clustered, (compression, IGF-1, compression + IGF-1, all
conditions) three interesting pairings were always present: MMP-1 and IGF-2, TIMP-3 and
1
2
3
4
5
ADAMTS-5, type II collagen and IGF-1. MMP-1 or collagenase-1 is shown to cleave key ECM
molecules including collagen I, collagen II, aggrecan (at the MMP cleavage site in the
interglobular domain), fibronectin, and link protein [25]. MMP-1 has been shown to play a role
in the regulation of paracrine signals, through the degradation of cytokines such as IL-10 [26].
Collagenase-1 has also been shown to degrade insulin-like growth factor binding proteins
(IGFBP) 3 and 5, which indirectly increases presence of free (unbound) IGF [27, 28]. IGF-1 and
IGF-2 are known to bind IGFBP-3, the most abundant IGF binding protein in human serum [29].
IGF-2 is known to stimulate DNA and proteoglycan synthesis in chondrocytes [30] and has been
shown to act in an autocrine fashion [31]. IGF-2 has also been shown to stimulate type 1 IGF
receptor, a key receptor for IGF-1 and also IGF-2 with lesser affinity [32, 33]. The co-
expression of MMP- 1 and IGF-2 suggests that the two contain each other through their anabolic
and catabolic activities and have the capability of a strong anabolic response, due to the
stimulatory secondary effects of MMP-1.
TIMPs act in a stochiometric fashion to reversibly inhibit metallo-proteinases [34]. Of
the four known TIMPs (1-4), TIMP-3 has been shown to be a strong inhibitor of Aggrecanase-1
(ADAM-TS4) and Aggrecanase-2 (ADAM-TS5) with Ki values in the subnanomolar range [35,
36]. When added exogenously to bovine nasal and porcine articular cartilage, TIMP-3 retains
the ability to inhibit aggrecanase activity induced by catabolic factors [37]. In the current study,
TIMP-3 is shown to be significantly upregulated with the addition of IGF-1, and acts in a
compression independent manner (Figure 3.3). Although Aggrecan can be degraded by multiple
members of the matrix metalloproteinase family, it has recently been shown that ADAMTS-5 is
the primary aggrecanase responsible for aggrecan degradation in a murine model of osteoarthritis
[38]. The constant grouping based on expression profile of TIMP-3 and ADAMTS-5 suggests a
biological control may present to ensure the turn over of aggrecan and the regulation of anabolic
and catabolic factors. Supporting these ideas, past clustering analysis with cartilage under
multiple conditions also grouped ADAMTS-5 and TIMP-3 together [19].
Type II Collagen, a key matrix protein, adds structure and strength to articular cartilage.
IGF-1 has been shown to elevate levels of type II collagen under a number of different
conditions [3, 10]. The co-expression of type II collagen and IGF-1 under compressive and/or
IGF-1 treated conditions suggests a positive feedback loop between IGF-1 and type II collagen.
Under IGF-1 treatment both are upregulated, while under compression, both are down regulated.
This supports previous data suggesting that IGF-1 acts in an autocrine fashion [1, 32]. Further
studies using promoter analysis must be performed to confirm if these pairings are co-expressed
or if these results are an artifact of the selected genes measured.
In contrast with previously published reports [3, 10, 11], the current results show only a
slight upregulation of type II collagen in response to IGF-1 alone, compared to a significant
upregulation (Figure 3.2H). A possible explanation for the discrepancy in the magnitude of type
II collagen expression induced by IGF-1 was the 0% compression control present in the current
study, where free swell conditions were used in previously published studies. Aggrecan was
previously shown to have no significant change in the first 48 hours [3], which this study
supports (Figure 3.2F). Previously published data show that MMP-1, MMP-3, and MMP-13
were unaffected by the addition of IGF-1 after 48 hours, while the current data suggests a
significant increase for 4 out of the 5 time points in MMP-1 and MMP-13 (Figure 3.21, 3.2B).
Again, reasons for this discrepancy may be due to the 0% static compression present during IGF-
1 treatment. IGF-1 mRNA levels were maximum at 32 hours (Appendix 3.8.1), where previous
studies reported them to peak at 24 hours [1]. Nixon et al. examined time points at 0, 4, 14, 24,
48, and 72 hours, thus finding a maximum of 32 hours is not in direct contradiction to the
previously published finding. Sox-9 expression was shown to be significantly upregulated by
IGF-1 at 4 of the 5 measured time points (2, 8, 32, 48), which previously was shown to be
unresponsive to IGF-1 at 72 hours (Appendix 3.8.1). Many differences in the two experiments
exist possibly explaining the difference in IGF-1 response, i.e., bovine vs. human, young tissue
vs. old tissue, explant tissue vs. monolayer, 300 ng/mL IGF-1 vs. 100 ng/mL IGF-1.
In agreement with previously published data [13, 15, 18, 19], under static compression, type II
collagen and aggrecan were initially upregulated and then down regulated to nearly control
levels (Figure 3.2H, 3.2G).
Examining the transcriptional effects of IGF-1 on aggrecan and link, IGF-1 appears to act
via a compression-dependent manner (Figure 3.3A, 3.3C), whereas the transcriptional effects of
IGF-1 on collagen II and fibronectin appear to be independent of compression (Figure 3.3F,
Appendix 3.8.2). This phenomenon could easily be explained by the compacted ECM present
under compression, dramatically restricting transport of IGF-1 to chondrocytes. To test this idea,
experiments were performed allowing IGF-1 to be incubated for 24 hours (transport studies
performed by Bonassar et al. [5]), to allow IGF-1 to diffuse completely into the cartilage explant.
Results of this experiment replicate the trends seen in Figure 3.3A, 3.3C, suggesting that
aggrecan and link act in a compression-dependent manner when treated with IGF-1. Whether
this change is due to decreased receptor-ligand affinity, or to mechanotransduction intracellular
signaling interference, remains to be determined.
A Aggrecan Protein B Aggrecan Gene
1.5
1-
0.5 -
0-
0 Synthesis
I
U50-o Comp
4
3
2
1
0
0 IGF 300 IGF 300 IGF 0 IGF 300 IGF 300 IGF
12hr 4hrOl8hr I-24hr948hr 12hrj 8hrE124hrL132hrj48hr
Figure 3.6. Aggrecan Protein Synthesis compared to Aggrecan Gene Expression. (A) Aggrecan
protein synthesis as measured by 35S radiolabel incorporation normalized to 0% compression 0
IGF-1 adapted from Bonassar et al [5]. Mean plotted. (B) Aggrecan gene expression
normalized to 18s and plotted relative to 0% compression 0 IGF-1. Significance was measured
by the Wilcoxon sign ranked test compared to like compression 0 IGF-1. (* p-value <0.07).
At the transcriptional level, the current study points out the anabolic response due to the
treatment of IGF-1 under 0% compression loading, and the mixed anabolic and catabolic signals
under 50% static compression coupled with IGF-1. To further investigate the transcriptional
response to the protein synthesis under IGF-1 treatment and compression, Figure 3.6 shows the
levels of aggrecan protein synthesis, normalized to 0% compression 0 IGF-1 compared to gene
expression of aggrecan. Aggrecan gene expression under 0% compression, 300 ng/ml IGF-1 is
upregulated compared to control for all 5 time points measured (Figure 3.6B). Examining the
corresponding aggrecan protein level at 0% compression, 300 ng/ml IGF-1, there is a strong
increase in aggrecan synthesis at 8, 24, and 48 hours (Figure 3.6A). These data suggest that
aggrecan synthesis is transcriptionally regulated by IGF-1. Examining the gene expression of
aggrecan under 50% compression 0 IGF-1, there is an initial bolus of transcript at early time
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points, followed by a return to control levels (Figure 3.6B). Examining the protein synthesis
levels of aggrecan, at the same early time points, aggrecan synthesis is reduced below control
and this reduction is sustained for all time points measured, suggesting that the inhibition of
aggrecan synthesis by compression, with no IGF-1, is not transcriptionally regulated (Figure
3.6A). Thus, in attempts to reconcile the responsiveness of aggrecan under 50% static
compression at the translational level with the unresponsiveness of aggrecan at the
transcriptional level, the authors support the hypothesis [4] that under static compression,
proteoglycan synthesis is regulated through post-transcriptional machinery.
3.6 Conclusion
Experiments have been performed to assess expression levels of a range of ECM related
genes in response to static loading in the presence and absence of IGF-1. Through k-means
clustering analysis, major co-expression trends were elucidated, grouping genes into highly
responsive, non-responsive, and differentially active gene profile groups. The gene pairs MMP-
1 and IGF-2, TIMP-3 and ADAMTS-5, and type II collagen and IGF-1 were consistently co-
expressed in multiple clustering conditions, suggesting the possibility of strong regulation and
control relationships between members of each pair. Aggrecan and link protein responded to
IGF-1 in a compression-dependent manner, whereas type II collagen and fibronectin appeared to
respond to IGF-1 in a manner independent of compression. While aggrecan transcripts were
significantly upregulated with the addition of IGF-1 under 0% compression, IGF-1 was unable to
upregulate aggrecan when the cartilage explants were statically compressed to 50% strain. In
comparing aggrecan gene expression to aggrecan synthesis, these data suggest that aggrecan
synthesis is transcriptionally regulated by IGF-1 while the inhibition of aggrecan synthesis by
compression is not transcriptionally regulated. However, more studies are needed to elucidate the
specific stimulatory mechanism(s) induced by IGF-1 and the post-transcriptional inhibitory
effects of compression.
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Chapter 4
Influence of OP-1 and IGF-1 on Cartilage Subjected to
Combined Mechanical Injury and Co-culture with Joint
Capsule
* This chapter is a manuscript in preparation for submission
(Wheeler, Cameron A., Wilkinson, Samuel, Perez, Anthony R., Kurz, Bodo, and Grodzinsky,
Alan J.)
4.1 Introduction
Osteogenic Protein-i (OP-1), or Bone Morphogenetic Protein-7 (BMP-7), is a potent
growth factor and belongs to the TGF-3 super family [1]. Bone morphogenetic proteins have a
variety of effects on biologic activity, including: cell proliferation, apoptosis, differentiation,
migration, embryogenesis, development, and supporting tissue homeostasis [1-3]. For the past
30 years, studies have been compiled and therapeutics have been developed documenting and
exploiting the effects of OP-1 and BMPs on bone formation [4]; for the past ten years, studies
have shown the possible use of this growth factor in cartilage [5]. OP-1 is found in many tissues,
and was recently found to be expressed in articular cartilage [6-8]. The apparent advantage of
OP-1 over other members of the TGF-3 family for the treatment of cartilage pathologies is the
ability of OP-1 to upregulate chondrocyte metabolic activities and proteoglycan synthesis while
avoiding uncontrolled cell proliferation and differentiation [5, 8-10]. Studies have shown that
OP-1 stimulates key extracellular cartilage proteins such as collagen type II, VI, aggrecan,
decorin, fibronectin, hyaluronan, and superficial zone protein (lubricin) [5, 11-14] while others
have shown that OP-1 has little stimulatory effect on gene expression [15]. OP-1 also stimulates
proteoglycan synthesis in osteoarthritic and non-osteoarthritic chondrocytes [16]. In addition to
stimulating key extracellular matrix (ECM) molecules, OP-1 has been shown to modulate
various growth factors, i.e., IGF-1, TGF-P, BMPs, and cytokine mediators (IL-6 family of
cytokines) [17]. OP-1 has also been able to regulate synthesis of chondrocyte cytoskeleton
proteins such as talin, paxillin, and focal adhesion kinase (FAK) while enhancing expression of
tissue inhibitor of metalloproteinases (TIMP) in human normal and OA chondrocytes [8]. OP-1
has been linked to cell survival [ 10-12] and appears to act in a distinct regulatory pathway
independent of other growth factors, including IGF-1, while augmenting IGF- I1 anabolic effects.
OP-1 has been reported to increase levels of IGF-1, IGF-1 receptor, and IGF-1 binding proteins,
and authors speculate that this augmentation acts to restore in part the responsiveness of adult
human chondrocytes to IGF-1 lost through aging [9, 10, 17, 18]. IGF-1 has also been well
documented in its anabolic effects on cartilage tissue [19-21 ], and OP- combined with IGF-1
has shown a synergistic effect on cell survival and matrix synthesis, hinting at the use of both
OP- and IGF- 1 in combination therapy [11]. Interestingly, recent studies have shown that the
effects of the combination of these two potent growth factors can be reversed with the addition of
basic fibroblast growth factor (bFGF or FGF-2); proteoglycan synthesis induced by OP-1 and
IGF-1 either independently or together were strongly inhibited by bFGF [12]. Acting in an anti-
catabolic fashion, OP-1 has been shown to effectively counteract the effects of IL-113 treatment
[22], as well as harmful fibronectin fragments [23] and HA hexasaccharides [24]. Studies have
also shown that OP- blocks gene expression of MMP- 1 and MMP- 13 in response to cytokine
treatment [17].
Endogenous OP-1 is also very important to cartilage homeostasis. Normal adult human
cartilage tissue contains approximately 50 ng of OP-1 per gram of dry tissue, which is within the
concentration range of recombinant OP-1 (50-200 ng/ml) used in various studies [9]. OP-1 has
also been detected in synovium, ligament, tendon, menisci [18], and synovial fluid from normal,
OA, and RA joints [25]. Recent studies have shown that through a gene silencing technique
(antisense) in which OP-1 was inhibited, there was a significant decrease of aggrecan mRNA
expression and a -50% decrease in proteoglycan synthesis. Recovery experiments with the
addition of recombinant OP- were able to partially restore proteoglycan production [25].
Showing an anabolic response to injury, active OP-1 was highly elevated in response to a
capsular incision in a rabbit model [26].
OP-1 has been suggested to aid long-term healing of cartilage defects [27] and has been
recently used in a reparative fashion in horses, sheep, goats, and rabbits. OP-1 was put on an
adenoviral vector and delivered to a focal chondral defect via transfected allogenic chondrocytes
in a horse model [28]. The defects seeded with chondrocytes enhanced with the OP-1 vector
showed significantly better healing at four weeks post injection and more hyaline-like
morphology. Recent data from rabbits subjected to an ACL transection showed that OP-1 had a
protective effect on cartilage degradation [29], and in goats OP-1 has been shown to promote
cartilage formation in subchondral defects [30]. OP-1 also prevented post-traumatic
osteoarthritis in a sheep model when intra-articular injections were administered at time of
mechanical injury and one week post injury [31].
An in vitro model of injury has been established in our laboratory incorporating the
effects of a mechanical injury and injured joint capsule (JC) tissue [32, 33]. In vitro mechanical
injury to cartilage alone has been shown to increase hydraulic permeability [34] and water
content [35-37], decrease stiffness [36, 38], and increase glycosaminoglycan (GAG) lost to the
medium [36, 39-41]. Cells with cartilage subject to this mechanical injury have been shown to
decrease biosynthesis rates [36], undergo apoptosis and necrosis[35, 36, 42, 43], and have
elevated levels of protease transcript activity within the first 24 hours [44]. Co-culturing un-
injured cartilage with damaged joint capsule in vitro has resulted in a decrease in cartilage
biosynthesis rates [32, 45], as well as a loss of proteoglycan and collagen as seen though
histology staining [46]. GAG release from cartilage co-cultured with synovial or capsular tissue
was not decreased with the inhibition of IL-10, TNF-a, and ACITIC [47]. Under the same
conditions of cartilage co-cultured with joint capsule, GAG loss was blocked by treatment with
EDTA [47]. While the effects of JC co-culture appear to accelerate degradation, studies have
also shown that synoviocytes from joint capsule tissue provide chondrocytes with protection
against reactive oxygen species, which are known to induce membrane damage and lipid
peroxidation [48].
The objectives of this study was to (1) more fully explore the degradative effects of
mechanical injury co-cultured with excise joint capsule through changes in transcript levels,
protein biosynthesis rates, and apoptosis, and (2) to test whether combined treatment with IGF-1
and OP-1 could mitigate those degradative effects on a short time scale (3 days) and a longer
time scale (16 days).
4.2 Materials and Methods
Tissue Harvest
Cartilage-bone plugs (9mm in diameter) were harvested from the patello-femoral groove
of 1-2 week old calves. Cartilage disks (lmm thick x 3mm diameter) were sliced and punched
from the middle zone as described previously[49] and equilibrated for two days under free-swell
conditions (37°C, 5% CO 2) in the presence of serum-free, 1% ITS supplemented feeding
medium consisting of high glucose Dulbecco's modified essential medium supplemented with 10
nM Hepes Buffer, 0.1 mM nonessential amino acids, 20 ýtg/ml ascorbate, 100 units/ml penicillin,
100 ýtg/ml streptomycin, and 0.25 ýtg/ml amphoericin B. Joint capsule was excised adjacent to
the medial and lateral femoral condyles, cut into approximately 5mm x 5mm squares, and
equilibrated for two days (37°C, 5% CO 2). Each section of JC included a section of synovial
tissue and was approximately 0.5mm thick.
Injury
After two days of equilibration, disks were allocated into 1 of 8 conditions: (1) free swell,
(2) normal cartilage co-cultured with JC (Co), (3) cartilage mechanically injured, and (4) injured
cartilage co-cultured with joint capsule (INJ+Co), (5-8) conditions (1)-(4) repeated with addition
of growth factors (100ng/ml OP-1 + 300ng/ml IGF-1) throughout culture duration. Growth
factor concentration was determined through dose-dependent measure of OP-1 and IGF-1
independently, as previously presented [50]. A custom designed incubator-housed loading
apparatus [51] was used to compress cartilage disks. Each cartilage disk designated for
mechanical injury was loaded individually in a polysulfone chamber allowing for radially-
unconfined compression [36, 39, 40]. Cartilage disks were measured for height, compressed to a
final strain of 50% at a velocity of 1mm/sec, and promptly removed and placed in fresh culture
media as described previously [44]. Application of this strain and strain rate produced a peak
stress on the order of 20MPa. Three to five pieces (to ensure equal amounts of JC tissue) of cut
joint capsule were added to Co and INJ+Co conditions.
Short and Longer Term Gene Expression Time Courses
Short Term: Due to the limited amount of cartilage available in young bovine knee joints,
experiments were divided into three distinct groups, each containing a control (FS) and control
plus treatment (FS+GF). The three experiments consisted of 4 conditions each; all contained FS
and FS+GF, the first consisted of Co and Co+GF, the second of INJ and INJ+GF, and the third
of INJ+Co and INJ+Co+GF. At time = 0 plugs were injured or treated as prescribed, incubated
at 370 C, 5% CO2, and flash frozen in liquid N2 at 2, 8, 24, 48, and 72 hours, and placed in -80'C
(medium changed every 48 hours). Each of the time point-conditions in the three experiments
contained 6 cartilage disks which were pooled and purposely matched across depth, location, and
time to prevent any bias in the results. Joint capsule was also flash frozen in liquid nitrogen at 2,
8, 24, 48, and 72 hours for the Co and Co+GF experiment. Longer Term: To examine gene
expression for longer periods of time, in a separate experiment, cartilage disks were subjected to
the same 8 conditions and were cultured for 1, 4, 8, and 16 days, whereupon the plugs were flash
frozen in liquid N2 and stored in -80'C (medium changed every 2 days). The shorter term gene
expression experiment was repeated six times, using six different animals for each of the three
experiments for an n=6. The longer term gene expression experiments were repeated five times,
for an n=5.
RNA Extraction and Quantization, Primer Design, and Real-Time PCR
6 disks for each time point and condition were taken from the -80o C freezer and
pulverized. In order to prevent RNA degradation, the pulverizing apparatus was constantly
cooled using liquid nitrogen. Trizol (Sigma, MO) was added and the tissue was thoroughly
homogenized. After chloroform was added, the mixture was transferred to pre-spun phase gel
tubes, and spun at 13,000 rpm for 10 minutes at 40 C. The supernatant was removed, and RNA
was extracted using Qiagen RNAeasy mini kit protocol with recommended DNase digest
(Qiagen). RNA was stored in 50 ld of RNase free water under -80o C conditions. RNA
abundance and purity was measured using NanoDrop ND-1000 (NanoDrop Technologies, DE)
with abundance ~80ug/ml and purity -2 (260nm/280nm). 1 pg of RNA was reverse transcribed
using Applied Biosystems reagents as previously described [44]. Forward and reverse primers
for 48 relevant genes (Table 4.1) were designed using Primer3 Software
(http://fokker.wi.mit.edu/primer3/input.htm) and Primer Express (Applied Biosystems, CA)
based on bovine genomic sequences, and standard curves were calculated as previously
described [52].
Table 4.1. List of Cartilage relevant genes measured by qPCR
ECM ECM Proteases Protease Inhibitors Transcription Factors Growth Factors
Aggrecan Link MMP-1 TIMP-1 SOX-9 IGF-1
Collagen II CD-44 MMP-3 TIMP-2 c-Fos IGF-2
Collagen IX HAS2 MMP-9 TIMP-3 c-Jun OP-1
Collagen XI COMP MMP-13 bFGF
Fibromodulin 3-actin ADAMTS-1 TGF-0
Fibronectin ADAMTS-4 VEGF
Decorin ADAMTS-5
Assorted Genes Cytokines Oxidation Genes Stress Induced Genes Housekeeping Gene
Cox-2 LIF ALPL TXNIP 18s
iNOS IL-13 SOD1 HSP90
Osteocalcin IL-4 SOD2
Caspase-3 IL-6 GPX-3
TNF-a
IL-6R
Table 4.1 List of 48 cartilage relevant genes measured by qPCR. Primer3 and Primer Express
were used to design primers. Standard dilutions were used to calculate relative mRNA copy
number.
Once cDNA was obtained, Real-Time PCR was performed using Applied Biosystems ABI
7900ht instrument and SYBR Green Master Mix (SGMM, Applied Biosystems, CA). SGMM
was combined with cDNA, and RNase free water was combined with forward and reverse
primers. Using a multi-pipette, 8 different samples of cDNA and SGMM were aliquoted into a
384 well plate, followed by 48 different primer and water mixes. Plates were run and inspected
for proper amplification and melting curves using SDS 2.3 (Applied Biosystems, CA).
Measured threshold values (Ct) were obtained through SDS 2.3 and converted to RNA copy
number according to previously calculated primer efficiencies using standard curves.
Protein Biosynthesis
Radiolabel incorporation was measured at days 1, 4, 8, 12, and 16 post-injury. Bovine
explants were cultured in fresh media 24 hours prior to 1, 4, 8, 12, and 16 days in 5 jtCi/ml 35SO4
and 10 jtCi/ml 3H-proline. After culture, cartilage explants were washed four times over 60
minutes in lml phosphate-buffered saline (PBS) supplemented with 0.8 mM sodium sulfate and
0.5 mM proline to remove free radiolabel, and digested in 1 ml protease K solution (100 pg/ml in
SO mM Tris-HCI and 1 mM CaClz at pH 8) at 60 0C for 12-18 h. Digested explants were
homogenized in Optiphase Supermix scintillation fluid and measured using a Microbeta plate
reader.
Apoptosis
At 1, 4, 8, and 16 days post-injury, disks were fixed in 4% paraformaldahyde
supplemented with 0.1% 1M NaOH as previously described [42]. In brief, disks were embedded
in Paraplast, cut into serial sections (7ýtm), and sectioned sagitally throughout the entire
thickness of the disk. Sections were immobilized on glass slides and stained with Mayer's
hematoxylin to quantify the percentage of cells showing nuclear blebbing. Each explant was
evaluated in 3-5 sections, as previously described [42]. Since cutting of the explants induces
apoptosis at the edges of the tissue, the margins of the sections (-150itm thickness) were
excluded. Using a Zeiss Axiophot microscope (Zeiss, Wetzlar, Germany) with a 40x objective,
positive and negative cells were counted in 3 optical fields in each section (60-100 cells/field).
One optical field was located in the center of the explant sections and 2 were located more
peripherally, near the corners of the sections (but not including the margins). The mean value
from each field was recorded. In a secondary analysis, cell apoptosis rates in the central and
peripheral fields were compared. Encoded labels were used on all samples to ensure blind
scoring.
Gene Expression Data Analysis
All data are shown as mean ± SEM. Under each condition and time point, each gene
RNA copy number was normalized to the 18s housekeeping gene from that same condition and
time point [44, 52]. 18s was chosen in light of recent studies showing the variation in expression
of alternative housekeeping genes (i.e., GAPDH, f3-actin) in response to certain conditions of
loading of cartilage explants [53]. To examine the time course of gene expression, all conditions
were normalized to their corresponding free swell condition. Thus, gene expression values
below or above 1 represent a decrease or increase in expression, respectively, compared to FS.
Expression levels due to experimental error, as defined by 60 from mean, were removed. The
Wilcoxon sign-ranked test (a non-parametric test which incorporates the amount of data in the
significance statistic and avoids the assumption of a parameter-based distribution) was used to
judge significance at a p-value less than 0.05. Clustering and Principle Component Analyses: In
addition to measuring changes in the expression magnitude of each gene, we further explored
patterns of co-expression using principle component analysis (PCA) and clustering analysis,
performed on all normalized conditions (fold change compared to FS) and time points (2, 8, 24,
48, 72 hours, short term and 1, 4, 8, 16 days, long term) over 47 genes. This resulted in a 35 x 47
(short term) and a 28 x 47 (long term) matrix which were each standardized by expression
amplitude as described previously [52]. After normalization of the data using PCA, the maximal
dimensional space was reordered according to greatest dimensional variance, where the first
three detentions or principle components represent -70% of the variance in the data [54, 55].
Once the principle components had been calculated, a k-means clustering algorithm was applied
to cluster the components into k groups. The average and variance of each projected coordinate
group was calculated to give the group centroid. Centroid vectors were formed by combining the
three main principal components weighted by their projected centroid coordinate. The
uniqueness of each group's expression patterns was evaluated by the Wilcoxon sign-ranked test,
and special separation between the centroids was measured and deemed significant through
euclidean distance and student's t-test.
Biosynthesis and Apoptosis Data Analysis
All data are represented as mean ± SEM. A three-way analysis of variance was used to
test significant differences in biosynthesis data. P-values less than 0.05 were considered
significant.
4.3 Results
Short Term Cartilage Gene Expression
Matrix Molecules: Key ECM molecules were downregulated over the three-day period
under the in vitro injury model. Uninjured cartilage co-cultured with excised joint capsule
significantly downregulated Aggrecan (Figure 4.1A), Collagen IX (Figure 4.1B), Collagen XI,
Fibromodulin, and HAS2 in a transient manner (Appendix 4.7.1).
Figure 4.1 Aggrecan and Collagen IX gene expression
A Aggrecan B Collagen IX
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Figure 4.1 Aggrecan and Collagen type IX short-term gene expression. Data was plotted
relative to FS conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean ± SEM. Time points: m 2 Hrs, 0 8 Hrs, 17 24 Hrs, lO 48 Hrs, Q
72 Hrs.
At 72 hours, gene expression reached below 0.5 FS values (Aggrecan 0.36, Collagen IX 0.11,
Collagen XI 0.19, Fibromodulin 0.18, and HAS2 0.30). While Aggrecan, Collagen XI,
Fibromodulin, and HAS2 showed slight downregulation with INJ and INJ+Co, Collagen IX was
significantly downregulated when mechanical injury was present, with or without Co.
Fibronectin, Decorin, and CD-44 were significantly upregulated under the injury models, and
were most responsive to INJ+Co; reaching maximal values of 4.8-, 4.8-, and 16.6-fold FS values
respectively (24hrs) (Appendix 4.7.1). Collagen II was significantly downregulated with INJ
alone and INJ+Co but was unaffected with co-culture alone (Appendix 4.7.1). Link Protein,
Osteocalcin, and COMP were slightly upregulated with INJ alone, downregulated with co-
culture alone, and no different than FS with INJ+Co (Appendix 4.7.1). 3-actin was generally
unresponsive to the injury models and GF treatment (Appendix 4.7.1). Aggrecan was
significantly upregulated when GF was added under FS conditions (Appendix 4.7.2).
Fibromodulin was significantly upregulated at 2hrs, followed by a significant downregulation at
8, 48, and 72 hrs. Collagen II, Collagen IX, Collagen XI, Fibronectin, Decorin, Link, CD-44,
HAS2, Osteocalcin, and COMP were not dramatically altered by GF treatment under FS
(Appendix 4.7.2). Treatment of the GF combination had no effect on Aggrecan, Collagen II,
Collagen IX, Collagen XI, Fibromodulin, Fibronectin, Decorin, Link, CD-44, and Osteocalcin
under INJ, Co, or INJ+Co, and appeared to marginally upregulate HAS2 and COMP under the
same three injury conditions (Appendix 4.7.2).
Proteinases: MMP-3 (stromelysin) was significantly upregulated for 2, 8, 24, and 48 hrs
under Co alone, INJ alone, and INJ+Co and returned to FS levels at 72 hrs (Appendix 4.7.1).
INJ+Co facilitated the greatest fold upregulation (47x 8hrs) compared to co-culture alone (23x
24hrs) and injury alone (16x 8hrs). In a like manner, MMP-9 and MMP-13 were maximally
expressed with INJ+Co (Figure 4.2A, Appendix 4.7.1). MMP-9 and MMP-13 were transiently
upregulated and both peaked at the last time-point measured (72hrs). MMP-9 was significantly
upregulated at 8, 24, 48, and 72 hrs and peaked at 47x FS, while MMP-13 was significantly
upregulated at 24, 48, and 72 hrs and peaked at 46x FS.
Figure 4.2 MMP-9 and TIMP-1 gene expression
A MMP-9 B TIMP-1
Figure 4.2 MMP-9 and TIMP-1 short-term gene expression. Data was plotted relative to FS
conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean ± SEM. Time points: 1 2 Hrs, m 8 Hrs, 0 24 Hrs, O 48 Hrs, 2
72 Hrs.
MMP-1 was slightly upregulated with INJ+Co, but was unaffected by Co and INJ alone
(Appendix 4.7.1). Growth factors appeared to stimulate MMP-9 expression by nearly doubling
expression under INJ, (35x to 95x) and INJ+Co (47x to 74x) (Appendix 4.7.2). MMP-3 and
MMP-13 showed a slight decrease in expression levels when GF was added to INJ+Co, but were
unaffected by GF under all other culture conditions (Appendix 4.7.2). MMP-1 was not clearly
regulated by GF treatment for all conditions (Appendix 4.7.2). All matrix metalloproteinases
showed little to no response to GF treatment under FS conditions. ADAMTS-1 was highly
responsive to INJ (40x 8hrs) and INJ+Co (58x 24hrs) but showed little significant difference
with Co alone (Figure 4.3A).
Figure 4.3 ADAMTS-1 and iNOS gene expression
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Figure 4.3 ADAMTS-1 and iNOS short-term gene expression. Data was plotted relative to FS
conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean + SEM. Time points: m 2 Hrs, m 8 Hrs, O 24 Hrs, OE 48 Hrs, 1i
72 Hrs.
ADAMTS-4 was upregulated under Co, INJ, and INJ+Co, but again, the combination of INJ+Co
served as the most stimulant (Appendix 4.7.1). ADAMTS-5 appeared to be unresponsive to INJ
or Co alone, but the combination of the two lead to a synergistic transient increase of expression,
peaking at 14x FS (Appendix 4.7.1). Growth Factor treatment increased expression of
ADAMTS-1 and ADAMTS-5 (Appendix 4.7.2). ADAMTS-1 expression was increased at 8hrs
for both INJ (40x to 90x) and INJ+Co (49x to 81x) (Figure 4.3A and Appendix 4.7.2).
ADAMTS-5 retained the transient upregulation, as seen in the absence of GF, and reached values
of 18x FS. ADAMTS-4 showed a slight increase with GF treatment in magnitude of expression
for Co, INJ, and INJ+Co (Appendix 4.7.2).
TIMPS: TIMP-1, a general inhibitor of protease activity, was upregulated for INJ and Co
alone, but was significantly upregulated when the two were combined (INJ+Co) (Figure 4.2B).
Under this condition, TIMP-1 reached a maximum of 61x FS values at 24hrs. To a lesser effect,
TIMP-2 was stimulated by INJ, Co, and INJ+Co, and like TIMP-1 was maximally stimulated
under INJ+Co (5.7x FS) at 24hrs (Appendix 4.7.1). TIMP-3, an inhibitor which binds at high
affinity to ADAMTS-4, was also maximally stimulated at 24hrs, and in the combination of
INJ+Co, reached values 15x greater than FS condition (Appendix 4.7.1). GF treatment had little
effect on the TIMPS measured under FS conditions. While the changes in GF treatment were on
the same order of magnitude as without GF treatment, it appeared that the addition of GF slightly
stimulated all three TIMPS under the conditions of Co, INJ, and INJ+Co (Appendix 4.7.2).
Transcription Factors: c-Jun and c-Fos, both members of the AP-1 complex, were both
initially highly responsive to INJ and INJ+Co, but decreased over the time course (Appendix
4.7.1). After 2hr, c-Jun in INJ (23x) and INJ+Co (25x) returned to FS values and was not
responsive to Co alone. Alternatively, c-Fos was significantly upregulated for all time points
under INJ (transiently decreasing, 13x to 2x) and significantly upregulated for the first 48 hrs
(transiently decreasing, 19x to 8x) for INJ+Co. Sox-9 showed little response to Co, INJ, or
INJ+Co (Appendix 4.7.1). GF had little effect on expression of transcription factors measured
(Appendix 4.7.2).
Enzyme Mediators: Inducible Nitric Oxide Synthase (iNOS) was highly regulated when
Co was present (Figure 4.3B). In Co alone, iNOS expression peaked at 24hrs at a magnitude of
over 2000 times greater than FS values. iNOS was transiently upregulated under INJ+Co
peaking at 69x at 72hrs. INJ alone showed little effect on the production of iNOS. GF treatment
was effective in significantly lowering the transcript levels of iNOS under Co alone (2140x to
120x at 24hrs) but did not effect expression under INJ+Co (Figure 4.3B, Appendix 4.7.2). Cox-
2 was significantly induced by Co and INJ+Co at early time points, reaching levels of 42x (Co)
and 50x (INJ+Co), followed by a return to free swell levels at 72hrs (Appendix 4.7.1). GF
showed little difference in Cox-2 expression, with the exception of a slight decrease in
expression under INJ+Co (Appendix 4.7.2).
Growth Factors: IGF-2 showed sustained significant downregulation for INJ alone,
while IGF-1 was predominantly unaffected by Co, INJ, and INJ+Co (Appendix 4.7.1). OP-1 and
VEGF were significantly upregulated at 24 hrs in response to Co alone at magnitudes of 24x and
9x respectively (Appendix 4.7.1). Both were marginally upregulated by INJ alone, and
upregulated slightly with INJ+Co. bFGF and TGF-3 were upregulated for all conditions and
both were maximally expressed at 24hrs under INJ+Co (17x and 1lx respectively) (Appendix
4.7.1). GF treatment had little to no effect on IGF-1, IGF-2, bFGF, and TGF-P (Appendix 4.7.2).
OP-1 and VEGF showed a slight increase in expression with the GF under Co and INJ+Co
conditions (Appendix 4.7.2).
Cytokines: Leukemia Inhibitory Factor (LIF) was maximally expressed under the
combination of INJ+Co (76x 2hr), displaying a synergistic effect (Figure 4.4A). IL-4 and IL-1
were both significantly upregulated at 48 hrs under Co (4.7x and 4.0x) and showed an increase of
expression under INJ+Co (Appendix 4.7.1). IL-6 and its receptor, IL-6R, were upregulated
under Co (5.4x and 4.2x) and INJ+Co (5.4x and 4.6x) (Appendix 4.7.1). TNF-a was
significantly upregulated under INJ+Co (Appendix 4.7.1). GF treatment affected the measured
cytokines in a minimal amount, with the exception of IL-1 3 expression returning to FS levels
from statistically upregulated levels for INJ+Co (Appendix 4.7.2).
Stress Induced: TXNIP was primarily downregulated by Co alone and HSP90 was
significantly upregulated at 2 and 24hrs under INJ+Co (Appendix 4.7.1). GF showed little to no
effect on both TXNIP and HSP90 (Appendix 4.7.2).
Figure 4.4 LIF and Caspase-3 gene expression
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Figure 4.4 LIF and Caspase-3 short-term gene expression. Data was plotted relative to FS
conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean ± SEM. Time points: N 2 Hrs, E 8 Hrs, E 24 Hrs, O 48 Hrs, 2
72 Hrs.
Apoptosis and Oxidation Factors: Caspase-3 was significantly upregulated under Co
conditions, reaching a > 12x FS level at 24hrs (Figure 4.4B). Caspase-3 was also significantly
upregulated under INJ+Co for 2, 8, 24, and 48hrs after injury. Interestingly, caspase-3 under INJ
did not show significant difference from the corresponding FS values. When GF was added,
caspase-3 levels for Co alone and INJ+Co slightly decreased (Appendix 4.7.2). ALPL and GPX-
3 were synergistically upregulated under INJ+Co (Appendix 4.7.1). ALPL showed a peak at 24
hrs (8.4x FS) where GPX-3 was transiently upregulated achieving at value of 9.5x FS at 72hrs.
Superoxide Dismutase-1 (SOD 1) and Superoxide Dismutase-2 (SOD2) were both slightly
upregulated with INJ+Co, reaching levels less than 4 fold FS at 24hrs (Appendix 4.7.1). GF
treatment showed little to no effect on ALPL, GPX-3, SOD1, and SOD2 (Appendix 4.7.2).
Clustering: The 47 normalized genes were clustered using PCA and k-means clustering
algorithms. After multiple iterations of groups, it was determined through analytical (Pareto plot
and euclidean distance separation) measures that there existed 5 distinct groups of genes. The
I-+Ur r +Ur +Ur
groups were plotted in the first three principle components, as seen in Figure 4.5, where the first
three principle components represent 80% of the variation in the data.
Figure 4.5 Genes Clustered in PC Space
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Figure 4.5 Standardized gene expression visualized in principle component space. Principle
components 1, 2, and 3 represent 80% of the variance in the data. Genes were allocated to one of
five distinct groups by way of k-means clustering. Large solid black circles denote the centroid
of the corresponding group.
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The corresponding genes in each grouping are shown in Table 4.2. The centroid profile for each
of the 5 groupings were converted from principle component space and plotted relative to FS
values, as seen in Figure 4.6. The first group, Figure 4.6A, was composed of aggrecan, collagen
II, collagen IX, collagen XI, Fibromodulin, Link, and IGF-2. This profile was characterized by
the strong downregulation of expression due to Co, INJ, and INJ+Co. The growth factor
treatment slightly stimulated the expression of this centroid, but did not dramatically overcome
the effects of Co or INJ or the combination of INJ+Co. Group 2 is composed of Sox-9, iNOS,
OP-1, VEGF, IL-6R, HSP90, and Caspse-3 (Figure 4.6B). This centroid was characterized by a
very strong upregulation to Co (6.5x FS at 24hrs) and to a lesser extent, INJ+Co (3x at 24hrs).
GF treatment appeared to change the dynamics of the Co response showing a peak at 72 hrs, but
in other conditions GF treatment showed no magnitudinous changes in expression. The third
group was composed of fibronectin, decorin, CD-44, Osteocalcin, MMP-1, MMP-9, MMP-13,
ADAMTS-4, ADAMTS-5, TIMP-1, TIMP-2, TIMP-3, p-actin, IGF-1, IL-1P, IL-4, IL-6, and
GPX-3 (Figure 4.6C). This centroid was characterized by the strong upregulation of expression
due to INJ+Co. This centroid profile peaked at 24 hrs at 4x FS. GF treatment showed little
significant effect, but appeared to change the temporal dynamics of expression with INJ+Co by
altering the peak 24 hr expression to a clear transient upregulation ending at 72hrs (~4x FS).
Group 4 was characterized by a slight upregulation due to GF treatment and was composed of
COMP, bFGF, TXNIP, ALPL, SOD1 and SOD2 (Figure 4.6D). While INJ+Co stimulated this
centroid at levels on the order of 3x (24 hrs), when GF was added to INJ+Co, the centroid
reached values of 8x (24 hrs). The Group 5 centroid profile was similar to the Group 3 centroid
profile in that it was strongly induced by the combination of INJ+Co. Differing from Group 3,
Group 5 showed an increase in expression magnitude, on the order of 2x Group 3. Group 5 was
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composed of HAS2, MMP-3, ADAMTS-1, c-FOS, c-JUN, TGF-f3, LIF, TNF-a, and Cox-2
(Figure 4.6E). This group was upregulated by Co and INJ alone, but the combination of INJ+Co
increased levels of gene expression >6x FS conditions at 8hrs. GF treatment did not appear to
show a significant effect on centroid profile for any of the measured conditions for Group 5.
Figure 4.6 Centroid Profiles of Gene Clustering
A GROUP 1- "All reduced" B GROUP 2 - "Co-cult induced"
8
I.6
1.4
1.2
C GROUP
+GF +GF +GF +GF
3 - "INJ+Co induced"
T
CoINJ iNJ+o F
Co INJ INJ+Co FS
+GF
GROUP 4- "GF
Co INJ INJ+Co
+GF +GF +GF
induced"
4.5
4
3.5
2.5
2
1.5
0.5
o INJ INJ+Co FS o INJ INJ+Co
+GF +GF +GF +GF
E GROUP 5 - "INJ+Co induced"
8
7
6
5
4
3
2
Co INJ INJ+Co FS Co INJ INJ+Co
+GF +GF +GF
w~~tm 4FTI
Co INJ INJ+Co FS Co INJ INJ+Co
+GF +GF +GF +GF
Figure 4.6 Five expression profiles represent the combination of conditions and treatments.
Centroid profiles were calculated through the average projection coordinates of genes in each
group and transformed from principle component space through use of the calculated principle
components. Mean ± SEM (n varies based on group component number). Time points: 0 2 Hrs,
M 8 Hrs, O 24 Hrs, O 48 Hrs, •172 Hrs.
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Short-Term Joint Capsule Gene Expression
Understanding that there are multiple cell types and tissues in the joint capsule that may
contribute to cartilage homeostasis or degradation, the object of this section was to determine the
levels of expression of cartilage-relevant genes and to assess if GF had a stimulatory effect on
the JC. Gene expression of joint capsule was taken from the Co experiment, where uninjured
cartilage was co-cultured with excised joint capsule, with the addition or absence of GF. The
same 48 genes were measured in the JC and, interestingly, all 48 transcript levels were detected.
Examining the JC basal level of expression, many proteinases were abundantly expressed. The
basal level of gene expression in JC was compared to cartilage in Figure 4.7, where gene
transcript abundance was normalized to the least abundant gene (GPX-3 for JC and cartilage).
FIGURE 4.7. BASAL GENE EXPRESSION: JC vs. CARTILAGE
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Figure 4.7 Basal levels of gene expression for joint capsule and cartilage relative to
abundant gene. Proteinases are colored in red; ECM molecules are colored in blue.
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All measured proteases were expressed proportionally higher in JC compared to cartilage.
Cartilage had a much higher level of abundance compared to JC, but with this difference, MMP-
9 and TIMP-2 were more abundantly expressed in JC vs. cartilage (MMP-9 100x higher in JC,
TIMP-2 15x higher in JC). The effect of the growth factor on the JC gene expression was
primarily and predominantly stimulatory (Appendix 4.7.3). Almost all genes, with the exception
of ADAMTS-5, were strongly upregulated, and most genes showed a peak of expression at the
8hr time point. ADAMTS-5 was downregulated for the first 24 hours, returning eventually to
non-GF treated JC levels.
Longer-Term Cartilage Gene Expression
Matrix Molecules: Aggrecan, Collagen IX, and Collagen XI continued to be significantly
downregulated through day 4 under Co alone. At days 8 and 16, expression levels for Co alone
returned to FS levels (Figure 4.8A, Appendix 4.7.4). INJ alone showed no significant difference
from FS up to day 16, with the exception of a slight upregulation of Collagen IX at day 8 (1.3x
FS). INJ+Co showed no significant difference at later time points compared to FS values.
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Figure 4.8 Aggrecan and Fibronectin gene expression
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Figure 4.8 Aggrecan and Fibronectin longer-term gene expression. Data was plotted relative to
FS conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean ± SEM. Time points: 1 Day 2, E Day 4, El Day 8, [L Day 16
When growth factors were added for the time course, a significant upregulation was seen in
Collagen IX under FS and INJ conditions compared to FS (Appendix 4.7.5). Growth factor
treatment showed little significant increase in transcript levels in aggrecan (3x under Co at day
4), collagen IX (2x under Co at day 8, 1.5x under FS at day 16), and collagen XI (1.9x under Co
at day 4) (Appendix 4.7.5). Collagen II and osteocalcin showed no significant differences for the
time course in Co, INJ, or INJ+Co. When growth factor was present, collagen II was
significantly downregulated under INJ at day 1 and day 4 compared to FS, where osteocalcin
was unaffected. There was no significant change in expression when comparing the effects of
the growth factor treatment to like conditions (Appendix 4.7.5).
Fibromodulin, HAS2, and COMP were significantly downregulated at day 1 under Co,
and COMP was significantly downregulated through day 4 under Co (Appendix 4.7.4). Day 8
and day 16 were consistent with FS levels for the three genes under INJ and INJ+Co. When
growth factor was added, Co alone resulted in no significant differences at days 4, 8, and 16
compared with FS (Appendix 4.7.5). Under injury, fibromodulin showed a slight increase in
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expression at day 4 (1.2x FS) followed by a decrease in expression at days 8 and 16. HAS2 was
slightly upregulated at day 8 under INJ+GF (1.4x FS), where COMP was significantly
upregulated in a transient fashion, peaking at day 16 with a magnitude of 2.5x FS (Appendix
4.7.4). Fibromodulin, HAS2, and COMP showed no significant differences under INJ+Co
compared to FS for days 4, 8, and 16. Further examining the effects of GF treatment under like
loading conditions, HAS2 appeared unaffected by GF treatment while fibromodulin appeared to
be downregulated, particularly under INJ, and COMP was upregulated for FS, Co, INJ, and
INJ+Co (Appendix 4.7.5).
Fibronectin and decorin expression was consistent with FS values under Co, but both
were significantly upregulated under INJ (Figure 4.8B, Appendix 4.7.4). Fibronectin was
upregulated for all time points measured, with a peak value of 3.6x FS at day 4, and decorin was
upregulated at days 4 and 16 with a peak value of 4x FS at day 4. Under INJ+Co, fibronectin
was not significantly different than FS for days 4, 8, and 16, while decorin was upregulated at
days 4 (2.6x FS) and 8 (6.5x FS). With the addition of GF treatment, there appeared to be no
dramatic effect compared to FS (Appendix 4.7.5). When examining the effects of the growth
factor under similar injurious conditions, fibronectin and decorin were both dramatically
downregulated, with fibronectin significantly downregulated at days 8 and 16 of INJ, and
decorin downregulated at day 8 under Co and INJ (Appendix 4.7.5).
Link and CD-44 were not significantly different than FS values for days 4, 8, and 16
under Co and INJ+Co (Appendix 4.7.4). Under INJ alone, link was significantly upregulated at
days 4 and 8, while CD-44 was significantly upregulated at day 4. GF treatment appeared to
have little effect on Link when comparing the FS values, and a slight increase in expression was
found in CD-44 under Co and INJ+Co conditions. Looking at the effects of GF treatment under
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like conditions, GF had no effect on CD-44 expression under all conditions and had a slight
effect on link under INJ and INJ+Co (Appendix 4.7.5). p-actin showed a slight but significant
upregulation under INJ for days 4, 8, and 16 (Appendix 4.7.4). When GF was added, there was
no dramatic change in expression compared to FS or like injury condition (Appendix 4.7.5).
Proteinases: MMP-9 showed sustained and dramatic upregulation for Co (peak 144x FS at day
16), INJ (peak 13.3x FS at day 8) and INJ+Co (peak 46x FS at day 16) at days 4, 8, and 16
(Figure 4.9B).
Figure 4.9 MMP-3 and MMP-9 gene expression
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Figure 4.9 MMP-3 and MMP-9 longer-term gene expression. Data was plotted relative to FS
conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean + SEM. Time points: N Day 2, U Day 4, E Day 8, O Day 16
GF treatment appeared to slightly decrease the levels of MMP-9 in Co and INJ compared to FS.
Normalizing the effects of GF by like injury condition, the data revealed there was no significant
difference with the GF treatment (Appendix 4.7.5). MMP-1 transcript levels were consistent
with FS for Co and INJ for days 4, 8, and 16 (Appendix 4.7.4). Under INJ+Co, there appeared to
be a trend of upregulation, with day 8 values significantly different than FS (4x FS). Growth
factor treatment had no significant effect on MMP-1 expression compared to FS, but when
examining treatment under like conditions, MMP-1 was slightly downregulated at day 4 under
INJ alone (Appendix 4.7.5). MMP-3 and ADAMTS-1 were initially upregulated under INJ and
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INJ+Co followed by a decrease to FS conditions at day 16 (Figure 4.9A, Appendix 4.7.4).
MMP-3 was significantly upregulated at days 4 and 8 of culture under INJ, and ADAMTS-1 was
significantly upregulated at day 4 under INJ+Co. When GF treatment was added, MMP-3 and
ADAMTS-1 were significantly upregulated at later time points. MMP-3 was transiently
upregulated under FS conditions, peaking at a significant 6.9x FS at day 16. MMP-3 was also
significantly upregulated at day 16 under INJ (3.2x FS) and day 4 under INJ+Co (3.4x FS).
ADAMTS-1 was significantly upregulated for all time points under INJ+GF with a
sustained 2.7x FS at day 16. GF treatment appeared to have no effect on ADAMTS-1 under Co
and FS conditions. Looking at GF treatment under like loading conditions, MMP-3 was strongly
stimulated by GF under FS conditions and was stimulated to a lesser extent by Co and INJ
(Appendix 4.7.5). GF transiently stimulated ADAMTS-1 expression under Co conditions, while
uniformly upregulating expression under INJ (Appendix 4.7.5). MMP-13 and ADAMTS-5 were
both not statistically different than FS under Co, INJ, and INJ+Co at days 4, 8, and 16, with or
without the treatment of GF (Appendix 4.7.4). MMP-13 and ADAMTS-5 were slightly
downregulated under INJ and INJ+Co when GF treatment was normalized by like injury
conditions (Appendix 4.7.5). ADAMTS-4 was initially upregulated followed by a transient
return to slightly above FS levels under INJ and INJ+Co (Appendix 4.7.4). Under Co,
ADAMTS-4 showed a trend of upregulation over 16 days, but was not statistically different than
FS levels. GF treatment had little to no effect on each of the conditions when compared to FS or
when comparing like injury conditions (Appendix 4.7.5).
TIMPS: TIMP-1 and TIMP-3 showed a significant initial increase of expression followed
by a transient decrease in expression, returning to FS levels over the 16 days under Co, INJ, and
INJ+Co (Figure 4.10A, Appendix 4.7.4). GF treatment did not alter the magnitude of kinetics of
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transcript expression of TIMP-1 or TIMP-3 for any of the conditions measured (Appendix 4.7.5).
TIMP-2 showed a trend of sustained upregulation under INJ and an initial upregulation followed
by a transient return to FS values under Co (Appendix 4.7.4). GF treatment did not induce
significant changes in the conditions when compared to FS, but when examining the effect of GF
treatment normalized to like injury condition, GF significantly decreased levels of TIMP-2 under
INJ conditions (.14x INJ alone at day 16) (Appendix 4.7.5).
Figure 4.10 TIMP-1 and c-Fos gene expression
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Figure 4.10 TIMP-1 and c-Fos longer-term gene expression. Data was plotted relative to FS
conditions, and stars indicate significance (p-values < 0.05) between condition and
corresponding FS value. Mean ± SEM. Time points: M Day 2, M Day 4, O Day 8, Ol Day 16
Transcription Factors: Sox-9 showed no significant difference from FS at days 4, 8, and
16 for Co, INJ, and INJ+Co (Appendix 4.7.4). When GF was present and values were
normalized to like injury condition, there were no significant alterations of expression with the
exception of Co+GF, where day 4 was significantly upregulated compared to Co. c-Fos showed
significant slight upregulation under Co (day 8) and INJ (day 4, 8) (Figure 4.10B). When GF
was added, there was an increase in time points that were significantly upregulated (compared to
FS), but none were upregulated above 3x FS values. Isolating the effects of GF by normalizing
by like injury condition, GF significantly increased c-Fos at days 8 and 16 but had no effect on
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Co, INJ, or INJ+Co (Appendix 4.7.5). c-Jun followed a similar trend as c-Fos, where in the
absence of GF, there were few values significantly different than free swell, and under GF, many
time points were significantly different than FS (FS+GF day 8, 16; INJ+GF day 4, 16)
(Appendix 4.7.4). Isolating the effects of the GF treatment, only FS+GF showed any significant
change (Appendix 4.7.5).
Enzyme Mediators: iNOS was initially upregulated under Co conditions, and returned to
FS levels over the 16-day period (Appendix 4.7.4). GF treatment strongly stimulated iNOS
expression under Co (24x at day 4) and INJ+Co (7.3x at day 8). Normalizing to like loading
conditions, iNOS was slightly stimulated or not affected by GF (Appendix 4.7.5). Though not
significantly different compared to FS, Cox-2 expression tended to increase over the 16-day time
course for Co, INJ, and INJ+Co (3x, 2.3x, 4x, respectively at day 16) (Appendix 4.7.4). GF
treatment appeared to decrease levels of Cox-2 but no significant differences were seen when
isolating the effects of GF (Appendix 4.7.5).
Growth Factors: After slightly above or below FS levels of expression, IGF-1 and IGF-2
appeared to be upregulated at days 8 and 16 under Co, INJ, and INJ+Co (Appendix 4.7.4).
Under the treatment of GF, IGF-2 showed a strong upregulation due to GF under FS and Co
conditions (Appendix 4.7.5). IGF-1 showed little to no effect when treated with GF (Appendix
4.7.5). OP-i and VEGF showed significant upregulation at day 8 under Co conditions (2x FS,
6.4x FS respectively). They both also showed little long-term response under INJ alone but an
upregulation under INJ+Co at day 8. With GF present, the magnitude of expression of both OP-
1 and VEGF declined under Co at day 8 (Appendix 4.7.4). GF treatment on other conditions and
time points had little effect. bFGF and TGF-P were both upregulated for later time points (days
8 and 16) under Co and INJ+Co. Under INJ, bFGF and TGF-3 were initially upregulated at days
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1 and 4 and returned to FS levels at days 8 and 16 (Appendix 4.7.4). The treatment of GF
induced a significant increase of expression at day 8 of FS+GF for TGF-P and appeared to have a
negative or downregulatory effect on bFGF expression for Co, INJ, and INJ+Co (Appendix
4.7.5).
Cytokines: IL-1 3 and TNF-a were generally consistent with FS values for days 1, 4, and
8, but tended to increase expression at day 16 for all conditions (Appendix 4.7.4). GF treatment
had little effect on IL-13p or TNF-a (Appendix 3.7.5). IL-6 and its receptor, IL-6R, were both
upregulated under Co and INJ+Co and unaffected by INJ alone (Appendix 4.7.4). When GF
treatment was added, IL-6 showed a slight decrease in expression for Co, INJ, and INJ+Co for
days 4, 8, and 16, while IL-6R appeared to be decreased to a lesser degree for INJ and INJ+Co at
days 4, 8, and 16 (Appendix 4.7.5). IL-4 and LIF both exhibited trends of transiently increasing
expression under Co, INJ, and INJ+Co (Appendix 4.7.4). The effects of GF on IL-4 and LIF
expression appeared to slightly downregulate expression at days 4, 8, and 16 under INJ
(Appendix 4.7.5).
Stress Induced Factors: TXNIP and HSP90 were both upregulated in response to Co
alone. HSP90 was also strongly upregulated under INJ+Co, whereas TXNIP did not appear to
respond to INJ and INJ+Co at later time points (Appendix 4.7.4). GF treatment seemed to
decrease TXNIP and HSP90 expression compared to FS. TXNIP was significantly
downregulated by GF when data was normalized to like injury conditions at day 4 for INJ and
INJ+Co (Appendix 4.7.5). HSP90 showed a general increase of expression with the addition of
GF, with the exception of INJ+Co, where GF appeared to downregulate HSP90 expression
(Appendix 4.7.5).
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Apoptotic and Oxidation Factors: Caspase-3 was constantly upregulated for the 4 time
points measured for Co and INJ+Co, and to a lesser extent, INJ alone. For each injury condition,
Caspase-3 was upregulated at day 1, which was followed by a decrease in expression (Appendix
4.7.4). With the addition of GF, Caspase-3 appeared to be upregulated under INJ and slightly
downregulated under Co and INJ+Co. Isolating the effects of GF, GF treatment had very little
effect on transcript levels under Co and INJ+Co, and significantly upregulated caspase-3 at day 8
under INJ+GF (1.7x INJ) (Appendix 4.7.5). ALPL and SOD2 showed little to no significant
differences compared to FS under Co, INJ, and INJ+Co (Appendix 4.7.4). With the addition of
GF, SOD2 showed a slight increase in expression under INJ+Co, and ALPL showed a strong
stimulation of expression under INJ and INJ+Co compared to FS at 16 days (Appendix 4.7.5).
SOD1 and GPX-3 showed slight upregulation due to Co, INJ, and INJ+Co (Appendix 4.7.4).
The treatment of GF decreased expression levels of GPX-3 and SOD 1, as seen in INJ+Co.
Examining the effects of GF, normalized by like injury condition, GF downregulated GPX-3 at
days 4 (INJ, INJ+Co), 8 (Co, INJ+Co), and 16 (INJ, INJ+Co) (Appendix 4.7.5).
Clustering: Clustering analysis revealed three distinct trends for the 47 genes measured
(Figure 4.11, Table 4.3).
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Figure 4.11 Genes Clustered in PC Space
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Figure 4.11 Standardized gene expression visualized in principle component space. Principle
components 1, 2, and 3 represent 70% of the variance in the data. Genes were allocated to one of
five distinct groups by way of k-means clustering. Large solid black circles denote the centroid
of the corresponding group.
The first group (11 genes) was composed of Collagen II, Osteocalcin, MMP-13, IGF-1, LIF, IL-
113, IL-4, TNF-a, IL-6R, TXNIP, and GPX-3. This group showed a late response to Co, INJ, and
INJ+Co, where all three conditions peaked at 8 or 16 days at a magnitude of 2x FS. The
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magnitude of the transcripts was diminished with the addition of GF treatment, while the kinetics
of the response was unaffected (Figure 4.12A). Group 2 (17 genes) was composed of Aggrecan,
Collagen IX, Collagen XI, Fibromodulin, Fibronectin, Decorin, Link, HAS2, COMP, MMP-1,
TIMP-2, SOX-9, c-Jun, f3-actin, IGF-2, HSP90, and SOD 1.
Figure 4.12 Centroid Profiles of Gene Clustering
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Figure 4.12 Five expression profiles represent the combination of conditions and treatments.
Centroid profiles were calculated through the average projection coordinates of genes in each
group and transformed from principle component space through use of the calculated principle
components. Mean + SEM (n varies based on group component number). Time points: U Day
2, E Day 4, E Day 8, O Day 16
With many of the key ECM molecules in this group, the centroid expression was characterized
by initial low levels of expression at day 1 compared to FS, followed by increased expression of
up to 2x for Co, INJ, and INJ+Co (Figure 4.12B). INJ+Co appeared to be the most effected
condition with days 4 and 8 reaching levels above 2x FS. GF slightly increased basal level of
expression under the injury models, while FS combined with GF showed an increase in
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expression. Group 3 (19 genes) contained CD-44, MMP-3, MMP-9, ADAMTS-1, ADAMTS-4,
ADAMTS-5, TIMP-1, TIMP-3, c-Fos, iNOS, OP-1, bFGF, TGF-P, VEGF, IL-6, Cox-2,
Caspase-3, ALPL, and SOD2. This group showed sustained upregulation for 16 days with Co
alone, decreased expression with INJ, and maximum decreased expression with INJ+Co (Figure
4.12C). GF appeared to have little effect on group 3.
Longer-Term Cartilage Biosynthesis
Radiolabel incorporation was calculated as described previously [32]. Each plug was
digested and measured for radiolabeled [35S]-sulfate and [3H]-proline, which was normalized to total
DNA. Sulfate incorporation can be seen in Figure 4.13A. Incorporation in all conditions was
normalized to incorporation of free swell plugs. Over the 16-day period, INJ+Co showed the most
dramatic decrease in incorporation rates and had significantly lower rates at days 1, 8, and 16
compared to FS. INJ alone and Co alone showed no significant change from FS over 16 days.
When growth factor was added to the medium, over 16 days there was increased synthesis. INJ
alone resulted in a significant improvement in synthesis for days 12 and 16, and INJ+Co
significantly improved synthesis for day 8. These growth factor effects on sulfate incorporation can
be seen in Figure 4.13B.
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Figure 4.13 Sulfate incorporation over 16 days
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Figure 4.13 Sulfate incorporation measured over 16 days. Data was plotted relative to FS
conditions (A) and relative to the corresponding treatment (B). Stars indicate significance (p-
values < 0.05) between condition and corresponding FS (A) or treatment (B) value. Mean +
SEM. Time points: U Day 2, E Day 4, 0 Day 8, O Day 12, 9 Day 16.
Examining [3H]-proline incorporation, INJ+Co biosynthesis rates were significantly lower than
FS levels, similar to sulfate incorporation results (Figure 4.14A). The addition of growth factor
stimulated synthesis in FS, INJ, and INJ+Co conditions relative to FS conditions. There was a
significant improvement in biosynthesis for all injury models with the addition of growth factors
when comparing to like injury. As seen in Figure 4.14B, when the effects of growth factor
treatment are isolated by normalizing to similar injury conditions, there is a significant
improvement in biosynthesis rates for all conditions: FS, Co, INJ, and INJ+Co. INJ alone
improved greater than 4-fold with the addition of growth factor at days 12 and 16. Slight, but
significant, increases were seen at day 4 (FS, INJ+Co), day 8 (FS, INJ+Co), day 12 (FS, Co,
INJ+Co), and day 16 (FS, INJ+Co).
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Figure 4.14 Proline incorporation over 16 days
A Proline Relative to FS B Proline - Effects of GF
Figure 4.14 Proline incorporation measured over 16 days. Data was plotted relative to FS
conditions (A) and relative to the corresponding treatment (B). Stars indicate significance (p-
values < 0.05) between condition and corresponding FS (A) or treatment (B) value. Mean +
SEM. Time points: N Day 2, U Day 4, 0 Day 8, OI Day 12, El Day 16.
Longer-Term Cartilage Apoptosis
Disks at day 1 showed little to no amounts of apoptosis. Disks at day 4 were sectioned
and examined to find the intensity of nuclear blebbing to be insufficient to determine apoptosis
accurately. At day 8, INJ and INJ+Co showed significantly larger amounts of apoptosis (Figure
4.15).
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Figure 4.15 Levels of apoptosis 8 days after loading. Percentage apoptotic cells represent the
amount of apoptotic cells divided by the total number of cells. Stars indicate significance (p-
values < 0.05) between condition and FS. Bar indicates statistical difference (p-values < 0.05)
between the two end points. Mean ± SEM.
INJ alone produced 48% apoptotic cells, INJ+Co produced 39% apoptotic cells, and FS
produced 0.3%. Co alone produced 6% apoptotic cells and was not statistically different than
FS. Examining the effects of GF treatment under INJ alone, GF treatment significantly lowered
the amount of apoptosis (p-value = 0.007), from 48% under INJ to 21% under INJ+GF. Day 16
samples were also prepared and can be seen in Figure 4.16. These data show INJ alone has a
significant effect on levels of apoptosis after 16 days, where INJ+Co was not significantly
different compared to FS conditions. GF treatment reaffirmed the trend seen in the day 8
samples under mechanical injury and mechanical injury co-cultured with joint capsule, though
there was no statistically significant difference between GF and non-GF treatment.
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Figure 4.16 Levels of Apoptosis at Day 16
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Figure 4.16 Levels of apoptosis 16 days after loading. Percentage apoptotic cells represent the
amount of apoptotic cells divided by the total number of cells. Stars indicate significance (p-
values < 0.05) between condition and FS. Mean ± SEM.
4.4 Discussion
Short-Term
Mechanical injury co-cultured with excised joint capsule caused modulation of most of
the 47 relevant cartilage genes tested by 3 days post-injury. Interestingly, aggrecan, collagen II,
collagen IX, collagen XI, fibromodulin, link, and HAS2 were significantly downregulated for
Co, INJ, and/or INJ+Co (Figures 4.1). These data agree with previous transcript data reported
for aggrecan and collagen type II [33]. The addition of excised joint capsule showed the most
significant change in expression for aggrecan, collagen IX, collagen XI, fibromodulin, link, and
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HAS2, supporting evidence that there is a key mediator, originating in damaged joint capsule,
which has a more suppressive effect on these transcripts' expression than mechanical injury
alone.
Having the opposite response as the injury models, fibronectin, decorin, and CD-44 were
significantly upregulated when placed in Co, INJ, and/or INJ+Co conditions. The response of
CD-44 (a cell-surface glycoprotein known to bind hyaluronic acid and interact with collagens
and MMPs) and decorin (proteoglycan that aids structure of collagen network) appears to be an
anabolic or reparative response to injury. However, it is unclear whether fibronectin
upregulation is an anabolic response, contributing towards its function as a building block of the
ECM and cell adhesion, or a catabolic response; when cleaved by proteolytic activity, fibronectin
fragments (upregulated in injury models) stimulate protease activity and cartilage degradation
[56, 57].
Matrix metalloproteinases 1, 3, 9, and 13 were upregulated and all showed maximal
stimulation under the combination of INJ+Co. As previously reported, MMP-1, MMP-3, and
MMP-13 were upregulated within the first 24 hours post injury [33, 53, 58], and these data show
a continued upregulation of MMP-13 through day 3, reaching 46x FS levels. Not previously
reported, MMP-9 was highly upregulated under INJ+Co and mirrored expression of the most
highly expressed TIMP, TIMP-1. Both were significantly upregulated under Co, INJ, and
INJ+Co (Figure 4.2A, B). This finding supports the notion that TIMP-1, a general inhibitor of
protease activity and a known inhibitor of MMP-9 [59, 60], and MMP-9, a collagenase
responsible for degrading decorin, collagens, and activating proTNF-a, are co-regulated in
chondrocytes in order to maintain a proper balance of proteolytic activity [61-63]. ADAMTS-1,
ADAMTS-4, and ADAMTS-5 were maximally expressed under INJ+Co, again showing that the
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combination of mechanical injury co-cultured with joint capsule has an additive (ADAMTS- 1,2)
and synergistic effect (ADAMTS-5) (Figure 4.3A).
iNOS induction has been reported in crushed or injured tendon and synovium [64], and
through autocrine signaling coincides with the significant upregulation in cartilage iNOS in
response to excised joint capsule shown here (Figure 4.3B). Leukemia inhibitory factor (LIF),
an IL-6 class cytokine, was highly upregulated with the addition of Co, INJ, and INJ+Co,
reaching values above 100x FS (Figure 4.4A). Previous studies have also shown a strong
upregulation of LIF in response to chondrocytes treated with IL-10 [65]. This suggests that IL-
1 3 stimulation and INJ+Co stimulation have common mediators responsible for stimulation of
LIF.
Previous studies have shown that OP-1 transcript expression acts in an initial reparative
response in reaction of capsular incision [26]; though a different model of injury was used, our
data agree with this finding and show that OP-1 transcripts were highly upregulated when excise
joint capsule was present (Co and INJ+Co). Following a similar response to OP-1, growth
factors bFGF and VEGF were strongly upregulated in the case of Co, INJ, and INJ+Co. Yet
unlike OP-1, bFGF at elevated levels has been shown to inhibit and reduce anabolic activity by
IGF- 1 and OP-1 [12] and has been shown to stimulate matrix metalloproteinases, such as MMP-
13 [66]. VEGF, like bFGF, has been shown to promote cartilage degradation pathways [67], and
here we report a strong upregulation of VEGF under Co, INJ, and INJ+Co. Together this
suggests that VEGF and bFGF result in catabolic responses in our injury models.
Growth factor treatment was generally insufficient to negate the strong catabolic effects
of the injury model on the transcript level. The combination of OP- and IGF- 1 actually
appeared to stimulate, not abrogate, protease transcript levels, as seen in MMP-9, ADAMTS-1,
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and ADAMTS-5. In addition, known catabolic factors bFGF and VEGF were stimulated to a
greater extent with the addition of GF. GF treatment did significantly downregulate the response
of inducible nitric oxide synthase, and to a lesser extent, the expression of tumor necrosis factor-
a.
Clustering analysis showed genes allocated into 5 significantly separated groups (Table
4.4). Clustering allocated genes into groups that were highly upregulated (Group 2) or
downregulated (Group 1) in response to co-culture, the combination of injury and co-culture
(Groups 3 and 5), and a slight responsiveness to GF treatment (Group 4) (Figure 4.6). Clustering
showed robust grouping of key ECM molecules including aggrecan, collagen II, collagen IX,
collagen XI, fibromodulin, and link protein. Interestingly, all proteases and cytokines measured
were clustered in groups that were maximally expressed under the combination of mechanical
injury co-cultured with joint capsule. This introduces the idea that protease transcripts in
chondrocytes are modulated by mechanical forces and factors from surrounding tissues
(additive/synergistic manner), whereas iNOS, OP-1, and caspase-3 transcripts are modulated
predominantly by factors from the surrounding tissue.
Table 4.2 Centroid Uniqueness- Short Term
P-value of
Centroid Centroid 1 Centroid 2 Centroid 3 Centroid 4
Separation
Centroid 2 0.009
Centroid 3 0.000 0.035
Centroid 4 0.014 0.049 0.048
Centroid 5 0.004 0.039 0.023 0.014
Table 4.2. P-value of Centroid Profile Separation. P-values were obtained through student T-
test, comparing centroid to centroid Euclidean distance. Degrees of freedom were taken as the
number of genes in each group.
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Joint capsule is composed of multiple different cell types including synoviocytes,
synovial fibroblasts, and lymphocytes [68]. Understanding that multiple cell types may
contribute to an analysis of joint capsule gene expression, samples were taken to investigate a
global expression level of cartilage relevant genes and the tissue's response to the combination
GF treatment. The basal level of joint capsule gene expression reveals a proportionally large
number of proteolytic transcripts being produced in the JC (Figure 4.7). MMP-1, MMP-3,
MMP-9, and MMP-13 and ADAMTS-1, ADAMTS-4, and ADAMTS-5 were expressed
abundantly, as seen in previous experiments [69-72]. In particular, MMP-9 was expressed orders
of magnitude greater in joint capsule compared to cartilage. MMP-9 or gelatinase-B has been
shown to be increased in osteoarthritis [73]. This tissue also produced small amounts of
aggrecan and collagen type II, two transcripts that are characteristic of a chondrocyte phenotype
and that have been previously reported within joint capsule cells [74]. GF treatment stimulated
all measured genes in the JC with the exception of ADAMTS-5, hinting at a possible positive
effect of the treatment in an adjacent tissue (Appendix 4.7.3). This transcriptional data supports
the idea that the synovial membrane is a good target for investigation for both the pathogenesis
and progression of osteoarthritis [75].
Longer-Term
Examining gene expression over a longer period of time, up to 16 days, showed most
ECM molecules return to their respective FS values by day 16. Aggrecan was slightly
upregulated with the addition of joint capsule (Co and INJ+Co) at day 8, which was followed by
FS levels at day 16 (Figure 4.8A). Fibronectin was dramatically and significantly upregulated by
INJ alone for all 4 time points measured (Figure 4.8B). Growth factor treatment tended to
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slightly alter dynamics in expression over the 16 days, and collagen IX and COMP were
statistically upregulated under FS and INJ conditions for longer time points (days 8 and 16).
These data might explain the slight increase in proteoglycan synthesis with growth factor
treatment on the same timescale. Also interesting to note, levels of COMP in the synovial fluid
has recently been suggested to be a marker for cartilage degradation and possibly play a role in
cartilage degradation and inflammation [76-78].
Matrix metallo-proteinases showed significant increases in gene expression over the 16-
day period. MMP-9, shown to be extremely active in the first three days post-injury, was
upregulated at day 16 under Co and INJ+Co (Figure 4.9B). TIMPs, ADAMs, and transcription
factors returned to FS levels by day 16. GF treatment increased transcript levels of MMP-3, c-
Fos, and c-Jun at days 8 and 16 (Figure 4.9A, 4.10B). As reported here and previously [44, 50,
52, 79], c-Fos and c-Jun are regulated by injury or mechanical forces on small time scales (i.e.
hours). These data show that c-Fos and c-Jun are positively regulated by GF treatment on longer
time scales (i.e. days, weeks) as well. The upregulation of components of the activator protein-i
complex (AP-1) due to GF treatment supports the corresponding upregulation of MMP-3
(stromelysin-1) and MMP-9 (gelatinase-B) as previous reports have shown AP-1 to be a
promoter of many MMPs, including MMP-3 and MMP-9 [80-83]. Interestingly, TIMP-1 tracked
expression of MMP-9 in the first 3 days, but at days 8 and 16, TIMP-1 returned to FS levels
while MMP-9 continued high levels of expression (Figure 4.9B, 4. 10A). TIMP-2 transcript
levels were downregulated at day 16 when joint capsule was present (Co and INJ+Co), and
previous studies have shown TIMP-2 to be significantly reduced in canine OA cartilage [84].
Previous studies have shown that in late-stage osteoarthritic chondrocytes GPX-3, SOD2,
SOD3, and TXNIP were significantly downregulated in comparison to non-osteoarthritic
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chondrocytes [85]. In our longer-term investigation of genes involved in the defense of
oxidative damage, TXNIP, SOD 1, SOD2, and GPX-3 were not significantly downregulated at
day 16, but SOD 1, SOD2, and TXNIP showed signs of downregulation under many of the
conditions, particularly INJ+Co. This downregulation of oxidation enzymes and TIMP-2, as
seen in OA tissue, validates the co-culture model as an in vitro model of OA. Interestingly, key
cytokines measured, TNF-a, IL-10, IL-4, and LIF, were highly expressed, though quite variable,
after 16 days post-injury. This suggests an additional transcriptional cue that might explain the
onset of cartilage degradation on longer-term time scales, similar to MMP-9 expression
mentioned previously.
Clustering analysis partitioned the genes in three groups: (1) transcript levels are
increased at later time points (days 8. 16), (2) transcript levels peak at days 4 and 8 and return to
FS, and (3) transcripts that are generally upregulated under different dynamics with Co, INJ, and
INJ+Co (Figure 4.12). These groupings were statistically unique compared to one another
(Table 4.5). As seen in expression levels over a shorter-time period, GF treatment generally
showed little effect on transcript levels.
Table 4.3 Centroid Uniqueness- Longer Term
P-value of
Centroid Centroid 1 Centroid 2
Separation
Centroid 2 0.008
Centroid 3 0.006 0.009
Table 4.3. P-value of Centroid Profile Separation. P-values were obtained through student T-
test, comparing centroid to centroid Euclidean distance. Degrees of freedom were taken as the
number of genes in each group.
Proteoglycan incorporation rates showed significantly lower rates under INJ+Co for 35S
and 3H. GF treatment showed a significant increase in biosynthesis rates for 35S under INJ for
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later time points (days 12 and 16) and INJ+Co (Figure 4.13B). This result is not seen with the
aggrecan transcript levels, showing the discrepancy between GF action on transcription
compared to translation. When GF treatment was examined for 3H, biosynthesis rates
dramatically increased for all conditions (FS, Co, INJ, INJ+Co) (Figure 4.14B). While 3H is not
a specific marker of a particular molecule like 35S (aggrecans have abundant sulfated GAG
chains), from our clustering data, a majority of the collagens and ECM molecules measured were
allocated to group 2, which showed an increase in expression at days 4 and 8. While we cannot
definitively state that transcript levels correspond to 3H incorporation, the data suggests a
correlation between transcript and translated protein levels.
As seen previously, apoptosis was increased when mechanical injury was present [42].
Although apoptosis has been shown to be initiated as quickly as 24 hours post-injury [38], we
found examining later time points distinctly showed the effect of apoptosis on the cartilage
explants. Day 8 showed significant levels of apoptosis under injury. While co-culture alone did
not show a significant difference compared to FS, there was a trend of Co increasing the amount
of apoptosis (Figure 4.15). Caspase-3, cysteine-aspartic acid protease, is a known player in the
execution of cell suicide. Caspase-3 transcript was found to be upregulated in the first three days
under Co alone (Figure 4.4B), and continued to be upregulated until day 16. Caspase-3
transcript significantly increased with the addition of GF under all conditions, and particularly in
injury. Where previous work with human articular chondrocytes and murine bone marrow
neutrophils has shown that the inhibition of caspase-3 activity leads to apoptosis mitigation [86,
87], these data show that increase of caspase-3 transcript does not correlate with cell apoptosis.
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4.5 Conclusion
This study has examined the transcriptional, translational, and apoptotic effects of various
models of cartilage injury in combination with growth factor stimulus. ECM genes were
generally downregulated and proteases upregulated in response to Co, INJ, and/or INJ+Co,
where genes predominantly responded most dramatically to INJ+Co for both short-term and
longer-term expression. GF treatment failed to rescue the downregulation of ECM transcripts
and the upregulation of protease transcripts. Clustering analysis of both short-term and longer-
term gene expression showed distinct groupings of co-regulated genes. Joint capsule gene
expression was also measured and revealed that protease production is much higher in joint
capsule when compared to cartilage tissue. Growth factor treatment stimulated all genes
measured in the JC, with the exception of ADAMTS-5. Examining the rates of biosynthesis, Co
and INJ+Co dramatically affected uptake of 35S and 3H over the 16 day time period measured.
After treatment with OP-1 and IGF-1, protein biosynthesis rates (3H-proline incorporation)
improved dramatically, while proteoglycan biosynthesis (35S-sulfate incorporation) only slightly
increased. Dramatic amounts of apoptosis were measured after mechanical injury. JC appeared
to have little effect on apoptosis. Growth factor treatment significantly decreased levels of
apoptosis under mechanical injury alone.
In conclusion, the in vitro models of injury, Co, INJ, and INJ+Co, mimic certain aspects
of joint injury result in changes in cartilage metabolism in vivo. Growth factor treatment had a
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slightly stimulatory effect on biosynthesis rates, caused a significant decrease apoptosis, and had
little effect on recovering gene transcripts after injury. While OP-1 and IGF-1 had a positive
effect on apoptosis, these data support the role of OP-1 and IGF-1 as remodeling factors, as
opposed to anti-catabolic and pro-anabolic factors as has been previously reported. Further
studies are needed to understand the mechanistic action of OP-1 and IGF-1 to clarify their
reparative and possible therapeutic capabilities.
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4.7.3 Joint Capsule Gene Expression
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4.7.4 Longer Term Gene Expression
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4.7.5 Effects of GF Treatment- Longer Term Gene Expression
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Chapter 5
Human Tissue Response to Mechanical Injury and Co-
culture with excised Joint Capsule
* This study is in collaboration with Professors Anna Plaas and John Sandy, Rush University
Medical School, Chicago, IL.
163
5.1 Introduction
An in vitro model of injury has been established in our laboratory incorporating the
effects of mechanical injury cartilage co-cultured with injured joint capsule (JC) tissue [1, 2]. In
vitro mechanical injury of cartilage alone has been shown to increase hydraulic permeability [3]
and water content [4-6], decrease stiffness [5, 7], and increase glycosaminoglycan (GAG) lost to
the medium [5, 8-10]. Cells in cartilage subjected to this injury have been shown to decrease
biosynthesis rates [5], undergo apoptosis and necrosis [4, 5, 11, 12], and have elevated levels of
protease transcript activity within the first 24 hours [13]. Co-culturing un-injured cartilage with
damaged joint capsule in vitro has resulted in a decrease in cartilage biosynthesis rates [1, 14] as
well as a loss of proteoglycan and collagen as seen though histology staining [15]. GAG release
from cartilage co-cultured with synovial or capsular tissue was not decreased with the inhibition
of IL-1 3, TNF-a, and ACITIC [16]. Under the same conditions of cartilage co-cultured with
joint capsule, GAG loss was blocked by treatment with EDTA [16]. While the effects of JC co-
culture appear to accelerate degradation, studies have also shown that synoviocytes from joint
capsule tissue provide chondrocytes with protection against reactive oxygen species, which are
known to induce membrane damage and lipid peroxidation [17]. This model of injury has not
been fully investigated in non-arthritic human cartilage tissue.
The objectives of this study was to more fully explore the degradative effects on human
cartilage of mechanical injury combined with co-cultured excise joint capsule as measured by
protein biosynthesis rates, the amount of GAG lost to the medium, and the prevalence of select
key cartilage proteins, including aggrecan and versican, using western blot analysis and
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immunohistochemistry. We hypothesize that the combination of mechanical injury co-cultured
with excised joint capsule will have a greater degradation effect compared to either mechanical
injury alone or co-cultured joint capsule alone, and that these will be evident in the measures of
GAG loss, biosynthesis rates, and protein levels.
5.2 Materials and Methods
Tissue Harvest
Human tissue composed of knees, ankles, and joint capsule were obtained through the
Gift of Hope Organ and Tissue Donor Network (Elmhurst, Illinois) and in collaboration with
Rush Medical Center (Chicago, Illinois). All research was approved by the Office of Research
Affairs at Rush-Presbyterian-St. Luke's Medical Center and by the Committee on the Use of
Humans as Experimental Subjects at the Massachusetts Institute of Technology. Five donors
with normal body mass index (BMI) levels (less than BMI 24.9) and no history of osteoarthritis
or autoimmune disease were obtained. The 5 donors included various ethnic backgrounds,
different sexes, and were of the ages 19, 19, 42, 55, and 74. A full description of the donors can
be seen in Table 5.1.
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Table 5.1 Information on Donor Tissue
Donor Age Grade Tissue M/F RACE
Human 1 42 0 Knee M Caucasian
Human 2 19 0 Knee and Ankle M Caucasian
Human 3 19 0 Knee and Ankle M Black
Human 4 74 1 Ankle M Asian
Human 5 55 0 Ankle F Caucasian
Table 5.1 List of human donor information and tissue provided by Gift of Hope Organ and
Tissue Donor Network.
In addition, all joint surfaces were scored as grade 0 or 1 on a modified Collins scale
[18], and only cartilage from an area that was smoothly reflective and unfibrillated to visual
inspection was harvested for these experiments. Joint capsule was extracted from the knee joint
of each donor and taken from the areas adjacent to the medial and lateral condyles (Figure 5.1).
Tissue was received and processed within 24 hours of donor death. Upon obtaining the femoral
portion of the knee joint and/or talus of the ankle joint, under sterile techniques articular cartilage
was removed from the medial and lateral femoral patello groove and medial and lateral condyles
(knee) and/or from the trochlear surface, the lateral and medial malleolus, and the anterior and
posterior calcaneal surfaces (ankle) and placed in feeding medium. Feeding medium consisted
of serum-free, 1% ITS supplemented feeding medium consisting of high glucose Dulbecco's
modified essential medium supplemented with 10 nM Hepes Buffer, 0.1 mM nonessential amino
acids, 20 tg/ml ascorbate, 100 units/ml penicillin, 100 ptg/ml streptomycin, and 0.25 ptg/ml
amphoericin B. Articular cartilage was punched with a 3mm diameter dermal punch and
allowed to equilibrate in medium at 370 C and 5% CO 2 for 1 day. After equilibration, 3mm
diameter cylinders were sliced into approximately 800-1000 ýpm thick disks using a brain cutter
instrument (TM-1000, ASI Instruments, Warren, MI). Disks were allocated into 1st mm
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(cartilage disks containing superficial zone of articular cartilage) and 2 nd mm (cartilage disks
absent of superficial zone) pools. These plugs were placed in fresh medium and allowed to
equilibrate for 1 day. JC excised adjacent to the lateral and femoral condyles was cut into -5mm
x 5mm sections approximately 0.5mm thick and equilibrated for 2 days in feeding medium.
Figure 5.1 Location of Joint Capsule and Articular Cartilage
A '
I.".,
JC
Figure 5.1 Schematic of knee joint where orange circles denote location of joint capsule
excision and white ovals denote areas of cartilage harvest. Adapted from Patwari, 2003 [19].
Injury
After two days of equilibration, disks were allocated into one of 4 conditions; (1) free
swell, (2) normal cartilage co-cultured with JC (Co), (3) cartilage mechanically injured, and (4)
injured cartilage co-cultured with joint capsule (INJ+Co). A custom designed incubator housed
loading apparatus[20] was used to compress cartilage disks. Each cartilage disk designated for
mechanical injury was loaded individually in a polysulfone chamber allowing for radially-
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unconfined compression [5, 8, 9]. Cartilage disks were measured for height, compressed to a
final strain of 65% at a velocity of 400% per second, and promptly removed and placed in fresh
culture media as described previously [13]. As has been described previously [8], the different
size and mechanical properties of human cartilage compared to bovine cartilage necessitates an
increase in final strain and strain rate to obtain qualitatively similar mechanical injury.
Application of this strain and strain rate produced a peak stress on the order of 20MPa, and after
injury, visual inspection revealed most plugs altered their round disk shape to an elliptical shape
with samples occasionally showing substantial tissue fracture. Three to five pieces (to ensure
equal amounts of JC tissue) of cut joint capsule were added to Co and INJ+Co conditions.
Protein Biosynthesis
Radiolabel incorporation was measured at days 2, 6, and 16 post-injury for knee cartilage,
and days 2 and 6 for ankle cartilage. In some cases, due to the lack of cartilage tissue harvested,
knee experiments were limited to two time points, days 2 and 6. Human explants were cultured
in fresh media 24 hours prior to 2, 6, and 16 days in 10 jtCi/ml [35S]-sulfate and 20 gtCi/ml [3H]-
proline. After culture, cartilage explants were washed four times over 60 minutes in 1 ml
phosphate-buffer saline (PBS) supplemented with 0.8 mM sodium sulfate and 0.5 mM proline to
remove free radiolabel, and digested in 1 ml protease K solution (100 pg/ml in 50 mM Tris-HCI
and 1 mM CaClz at pH 8) at 600C for 12-18 h. Digested explants were homogenized in
Optiphase Supermix scintillation fluid and measured using a Microbeta plate reader.
Biosynthesis rates were normalized to levels of DNA in the tissue, which was measured by
CyQUANT Cell proliferation assay kit (Molecular Probes, Inc. Eugene, OR) and DNAse
(Applied Biosystems, Foster City, CA).
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Antibodies
Anti-CDAG antibody is used to detect HA binding sequence of aggrecan, versican, and
Link protein as well as the NITGE and VDIPEN neoepitopes. CDAG predominantly binds to
aggrecan species in cartilage [21]. Anti-DPE antibody binds to the N-terminus of versican, a
molecule known for its anabolic response to injury [22, 23].
Western Blotting:
Explants were placed in protease inhibitor and stored at -800 C until extraction. Cartilage
was washed in ice-cold phosphate-buffered saline (PBS) (supplemented with proteinase
inhibitors), and 6 plugs (-50 [tg wet weight) were pooled followed by extraction in 4 M
guanidine HCI (supplemented by proteinase inhibitors), 50 mM sodium acetate, pH 7.3, purified
by G50 and DE52 chromatography as described [24] and deglycosylated core protein from 75
mg dimethylmethylene blue-glycosaminoglycan (DMMB-GAG) was loaded per lane [25].
Immunohistochemistry
Select plugs were fixed in 10% formalin at appropriate time points, sectioned, treated,
and imaged as previously described [25]. IHC probes were individually optimized for
sensitivity, specificity and reproducibility. Thin (4 tm) sections were deparaffinized as described
[26] and incubated in dilute goat serum (1.5% v/v in PBS) for 20 min, prior to exposure to
specific IgGs, diluted to 1, 2, 5 and 10 mg/ml with 1.5% (v/v) goat serum for 30 min at RT. IgG
solutions were removed, and sections were washed extensively in PBS before incubation at RT
for 30 min with 7.5 mg/ml biotinylated goat anti-rabbit IgG (Vector labs). Sections were rinsed
in PBS and then treated with 3% hydrogen peroxide (v/v) in tap water for 10 min, rinsed again in
PBS, and incubated with horseradish peroxidase (HRP) labeled avidinebiotin complex (Vector
labs) for 30 min at RT, washed with PBS and incubated with 3,30-diaminobenzidine (DAB)
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substrate for 30 min. Negative controls (background staining) for each antibody were established
by omission of primary antibody and incubation with non-immune rabbit IgG at the same
concentration and under the same conditions. Specificity was independently established by
Western analysis with human, bovine, and recombinant antigens and antigenic peptide blocking
experiments [21, 24, 26-28].
GAG Loss
The amount of sulfated glycosaminoglycan (GAG) content within the condition medium
and within each cartilage plug was quantified using dimethylmethylene blue (DMMB) dye-
binding assay [29]. Standard curves were generated using known amounts of GAG (Sigma, St.
Louis, MO). Cartilage plugs were proteolytically digested through incubating overnight in
protease K at 600 C. GAG from plugs was measured though DMMB dye. For ease of
comparison, GAG loss data was expressed in percentage of GAG loss to the medium, normalized
by the total GAG (GAG in medium + GAG in plug).
GAG Loss and Biosynthesis Analysis
All data are represented as mean ± SEM. A three-way analysis of variance was used to
test significant differences in biosynthesis data. P-values less than 0.05 were considered
significant.
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5.3 Results
Biosynthesis
Generally the rates of biosynthesis measured over the five different subjects decreased
over time, having the greatest amount of biosynthesis on day 2, followed by a decrease in
biosynthesis on days 6 and 16. Knee Cartilage: Knee cartilage not containing the superficial
zone (2 nd mm) was not significantly responsive to mechanical injury or co-culture treatments, yet
cartilage containing the superficial zone (1st mm) was significantly downregulated in the
presence of INJ and INJ+Co, for 19-year-old tissue (Sulfate and proline) (Figure 5.2A, B,
Appendix 5.7.1), and significantly downregulated 42-year-old tissue by 14% under INJ (Proline)
(Appendix 5.7.1).
Figure 5.2 Biosynthesis rates of 1st mm Human 2 (19 years) Mean ± SEM (n=5)
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Figure 5.2 Biosynthesis rates of [35S]-Sulfate and [3H]-Proline 1st mm knee tissue in Human 2
(19 years). Stars represent significant difference compared to FS conditions (p-values <0.05).
Ankle Cartilage: Ankle cartilage was not significantly affected by co-culture, mechanical injury,
or the combination of co-culture and mechanical injury (Appendix 5.7.1). Interestingly, most of
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the conditions for the 4 tissue samples were transiently upregulated from days 2 to 6 (Figure
5.3A, B, Appendix 5.7.1). This trend was apparent in the youngest tissue, 19 years old (Figure
5.3A, B), as well as the oldest tissue tested, 74 years old (Figure 5.4A, B). This was most
apparent under all tissue specimens when mechanical injury alone was applied. Age: No clear
age-dependent trend was apparent when examining biosynthesis data in both knee and ankle
cartilage (Appendix 5.7.1).
Figure 5.3 Biosynthesis rates of Ankle Human 3 (19 years) Mean ± SEM (n=5)
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Figure 5.3 Biosynthesis rates of [35S]-Sulfate and [3H]-Proline ankle tissue in Human 3 (19
years).
Figure 5.4 Biosynthesis rates of Ankle
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Figure 5.4 Biosynthesis rates of [35S]-Sulfate and [3H]-Proline ankle tissue in Human 5 (74
years). Bars represent statistical significance between ends (p-value < 0.05).
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GAG Loss
Total sGAG content varied from donor to donor. Knee Cartilage: The combination of
mechanical injury and co-cultured JC produced the greatest sGAG loss to the medium in plugs
containing the knee superficial zone. The younger 19-year-old ist mm cartilage appeared more
resilient to the combination of joint capsule and mechanical injury (15% sGAG loss day 6)
compared to middle-age 1st mm cartilage (age 42) samples (40% sGAG loss, Day 6) (Figure
5.5A, Appendix 5.7.2). This age-dependent degradation was not seen in the 2 nd mm (Figure
5.5B, Appendix 5.7.2). The 2 nd mm of knee cartilage produced generally greater amounts of
GAG loss to the medium, as illustrated in Human 2 (Figure 5.5A, B). Injury had a significant
effect on the 19-year-old's GAG loss when comparing the 1st mm of INJ and INJ+Co to FS
conditions (Figure 5.5A). This difference was only apparent at the last time point measured, 16
days after the injury.
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Figure 5.5 Percentage GAG Loss- 19 year
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Figure 5.5 GAG loss to the medium in 1st mm Knee, 2nd mm Knee, and Ankle from Human 2
(19 years old). Percentage GAG loss was determined by GAG lost to the medium divided by
total GAG measured (GAG lost to medium + GAG in plug). Stars represent statistical
significance compared to FS conditions (p-value < 0.05).
Ankle Cartilage: The ankle tissue showed less sGAG loss (generally less than 10% after day 6,
depending on tissue) than the knee (generally 15%-20% after day 6) from human 3 (19 year old).
The older tissue, from donors 74 and 55, was more affected by INJ+Co compared to the two
other younger tissue samples (19 and 19 years) (Appendix 5.7.2).
Western Analysis
Using anti-CDAG antibodies, aggrecan levels were not significantly different under the
conditions of mechanical injury, uninjured cartilage co-culture with joint capsule, or
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mechanically-injured cartilage co-cultured with joint capsule. G -NITEGE/VDIPEN levels
showed no significant changes in aggrecan species within the tissue over the 4 conditions tested
(data not shown).
IHC
Sections were probed using anti-DPE and anti-CDAG antibodies. Versican-DPE showed great
abundance in the 1st mm in vitro injury model, in both the mechanical injury and mechanical
injury co-cultured with joint capsule conditions (Figure 5.6A). Versican, production of which is
indicative of an anabolic response to injury, was detected strongly in mechanical injury
conditions and, with the addition of joint capsule, was more prevalent in the 2 nd mm than in the
1st mm (Figure 5.6A, B).
175
Figure 5.6 Versican-DPE 19 year
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Figure 5.6 IHC samples stained with Anti-DPE targeting Versican expression from 1st mm and
2nd mm knee cartilage from Human 2 (19 years old). Plugs were placed in 10% formalin after 2,
6, and 16 days of treatment post treatment/injury.
Nuclear staining of versican GI domain is also present in the deeper half of the 1st mm
samples (Figure 5.6A). The 2 nd mm plugs are more affected by co-culture than the 1 st mm plugs,
as evidenced by the versican activation (Figure 5.6B). CDAG antibodies pointed out the new
population of aggrecan (Figure 5.7A, B). This staining shows cells in a hyper-anabolic state, and
cells were activated in groupings. These groupings of aggrecan stimulated cells were randomly
activated with no clear trend of spatial or depth dependence.
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Figure 5.7 CDAG 19 years
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Figure 5.7 IHC samples stained with Anti-CDAG targeting aggrecan expression from 1st mm
and 2nd mm knee cartilage from Human 2 (19 years old). Plugs were placed in 10% formalin
after 2, 6, and 16 days of treatment post treatment/injury.
5.4 Discussion
The in vitro injury model demonstrated little effect on the aggrecan species profile within
cartilage, as seen via Western blotting. This result agrees with previous studies [5] from injured
and late stage human OA tissue where no major differences in aggrecan were observed. The
IHC presented for mechanically-injured cartilage with the addition of joint capsule (INJ+Co)
(Figure 5.6, 5.7) have striking similarity to previous IHC where tissue underwent notchplasty
post-ACL reconstructive surgery (Figure 5.8, 5.9) [30].
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Figure 5.8 Notchplasty injured cartilage- Versican-DPE
Anti-DPE
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Figure 5.8 IHC samples stained with Anti-DPE targeting versican expression from human
cartilage tissue taken from notchplasty experiment post-ACL reconstructive surgery. Tissue was
examined 0, 1, 3, and 57 months post-surgery [30].
Human cartilage biopsies were obtained from the lateral femoral condylar notch
expansion as part of ACL repair surgery. Similarities exist in the versican-DPE signaling
abundance (Figure 5.6, 5.8) as well as the cell-associated localization (Figure 5.6, 5.8). From the
IHC, it appears the JC is less effective in the superficial zones of cartilage (1 st mm), and more
effective in the middle to deep zones (2 nd mm) of the cartilage (Figure 5.6, 5.7).
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Figure 5.9 IHC samples stained with Anti-CDAG targeting aggrecan expression from human
cartilage tissue taken from notchplasty experiment post-ACL reconstructive surgery. Tissue was
examined 0, 1, 3, and 57 months post-surgery [30].
Biosynthesis rates of both sulfate and proline were significantly downregulated only at
day 2, under mechanical injury and mechanical injury co-cultured with JC for a 10-year-old
tissue under the 1st mm. Knee cartilage showed a strong transient downregulation over time,
where ankle cartilage showed a transient increase in biosynthesis rates (Figures 5.2, 5.3, 5.4,
Appendix 5.7.1). Mechanical injury alone and mechanical injury plus co-cultured joint capsule
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only affected GAG loss in the 19-year-old cartilage significantly in the 1st mm at day 16 (Figure
5.5A). Ankle tissue showed to be more resilient to cartilage degradation measured through GAG
loss (Figure 5.5C). This point, coupled with the trend that biosynthesis rates increased over time,
provides a substantial difference between knee cartilage and ankle cartilage. The ankle cartilage
appears to have the ability to turn the insult into a stimulatory event, while minimizing the
amount of degradation compared to the control (FS). Knee cartilage, from both 1 st and 2 nd mm
does not exhibit this trend, but responds in an opposite fashion to an injury insult, where the
biosynthesis rates show substantial downregulation at early time points, and the GAG loss to the
medium shows significant changes at later time points compared to the control (FS).
Interestingly the 2 nd mm of knee cartilage tended to exhibit large amounts of GAG loss, while
maintaining comparable biosynthesis rates to the 1st mm. The surface area of the second mm
plugs were all cut, assumably causing major damage to the intricate collagen and general ECM
matrix. The 1st mm plugs still contained an intact superficial zone. This difference is likely a
factor accounting for the difference in GAG loss between the 1st mm and 2nd mm of knee
cartilage.
Taken together, it appears that our in vitro model of injury model mimic certain aspects
of changes in bone-cartilage plugs harvested from patients as part of the surgical procedure
involved in ACL repair. This work further verifies the viable model of mechanical injury co-
cultured with joint capsule in human articular cartilage, and therefore vindicates the mechanical
injury co-cultured with joint capsule model in bovine as has been reported in chapter 4 and
which has been previously investigated [2].
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5.5 Conclusion
An in vitro model of joint injury that includes the combination of mechanical injury to cartilage
and subsequent co-culture with excised joint capsule mimics specific changes observed in human
articular cartilage obtained from notchplasty post anterior cruciate ligament reconstructive
surgery, as seen through IHC analysis. After in vitro injury, knee cartilage exhibited increased
GAG loss and lower biosynthesis over time, while ankle cartilage exhibited less GAG loss over
time and increased biosynthesis rates. The consequence of mechanical injury took 16 days to
fully develop into a significant difference in GAG loss compared to FS. Biosynthesis rates in
knee cartilage were significantly downregulated with the addition of mechanical injury at the
first time point measured, two days after injury.
As previously reported, injurious conditions showed no significant difference in aggrecan species
profile as examined by immunoblotting, up to six days after injury. Ongoing studies are aimed at
further elucidating the molecular responses and cellular signaling pathways underlying the
response of human tissue to combined mechanical injury and joint capsule co-culture.
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5.7.1 Biosynthesis Data- Radiolabel incorporation between conditions
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5.7.2 GAG Loss to the medium
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Chapter 6
The Effects of SODm on Cartilage Subjected to Cytokine
Treatment Combined with Mechanical Injury
* This chapter is a manuscript in preparation for submission
(Wheeler, Cameron A., Perez, Anthony R., Wilkinson, Samuel, Kurz, Bodo, and Grodzinsky,
Alan J.)
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6.1 Introduction
Osteoarthritis (OA) is the most common disabling condition of man in the western world.
OA is a disease of the joint, and includes cartilage, synovial capsule, connective and muscular
tissue, as well as subchondral bone [1]. Adult cartilage is an avascular and hypoxic tissue, which
chondrocytes, the cells within cartilage, are well adapted to. Recently, many researchers have
sought to understand the role of oxygen levels and oxidative stress during the process of cartilage
degradation [2, 3]. In particular, researchers have investigated the role of reactive oxygen
species (ROS), which are byproducts of 02 processing. These ROS include hydrogen peroxide,
radicals (hydroxyl radical), ions (i.e. hypochlorite ion), and anions (superoxide anion). These
ROS have been shown to oxidize nucleic acids, transcription factors, lipids, and different cellular
components which hinder biologic activity, facilitate cell death, and promote extracellular matrix
breakdown [4-9]. Studies have also shown that ROS scavengers or ROS production inhibitors
decrease cartilage loss [10, 11]. ROS species have also been shown to be involved with
chondrocyte apoptosis induced by mechanical injury [12-14].
Superoxide dismutase catalyzes the dismutation of superoxide into oxygen and hydrogen
peroxide [15] As a protein SOD is not able to enter living cells. For that reason SOD mimetics
(SODm), like Manganese(III)tetrakis (1 -methyl-4-pyridyl) porphyrin pentachloride (Figure 6.1)
have been used in many studies in order to influence ROS-dependent cell mechanisms. SODm
has for example the potential to reduce chondrocyte apoptosis induced by injurious compression
[12].
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Figure 6.1 Superoxide Dismutase Mimetic
CH3
Figure 6.1 Superoxide dismutase mimetic structure, Manganese(III)tetrakis (1-methyl-4-pyridyl)
porphyrin pentachloride.
Extra-cellular SOD, the major scavenger of ROS in extracellular spaces, is decreased in
humans with OA, suggesting that inadequate controls of ROS plays a role in the pathophysiology
of OA [16]. While it has been suggested that superoxide dismutase mimetic, SODm (cell
permeable form of SOD), reduces cartilage degradation in mechanically-injured tissue, the
mechanisms by which SODm affect chondrocyte transcription, translation, or post-translational
machinery are not well known.
In vitro mechanical injury has been shown to increase hydraulic permeability [17] and
water content [18-20], decrease stiffness [19, 21], and increase glycosaminoglycan (GAG) lost to
the medium [19, 22-24]. Cells subject to this injury have been shown to decrease biosynthesis
rates [19], undergo apoptosis and necrosis [12, 18, 19, 25], and have elevated levels of protease
192
NC /
H.C=
transcript activity within the first 24 hours. Recent studies showed treatment with cytokines
(e.g., IL-1, TNF-a, IL-6 [22, 26]) following injurious compression in vitro increased GAG loss
and decreased biosynthesis greater than either mechanical injury or cytokine treatment alone.
The objectives of this study was to (1) more fully explore the degradative effects of
mechanical injury and subsequent treatment of inflammatory cytokines on chondrocyte transcript
levels in cartilage explants as well as on levels of tissue degradation (GAG loss), and (2) to test
whether an antioxidant, specifically superoxide dismutase mimetic (SODm), could ameliorate
the degradative effects on cartilage caused by mechanical injury followed by treatment with
selected cytokines.
6.2 Materials and Methods
Tissue Harvest
Cartilage-bone plugs (9 mm in diameter) were harvested from the patello-femoral groove
of 1-2 week old calves. Cartilage disks (1 mm thick x 3 mm diameter) were sliced and punched
from the middle zone as described previously [27], and equilibrated for two days under free-
swell conditions (370 C, 5% CO2) in the presence of serum-free, 1% ITS supplemented feeding
medium consisting of no phenol red, high glucose Dulbecco's modified essential medium
supplemented with 10 nM Hepes Buffer, 0.1 mM nonessential amino acids, 20 ýpg/ml ascorbate,
100 units/ml penicillin, 100 ptg/ml streptomycin, and 0.25 gg/ml amphoericin B.
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Combined Injury Cytokine Model
After two days of equilibration, disks were allocated into one of 4 conditions: (1) free
swell (FS), (2) FS with the addition of 2.5[tM SODm (FS+SOD), (3) cartilage mechanically
injured with the addition of 25 ng/mL TNF-a, 50 ng/mL IL-6, and 250 ng/mL sIL-6R and (4)
injured cartilage with the addition of 25 ng/mL TNF-a, 50 ng/mL IL-6, 250 ng/mL sIL-6R, and
2.59tM SODm. SODm concentration was determined through a dose-dependent experiment (25,
2.5, 0.25, and 0.025 gM SODm) measuring key cartilage related gene transcripts (Appendix 6.1),
as previously presented [28]. A custom designed incubator-housed loading apparatus [29] was
used to compress cartilage disks. Each cartilage disk designated for mechanical injury was
loaded individually in a polysulfone chamber allowing for radially-unconfined compression [19,
22, 23]. Cartilage disks were measured for height, compressed to a final strain of 50% at a
velocity of 1 mm/sec, and promptly removed and placed in fresh culture media as described
previously [30]. Application of this strain and strain rate produced a peak stress on the order of
20MPa.
Gene Expression Time Courses
One hour prior to injury, plugs designated for SODm treatment were incubated under free
swell conditions with medium supplemented with 2.5 tiM SODm. At time = 0, plugs designated
for injury were injured as prescribed and placed in medium that was supplemented with 25
ng/mL TNF-a, 50 ng/mL IL-6, and 250 ng/mL sIL-6R, and incubated at 370 C, 5% CO 2. At
hours, 2, 8, 24, 48, and 72, plugs were flash frozen in liquid N2 and placed in -800 C. Medium
was changed every 48 hours. Each of the time point-conditions in the experiment contained 6
cartilage disks which were pooled and purposely matched across depth, location, and time to
prevent any bias in the results. The gene expression experiment was repeated five times, using
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five different animals for each experiment for an n=5. Positive Control: A positive control
experiment was performed to illicit cellular responses to known reactive oxygen species.
Cartilage disks were harvested as described above, and allowed to equilibrate for 2 days. At time
t = 0, hydrogen peroxide at concentrations of 0, 10, 100, or 1000 giM was added to free swell
plugs. Twenty-four hours post treatment, cartilage plugs were flash frozen and stored in -800 C.
The gene expression experiment was repeated three times, using three different animals for each
experiment for an n=3.
RNA Extraction and Quantization, Primer Design, and Real-Time PCR
Six disks for each time point and condition were taken from the -800 C freezer and
pulverized. In order to prevent RNA degradation, the pulverizing apparatus was constantly
cooled using liquid nitrogen. Trizol (Sigma, MO) was added, and the tissue was thoroughly
homogenized. After chloroform was added, the mixture was transferred to pre-spun phase gel
tubes and spun at 13,000 rpm for 10 minutes at 40 C. The supernatant was removed, and RNA
was extracted using Qiagen RNAeasy mini kit protocol with recommended DNase digest
(Qiagen). RNA was stored in 50 1l of RNase free water under -800 C conditions. RNA
abundance and purity was measured using NanoDrop ND-1000 (NanoDrop Technologies, DE)
with abundance -80gg/ml and purity -2 (260nm/280nm). 1 pg of RNA was reverse transcribed
using Applied Biosystems reagents as previously described [30]. Forward and reverse primers
for 36 relevant genes (Table 6.1) were designed using Primer3 Software
(http://fokker.wi.mit.edu/primer3/input.htm) and Primer Express (Applied Biosystems, CA)
based on bovine genomic sequences, and standard curves were calculated as previously
described [31].
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Table 6.1. List of Cartilage relevant genes measured by qPCR
Housekeeping Matrix Molecules Proteinases Proteinase Inhibitors Apoptotic Gene
18s Aggrecan MMP-1 TIMP-1 Caspase-3
Collagen2 MMP-3 TIMP-2
Link MMP-9 TIMP-3
Fibromodulin MMP-13
Fibronectin ADAMTS-4
ADAMTS-5
Transcrition Factors Growth Factors Cytokines Stress Activated Genes Oxidative Factors
Sox-9 IGF-1 IL-lb CD-44 SOD1
Cox-2 IGF-2 IL-4 HAS2 SOD2
c-Fos TGF-B IL-6 INOS GPX-3
c-Jun OP-1 TNF-a HSP90
bFGF
Table 6.1 List of 36 cartilage relevant genes measured by qPCR. Primer3 and Primer Express
were used to design primers. Standard dilutions were used to calculate relative mRNA copy
number.
Once cDNA was obtained, Real-Time PCR was performed using Applied Biosystems
ABI 7900ht instrument and SYBR Green Master Mix (SGMM, Applied Biosystems, CA).
SGMM was combined with cDNA, and RNase free water was combined with forward and
reverse primers. Using a multi-pipette, 8 different samples of cDNA and SGMM were aliquoted
into a 384 well plate, followed by 48 different primer and water mixes. Plates were run and
inspected for proper amplification and melting curves using SDS 2.3 (Applied Biosystems, CA).
Measured threshold values (Ct) were obtained through SDS 2.3 and converted to RNA copy
number according to previously calculated primer efficiencies using standard curves.
Gene Expression Data Analysis
All data are shown as mean ± SEM. Under each condition and time point, each gene
RNA copy number was normalized to the 18s housekeeping gene from that same condition and
time point [30, 31]. 18s was chosen in light of recent studies showing the variation in expression
of alternative housekeeping genes (i.e., GAPDH, P-actin) in response to certain conditions of
loading of cartilage explants [32]. To examine the time course of gene expression, all conditions
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were normalized to their corresponding free swell condition. Thus, gene expression values
below or above 1 represent a decrease or increase in expression, respectively, compared to FS.
Expression levels due to experimental error, as defined by 6a from mean, were removed. The
Wilcoxon sign-ranked test (a non-parametric test which incorporates the amount of data in the
significance statistic and avoids the assumption of a parameter-based distribution) was used to
judge significance at a p-value less than 0.05. Clustering and Principle Component Analyses: In
addition to measuring changes in the expression magnitude of each gene, we further explored
patterns of co-expression using principle component analysis (PCA) and clustering analysis
performed on all normalized conditions (fold change compared to FS) and time points (2, 8, 24,
48, 72 hours) over 47 genes. This resulted in a 20 x 35 matrix which was standardized by
expression amplitude as described previously [31 ]. After normalization of the data using PCA,
the maximal dimensional space was reordered according to greatest dimensional variance where
the first three detentions or principle components represent -79% of the variance in the data [33,
34]. Once the principle components had been calculated, a k-means clustering algorithm was
applied to cluster the components into k groups. The average and variance of each projected
coordinate group was calculated to give the group centroid. Centroid vectors were formed by
combining the three main principal components weighted by their projected centroid coordinate.
The uniqueness of each group's expression patterns was evaluated by the Wilcoxon sign-ranked
test and special separation between the centroids were measured and deemed significant through
euclidean distance and student's t-test.
+/- Injury +/- Cytokine Models
To elucidate the effects of mechanical injury, cytokine treatment, and SODm treatment,
plugs were allocated into one of eight different conditions: (1) free swell (FS), (2) FS with the
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addition of 100 ng/mL TNF-a (FS+TNF), (3) mechanically-injured cartilage (INJ), and (4)
mechanically-injured cartilage with the addition of 100 ng/mL TNF-a (INJ+TNF). Conditions
(5)-(8) consisted of the first four conditions treated with 2.5gM SODm.
GAG Loss Time Course
One hour prior to injury, plugs designated for SODm treatment were incubated under free
swell conditions with medium supplemented with 2.5 gM SODm. At time = 0, plugs designated
for injury were injured and placed in their allocated medium conditions. Three days post injury,
medium and plugs were collected and stored in -200 C until processing.
GAG Loss
The amount of sulfated glycosaminoglycan (GAG) content within the condition medium
and within each cartilage plug was quantified using dimethylmethylene blue (DMMB) dye-
binding assay [35]. Standard curves were generated using known amounts of GAG (Sigma, St.
Louis, MO). Cartilage plugs were proteolytically digested by incubating overnight in protease K
at 60 0C. GAG from plugs was measured though DMMB dye. For ease of comparison, GAG
loss data was expressed in percentage of GAG loss to the medium, normalized by the total GAG
(GAG in medium + GAG in plug). Values were normalizes to FS to determine GAG loss-fold
change compared to FS values. Each condition had a total of 5 distinct plugs which were
matched across depth, location, and condition to ensure unbiased. This experiment was repeated
with 6 different animals.
GAG Loss Analysis
All data are represented as mean ± SEM. A three-way analysis of variance with post-hoc
Tukey was used to test significant differences in GAG loss data. P-values less than 0.05 were
considered significant.
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6.3 Results
Gene Expression
Similar to previous studies using injurious loading alone (no cytokines) [30], MMP-3,
ADAMTS-5, TIMP-1, c-Fos, c-Jun, and TGF-3 were upregulated in response to INJ, while
aggrecan, SOX-9, IGF-2, IL-10, and TNF-a remained largely unaffected (Figure 6.2A, Appendix
6.7.2).
Figure 6.2 Aggrecan and Collagen 2 Gene Expression
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Figure 6.2 Aggrecan and collagen type II gene expression at 2, 8, 24, 48, and 72 hours after
treatment. Data was plotted relative to FS conditions, and stars indicate significance (p-values <
0.05) between condition and corresponding FS value. Mean ± SEM.
When comparing the effects of SODm under FS or INJ, most genes, including: aggrecan,
collagen II, link, fibromodulin, MMP-1, MMP-3, ADAMTS-4, ADAMTS-5, TIMP-1, TIMP-3,
SOX-9, COX-2, c-Fos, c-Jun, IGF-1, IGF-2, TGF-P, bFGF, IL-10, IL-4, IL-6, TNF-a, CD-44,
HAS2, iNOS, and HSP90 were upregulated by SODm independent of INJ (Appendix 6.7.2), as
exemplified by aggrecan and collagen type II (Figure 6.2A, 6.2B). MMP-3, MMP-9, MMP-13,
ADAMTS-4, and ADAMTS-5 were severely upregulated by injury, and appeared to be further
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stimulated by SODm treatment (Figure 6.3B, Appendix 6.7.2).
Figure 6.
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Figure 6.3 Caspase-3 and MMP-9 gene expression at 2, 8, 24, 48, and 72 hours after treatment.
Data was plotted relative to FS conditions, and stars indicate significance (p-values < 0.05)
between condition and corresponding FS value. Mean ± SEM.
TIMP-1 and TIMP-2 were expressed on the same order of magnitude as the key degradative
enzymes, MMP-9, MMP-13, and ADAMTS-5 (Appendix 6.7.2). Cyclooxygenase 2 (COX-2)
was highly upregulated with SODm treatment and was synergistically upregulated when injury
and SODm were combined (Appendix 6.7.2). Osteogenic protein 1 (OP-1) was highly
upregulated in response to injury, underlying the finding that OP-1 acts as an initial anabolic
response to cartilage insult [36]. Also of note, basic fibroblast growth factor (bFGF) was highly
upregulated with the addition of SODm and injury, individually and in combination (Appendix
6.7.2). This growth factor has been shown to negate the effect of key anabolic stimuli and can be
interpreted as a negative or catabolic response to SODm treatment and injury [37]. Inducible
nitric oxide synthase (iNOS) was highly upregulated in response to injury (as seen in chapter 3)
and the treatment of SODm did not inhibit iNOS transcriptional activity (Appendix 6.7.2).
Caspase-3 was significantly upregulated when exposed to INJ (Figure 6.3A). SODm did not
appear to have a significant effect on caspase-3 transcripts under FS or INJ conditions. SOD2
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showed little to no transcriptional effect of SODm treatment or injury (Appendix 6.7.2). SODI
and GPX-3 were upregulated slightly with the addition of SODm and were significantly
upregulated with INJ. SODm significantly downregulated SOD2 under FS conditions but had
the opposite effect post INJ (Appendix 6.7.2).
Effects of SODm: Isolating the effects of SODm, under INJ, only aggrecan and collagen
II showed a distinct monotonic transient up-regulation in the presence of SODm (Figure 6.4A,
B).
Figure 6.4 Effects of SODm treatment- Aggrecan and Collagen 2
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Figure 6.4 Effects of SODm treatment on aggrecan and collagen type II gene expression at 2, 8,
24, 48, and 72 hours after treatment. Data was plotted relative to corresponding loading
conditions (FS or INJ), and stars indicate significance (p-values < 0.05) between SODm
treatment and corresponding loading value. Mean ± SEM.
No genes measured were consistently downregulated by SODm under FS or INJ conditions,
while most genes measured were upregulated by SODm (Appendix 6.7.4). Caspase-3, HAS2,
TNF-at, bFGF, TGF-j3, COX-2, TIMP-1, TIMP-3, and fibromodulin showed at least a ten-fold
increase of expression with SODm treatment under FS and/or INJ conditions (Appendix 6.7.4).
Positive Control: H202 treatment differed from the profile obtained through the
mechanical injury + cytokines model. Cartilage explants subject to 1000pm H20 2 did not
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survive the treatment and no significant amount of mRNA could be extracted. Hydrogen
peroxide dramatically decreased expression of aggrecan, ADAMTS-4, ADAMTS-5, SOX-9, c-
Fos, and c-Jun at concentrations of 10[tM and 100[tM (Appendix 6.7.2). MMP-3 and collagen
type II were upregulated with the treatment of H202 (Appendix 6.7.2). Yet aggrecan, c-Fos, c-
Jun, ADAMTS-4, and ADAMTS-5 were upregulated in response to SODm treatment under
H202 conditions, and MMP-3 was downregulated (Appendix 6.7.2).
Clustering: Clustering analysis of all conditions and all time points revealed 5 distinct
groups of genes as seen plotted in principle component space (Figure 6.5).
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Figure 6.5 Genes Clustered in PC Space
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Figure 6.5 Standardized gene expression visualized in principle component space. Principle
components 1, 2, and 3 represent 79% of the variance in the data. Genes were allocated to one of
five distinct groups by way of k-means clustering. Large solid black circles denote the centroid
of the corresponding group.
Group 1 was composed of potent proteinases MMP-13, ADAMTS-5; growth factors OP-1 and
bFGF; all oxidative factors measures SOD 1, SOD2, and GPX-3; as well as, CD-44, HAS2,
iNOS, and Caspase-3. Group 2 was composed of the key ECM gene, Collagen II, protease
inhibitors, TIMP-2, TIMP-3, as well as, SOX-9, IGF-1, and TNF-a. Group 3 was composed of
most of the matrix metalloproteinases measured, MMP-1, MMP-3, MMP-9, as well as
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ADAMTS-4, TIMP-1, Cox-2, c-Fos, c-Jun, and TGF-3. Group 4 was composed of key ECM
genes, Aggrecan, Link, Fibromodulin, the growth factor, IGF-2, and HSP90. Group 5 was
composed of the measured interleukins, IL-1 3, IL-4, and IL-6, and Fibronectin. Following
combined INJ + SODm treatment, Groups 1 and 2 (Figure 6.6A, B) were dominated by the
effects of INJ, although SODm upregulated earlier (Group 1) and later (Group 2) time points.
Group 3 (Figure 6.6C), containing mainly ECM molecules and proteinases, showed additive
effects under the combination of INJ and SODm. Group 4 (Figure 6.6D) was upregulated and
showed peaks under all conditions at 24 hours. Composed primarily of cytokines, Group 5
(Figure 6.6E) exhibited a strong effect at 8 hours for INJ, which was negated by addition of
SODm.
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Figure 6.6 Centroid Profile
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Group 1 MMP-13, ADAMTS-5, OP-1, bFGF,CD-44, HAS2, iNOS, Caspase-3, SOD1, SOD2, GPX-3
Group 2 Collagen II, TIMP-2, TIMP-3, SOX-9, IGF-1, TNF-a
Group 3 MMP-1, MMP-3, MMP-9, ADAMTS-4, TIMP-1, Cox-2, c-Fos, c-Jun, TGF-B
Group 4 Aggrecan, Link, Fibromodulin, IGF-2, HSP90
Group 5 Fibronectin, IL-1b, IL-4, IL-6
Figure 6.6 Five expression profiles represent the combination of FS + 2.5 gtM SODm, INJ, and
INJ + 2.5 giM SODm. Centroid profiles were calculated through the average projection
coordinates of genes in each group, and transformed from principle component space through
use of the calculated principle components. Mean ± SE (n varies based on group component
number)
GAG Loss
To more fully understand and isolate the effects of cytokine treatment, mechanical injury,
and the treatment of superoxide dismutase, GAG loss to the medium was measured under 8
different conditions; FS, mechanical injury, TNF-a treatment, and mechanical injury combined
with cytokine treatment, all with or without SODm treatment. A 3-way ANOVA showed
significant difference with TNF-a treatment (p<0.001), SODm treatment (p<0.001), and INJ
(p<0.001) over all the data (Figure 6.7). As seen previously, bovine disks treated with TNF-a
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had significantly higher GAG loss, even more pronounced by the combination of TNF-a +
mechanical injury. SODm significantly increased GAG loss in TNF-a treatment alone (>2.75x
FS conditions). Although not significant in all conditions measured, all conditions showed the
trend of increasing GAG loss with SODm treatment (Figure 6.7).
Figure 6.7: sGAG Loss Relative to FS n 0 E 2.5pM
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Figure 6.7 sGAG loss to the medium in free swell (FS), mechanical injury (INJ), TNF-a
treatment (TNF), and mechanical injury with TNF-a treatment (INJ+TNF) and all conditions ±
2.5 gM SODm plotted relative to FS conditions. Stars indicate significance (p-values < 0.05)
between condition and FS, and bar indicates significance between two conditions. Mean ± SEM.
6.4 Discussion
Gene Expression
All genes examined were strongly stimulated by SODm treatment under FS conditions
suggesting SODm acts as a purely stimulatory factor. Consistent with the hydrogen peroxide
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positive control experiment, genes were upregulated when treated with the combination of the
strong oxidant hydrogen peroxide and SODm. Following INJ+C (mechanical injury + cytokine)
treatment plus SODm, most gene transcription levels were upregulated; this pattern was most
dramatic for aggrecan and IGF-2 (Figure 6.2A, Appendix 6.7.3). These findings suggest pro-
anabolic activity when INJ+C disks were treated with antioxidant.
The INJ+C+SODm condition elevated expression of COX-2, OP-1, bFGF, iNOS, and
HSP90 to levels greater than 100x FS. These highly responsive genes could be divided into two
groups: anabolic response to injury insult or catabolic response to injury insult. As has been
reported, OP-1 and HSP90 act as an initial anabolic response to injury, while COX-2, bFGF, and
iNOS are clearly catabolic factors [38-40]. The mechanical injury and cytokine model of injury
increased the magnitude of COX-2, OP-1, bFGF, iNOS, and HSP90 to a greater extent compared
to mechanical injury alone or cytokine treatment alone [30]. SODm had little effect on Caspase-
3 gene expression, although as expected, Caspase-3 was upregulated with INJ+C. Since SODm
has been shown to inhibit nuclear blebbing after mechanical injury significantly [12] it might be
suggested that the SODm effect on apoptosis is not based on an altered gene expression level of
caspase-3, but on an inhibition of the activation of pre-existing caspases. As part of the apoptotic
signaling pathway ROS seem to be generated at the mitochondrial membrane, resulting in
mitochondrial dysfunction and subsequent activation of caspases by release of cytochrome C and
other caspase activators [41-44]. SOD1 and GPX-3 responded positively through SODm
treatment but were dominated by the INJ+C response. SODm downregulated the injury-
dependent increase of SOD2 (primarily located in the mitochondria). Table 6.2 shows the
distinct separation of the 5 clustered groups.
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Table 6.2 Centroid Uniqueness
P-value of
Centroid Centroid 1 Centroid 2 Centroid 3 Centroid 4
Separation
Centroid 2 0.016
Centroid 3 0.021 0.031
Centroid 4 0.032 0.051 0.037
Centroid 5 0.064 0.107 0.116 0.036
Table 6.2. P-value of Centroid Profile Separation. P-values were obtained through student T-
test, comparing centroid to centroid Euclidean distance. Degrees of freedom were taken as the
number of genes in each group.
From clustering analyses, key cytokines (IL-113, IL-4, and IL-6) were grouped together in group
5 (Figure 6.6E) where the 8-hour peak under INJ+C conditions was significantly downregulated
by SODm treatment. These findings suggest a transcriptional mechanism by which the
antioxidant may abrogate the negative effects of the INJ+C model by upregulating anabolic
genes and downregulating cytokines. Examining the transcriptional effects of SODm on
ADAMTS-4, SOX-9, c-Fos, c-Jun, IGF-2, TGF-B, IL-1b, CD-44, and HAS2, SODm appears to
act via an INJ+C-dependent manner, whereas the transcriptional effects of SODm on fibronectin,
IL-4, and IL-6 were independent of INJ+C (Appendix 6.7.4).
GAG Loss
Surprisingly, GAG loss was increased with the addition of SODm. After three days in
culture, GAG loss is significantly increased compared to FS conditions, ranging from >2X FS
with TNF-a alone, to nearly 3X FS with TNF-a and mechanical injury. These values increase to
3x with TNF-a alone and 3.5x with TNF-a and mechanical injury when 2.5 jgM SODm is added.
These data further support the increases in transcription activity under INJ+C conditions of
MMP-1 (peak 10x FS), MMP-3 (peak 67x FS), MMP-9 (peak 62x FS), MMP-13(peak 26x FS),
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ADAMTS-4 (peak 25x FS) and ADAMTS-5 (peak 69x FS) with the addition of SODm over the
same time period measured. Previous studies have shown an upregulation of iNOS expression
with the addition of N-acetyl-l-cysteine (NAC), an antioxidant like SODm which may suggest a
role for antioxidants in GAG loss [45]. As a side note, NAC increased cell viability in isolated
chondrocytes, as seen with SODm [46]. In this study, iNOS was upregulated to peak values of
125x FS under the treatment of SODm alone (FS + SODm). When mechanical injury, cytokine
treatment, and SODm were combined, iNOS levels increased to peak values of 600x FS
(Appendix 6.7.3). This correlation with increased iNOS and GAG loss with the presence of an
antioxidant supports the idea that SODm mediates GAG loss through the increase of NO, a
product of the upregulated iNOS.
This work supports the notion that SODm does not have the general ability to protect
against cartilage matrix degradation. While SODm has been shown to decrease levels of
apoptosis post injury, it appears that SODm does not have the ability to protect the cartilage
matrix against the harmful effects of treatment with cytokines and/or mechanical injury and, in
some cases, exacerbates matrix degradation.
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6.5 Conclusion
In a complex model of injury, namely one composed of mechanical injury and treatment
of destructive cytokines, SODm, an antioxidant, does not demonstrate the ability to abrogate the
negative effects of this complex injurious assault on matrix degradation. On the contrary, the
treatment of SODm tended to stimulate all genes measured. In particular, it increased protease
transcript levels, as well as increased in GAG loss, a measure of cartilage degradation. The
injury model elicited dramatic responses of COX-2, OP-1, bFGF, iNOS, and HSP90 to levels
greater than 100 fold the control, suggesting these genes play a crucial role in the initial response
to traumatic injury within the first three days. The magnitude of these gene transcripts has not
been observed previously in the application of mechanical injury or cytokine treatment to our
knowledge. As has previously been suggested, the combination of cytokine treatment and
mechanical injury produced the most cartilage degradation, opening a possibly insightful in vitro
model of osteoarthritis. Since ROS influence on signaling pathways in chondrocytes depends on
the kind of ROS (superoxide versus hydrogen peroxide [1]), and SODm eliminates both
superoxides and hydrogen peroxide, further studies are needed with antioxidants with greater
specificity to determine the effect of ROS on chondrocytes. Whether antioxidants may serve as
therapeutics for osteoarthritis for their ability to decrease cell death, or as targets for therapeutics
because of their increased degradative effects on cartilage, as seen here, remains to be seen.
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Chapter 7
Summary and Conclusion
The onset of osteoarthritis (OA) is a fascinating subject to study because of the
multifactorial influences that contribute to the disease. While genetic and environmental factors
play a role in the development of OA (obesity, exercise health, traumatic injury), the time scales
at which these factors act and contribute to degradation of cartilage are on the order of years to
decades. Given this complex etiopathogenesis, in vitro models of the onset of cartilage
degradation have been developed to isolate specific aspects of mechanical compression,
molecular communication (growth factor and cytokine), and tissue communication (joint capsule
and synovium). This study investigated models of joint injury in combination with potential
therapeutic agents having the ability to abrogate the negative effects of these in vitro injury
models.
In Chapter 3, cartilage explants subjected to a ramp and hold compression with a final
strain of 50% were treated with IGF-1. Experiments were performed to assess expression levels
of a range of ECM related genes in response to static loading in the presence and absence of
IGF-1. Through k-means clustering analysis, major co-expression trends were elucidated,
grouping genes into highly responsive, non-responsive, and differentially active gene profile
groups. The gene pairs MMP-1 and IGF-2, TIMP-3 and ADAMTS-5, and type II collagen and
IGF-1 were consistently co-expressed in multiple clustering conditions, suggesting the
possibility of strong regulation and control relationships between members of each pair.
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Aggrecan and link protein responded to IGF-1 in a compression-dependent manner, whereas
type II collagen and fibronectin appeared to respond to IGF-1 in a manner independent of
compression. While aggrecan transcripts were significantly upregulated with the addition of
IGF-1 under 0% compression, IGF-1 was unable to upregulate aggrecan when the cartilage
explants were statically compressed to 50% strain. In comparing aggrecan gene expression to
aggrecan synthesis, these data suggest that aggrecan synthesis is transcriptionally regulated by
IGF-1 while the inhibition of aggrecan synthesis by compression is post-transcriptionally
regulated. However, more studies are needed to elucidate the specific stimulatory mechanism(s)
induced by IGF-1 and the post-translational inhibitory effects of compression.
Chapter 4 focused on an extensive study of the transcriptional, translational, and
apoptotic effects of various models of injury in combination with growth factor stimulus. ECM
genes were generally downregulated and proteases upregulated in response to Co, INJ, and/or
INJ+Co, where genes responded most dramatically to INJ+Co for both short-term expression and
longer-term expression. GF treatment failed to rescue the downregulation of ECM transcripts
and the upregulation of protease transcripts. Clustering analysis of both short-term gene
expression and longer-term gene expression showed distinct groupings of co-regulated genes.
Joint capsule gene expression was also measured and revealed that protease expression is much
higher in joint capsule than normal (free swelling) cartilage tissue. Growth factor treatment
stimulated all genes measured in the JC, with the exception of ADAMTS-5. Examining the rates
of biosynthesis, Co and INJ+Co dramatically affected uptake of 35S and 3H over the 16 day time
period measured. After treatment with OP-1 and IGF-1, biosynthesis rates measured by 3H-
proline incorporation improved dramatically, while biosynthesis measured by 35S-sulfate
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incorporation only slightly increased. Dramatic amounts of apoptosis were measured after
mechanical injury. JC appeared to have little effect on apoptosis. Growth factor treatment
significantly decreased levels of apoptosis under mechanical injury alone. The in vitro models of
injury, Co, INJ, and INJ+Co, mimic a physiologic system of in vivo injury. Growth factor
treatment had a slightly stimulatory effect on biosynthesis rates, decreased apoptosis, and had
little effect on recovering gene transcripts after injury. While OP-1 and IGF-1 have a positive
effect on apoptosis, the data presented support the role of OP-1 and IGF-1 as remodeling factors,
as opposed to anti-catabolic and pro-anabolic factors as has been previously reported. Further
studies are needed to understand the mechanistic action of OP-1 and IGF-1 to clarify their
reparative and possible therapeutic capabilities.
In Chapter 5 the model of mechanically injured cartilage co-cultured with excised joint
capsule was examined using adult human tissue. The data showed that the combination of
cartilage mechanical injury and subsequent co-culture with excised joint capsule strongly mimics
certain changes in human articular cartilage obtained from notchplasty during reconstructive
surgery following anterior cruciate ligament rupture, as seen through IHC analysis. After injury,
knee cartilage exhibited increased GAG loss levels and lower biosynthesis rates, while ankle
cartilage showed less GAG loss and increased biosynthesis rates over time. The conditions
including mechanical injury took 16 days to fully develop a significant difference in GAG loss
compared to FS controls. Biosynthesis rates in knee cartilage were significantly downregulated
with the addition of mechanical injury at the first time point measured, two days after injury. As
previously reported, injurious conditions showed no significant difference in aggrecan species
profile as examined by immunoblotting, up to six days after injury. Ongoing studies are aimed at
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further elucidating the molecular responses and cellular signaling pathways underlying the
response of human tissue to combined mechanical injury and joint capsule co-culture.
In Chapter 6 a complex model of joint injury, consisting of mechanical injury to cartilage
and subsequent treatment with inflammatory cytokines (TNF-a, IL-6, and IL-6R) in combination
with an antioxidant, superoxide dismutase mimetic (SODm) was investigated at the level of
transcription. SODm did not demonstrate the ability to abrogate the negative effects of this
complex injurious assault. On the contrary, the treatment of SODm tended to stimulate all genes
measured. In particular, it increased protease transcript levels, as well as increased in GAG loss,
a measure of cartilage degradation. The injury model elicited dramatic responses of COX-2, OP-
1, bFGF, iNOS, and HSP90 to levels greater than 100 fold the control, suggesting these genes
play a crucial role in the initial response to traumatic injury within the first three days. The
magnitude of these changes in gene transcript levels had not been observed previously in the
application of mechanical injury or cytokine treatment to our knowledge. As has previously
been suggested, the combination of cytokine treatment and mechanical injury produced the most
cartilage degradation, opening a possibly insightful in vitro model of osteoarthritis. Since ROS
influence on signaling pathways in chondrocytes depends on the kind of ROS (superoxide versus
hydrogen peroxide), and SODm eliminates both superoxides and hydrogen peroxide, further
studies are needed with antioxidants with greater specificity to determine the effect of ROS on
chondrocytes. Whether antioxidants may serve as therapeutics for osteoarthritis for their ability
to decrease cell death, or as targets for therapeutics because of their increased degradative effects
on cartilage, as seen here, remains to be seen.
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In conclusion, this work has extensively investigated the effects of multiple injury models
including the combination of static compression, injurious loading, cytokine treatment, co-
culture with injured or excised joint capsule, and selected combinations of these models.
Through studies in both bovine cartilage and human cartilage, we have found these models
mimic the onset of osteoarthritis. The growth factors and antioxidants, IGF-1, OP-1, and SODm,
were tested to examine if they had the capability to abrogate the negative effects of these injury
models. Taking a systems approach, through extensive measures of gene expression, cell
viability, biosynthesis data, protein expression, and GAG loss, OP-1 and IGF-1 were unable to
rescue transcriptional expressions due to injury, but were able to rescue cells from apoptosis, and
slightly increase biosynthesis rates. The antioxidant, SODm, showed no ability to selectively
diminish protease transcriptional activity, and cartilage treated with this antioxidant significantly
increased GAG loss to the medium, while diminishing levels of apoptotic cells. Taken together,
this work supports further investigation of 1) the mechanisms of action of OP-1, IGF-1, and
SODm in order to elucidate their possible therapeutic value, and 2) the validation of in vitro
injury models in mimicking the onset of OA.
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Appendix A: Experimental Protocols
A.1 RNA Extraction Protocol- Bovine
Base & Top of Pulverizer
Pulverizer ready to pound
Stopper & pole
Pulverizer ready to freeze
Tissue Tearor (Homogenizer)
Sheath and Blade Blade is flush within sheath
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Tissue preparation
0) You should prepare/label all required tubes before starting. Also make up the DNase used in
step 6 of the RNA extraction protocol ahead of time and store in ice bath. All steps for the
RNA extraction are taken from the QIAGEN RNeasy MiniKit for animal tissue. Pages 54-55.
Obtain volumes of chloroform, 100% ethanol and RLT buffer (with 3-Me added). Add
20mls of DI water to two 50ml tubes for cleaning the homogenizer. Pre-spin Eppendorf
phasegel tubes for 15 seconds.
1) Samples should be stored by either flash-freezing in liquid nitrogen and placing in a -80C
freezer, or placing in RNAlater solution and placing in -80C freezer. It is best if cartilage has
been dissected into multiple 3x3xlmm pieces.
2) Place pulverizer and pole in container and bathe in liquid nitrogen repeatedly to cool.
Remove two samples from the -800 C freezer and place in ice bath. Cool pulverizer again
with liquid nitrogen.
3) Remove pulverizer and bend its arms downwards. Add cartilage samples to top of pulverizer
(make sure metal stopper is in place). Place pole into top base. Hit pole firmly 8-10 times
with a hammer, while holding pole and top of pulverizer.
4) Lift top of pulverizer and gently tap pole to release metal stopper. Place a 5ml polypropylene
tube beneath pulverizer, turn pulverizer sideways and tap pole on side of bench to release the
smashed cartilage into tube. Place polypropylene tube with pulverized cartilage in -80 deg
Freezer. **
5) Clean pulverizer with sterile gauss and if necessary re-cool with liquid nitrogen. Repeat steps
2 to 5 with next sample.
6) Remove all polypropylene tubes from -80 deg freezer, take off caps, and add 5401l of Trizol
to each. Ensure that cartilage is submerged in trizol; change tips.
7) All samples should now be pulverized and have Trizol added. Set up the homogenizer so that
the blade is flush with the sheath.
8) Place homogenizer in first water tube, turn on and rinse, turn off, remove and shake dry.
Repeat in second water tube. The second water tube should still look clean at the end of the
Tissue preparation protocol.
9) Place homogenizer into first sample, turn onto low speed, and slowly increase speed. Sample
should be homogenized in less than 20 seconds. Never turn tissue tearor past level 2. Place
sample back in ice bath. Repeat steps 7 & 8 until finished.
10) Remove samples from ice bucket, wait 30 min for samples to soak in trizol.
11) Add 60Wl of chloroform (final 10%) to each tube.
12) Mix Trizol, chloroform, cartilage (should turn cloudy pink) and transfer sample to pre-spun
phasegel tubes. Cut off end of pipette tips if cartilage repeatedly clogs pipette.
13) Spin phasegel tubes at maximum speed for 10 minutes at 40C (room temperature if cold
room centrifuge is not available).
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RNA extraction
1) Make sure all QIAGEN reagents are ready. Buffer RPE should have ethanol added to the
bulk volume when the kit is first used. Each month a 10ml aliquot of Buffer RLT mixed with
1OOX P-Mercaptoethanol must be made. n-Me is highly toxic and must remain in the
chemical fume-hood.
2) The following steps are taken from the QIAGEN RNeasy Mini Protocol.
3) While the phasegel tubes are spinning add 250Wl of 100% ethanol to a set of RNase-DNase
free 1.5ml centrifuge tubes. Then add 3 5 0pl of RLT buffer (which contains n-Me).
4) Transfer the supernatant in a phasegel tube to the new centrifuge tube and immediately mix
the supernatant, ethanol and RLT buffer. Transfer half the solution to the pink RNeasy spin
column (less than 700gl). Repeat for each phasegel tube. Centrifuge spin columns for 15sec
at 10,000 rpm, allowing 5sec for ramping up, then discard flow through. The RNA is now
attached to the silica membrane in the pink tubes. Add the remaining sample from the
centrifuge tube to the spin columns and spin again at 10,000rpm. Discard flow through.
Steps 5 to 8 are the for DNase digestion to remove genomic DNA, and can be found in the
QIAGEN RNeasy Mini Protocol (p98-99).
5) Pipette 350l1 of Buffer RW1 into spin column and centrifuge for 15sec at 10,000rpm,
allowing 5sec for ramping up. Discard flow-through into separate bin and reuse collection
tube.
6) Prepare ahead: Make a mastermix of 10gl of DNase stock solution to 70•l of RDD Buffer
per sample. Once dissolved DNase should be stored in the -20C freezer in aliquots. Thawed
DNase aliquots should not be re-frozen, instead store in the 40 C fridge (generally choose
aliquot size carefully).
7) Pipette 80pl aliquots of DNase mix directly onto the spin column membrane, tap gently to
ensure the entire membrane is covered. Incubate on bench top for 15 minutes at room
temperature.
8) Pipette 350gl of Buffer RW1 into spin column and centrifuge for 15sec at 10,000rpm,
allowing 5sec for ramping up. Discard flow-through and collection tubes into appropriate
bins.
9) Place spin column into a new 2ml collection tube, add 500pl of Buffer RPE (with ethanol
previously added), centrifuge for 15sec at 10,000rpm, allowing 5sec for ramping up. Discard
flow-through into separate bin and reuse collection tube.
10) Pipette 500l of Buffer RPE (with ethanol added) into spin column, centrifuge for 2 minutes
at maximum speed. After spin remove spin column from collection tube and wipe the outside
gently with sterile gauze to remove any residual ethanol, which may interfere with
subsequent reactions.
11) Place spin column into 1.5ml collection tube (supplied, rounded bottom). Add 50gtl of Rnase-
Dnase free dH20 from QIAGEN kit. Spin at 10,000rpm for 1 minute, and then place
immediately in -800C freezer, discard column.
12) Keep RNA in -800 C to minimize degradation.
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A.2 RNA Extraction Protocol- Human Tissue
Small Scale Human Cartilage RNA Protocol - 11/21/04
This protocol is designed for harvesting intact RNA from ~ 0.05 - 0.2 g of snap frozen cartilage.
Expected yields should be about 10-15 gg RNA/g tissue.
Suggested reagents and materials:
All materials should be molecular biology grade or higher, and RNase-free. Gloves should be worn
at all times to prevent potential RNA degradation. Use of a fume hood is also recommended.
Ambion Pierce Chemicals
Acid Phenol:CHCl 3 - cat # 9720 Aquasil Silanizing Fluid - cat #
42799
Phenol:CHCl 3 :IAA - cat # 9730
1.5 ml Non-stick RNase free microfuge tubes - cat # 12450 Sigma Aldrich
Nuclease free water - cat # 9937 CHC13
Invitrogen Zymo Research
TriZol - cat # 15596-026 RNA clean up kit #R1015
Other materials
SPEX Certiprep 6750 Freezer mill
SPEX Certiprep Microvials # 6753
Microfuge
2 ml screw cap sample tubes
Barrier-tip pipet tips
Liquid nitrogen
Dry Ice
Wet ice
Methanol
Vortexer
Eppendorf Phase Lock Gel (Heavy, 2.0 ml) - Brinkman Instruments cat # 955154045
1. Silanize grinding microvials as per manufacturer's instructions, including impactors and end
caps. Air dry for 1 day in hood. Discard waste as appropriate. Store grinding microvials at -80
OC the day prior to RNA extraction, if possible..
2. Powder snap frozen cartilage (in liquid N2) using a SPEX 6750 Freezer mill. Pre-chill chamber
and grinding vials in liquid nitrogen prior to use (minimum of 10-15 minutes is recommended).
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Keep grinding vials cold at all times. Allowing the vials to warm even slightly will decrease
RNA yield and quality dramatically.
Powdered tissue using the suggested settings: Cycles: 3
Pre Cool: 5 minutes
Cool between cycles: 2 minutes
Rate: 10
Powder time: 1 minute
3. Remove one end cap from grinding microvial, and gently transfer powdered cartilage into 2 ml
screw cap tube on dry ice. Use 1-2 ml of TriZol per 100 mg tissue. Do not let powdered tissue
warm up! Vortex for 1 minute. Ensure powder is totally resuspended in TriZol. Rotate for 1
hour at RT.
4. Pellet samples, 12,000 x g, 5' at 4 OC. Transfer supernatant to 1.5 ml eppendorf tubes. (At this
point may need to split each sample equally into two tubes). Note initial starting volume. Add
0.2 volumes of CHC13 per tube. Vortex ~ 15 - 30 seconds. Incubate at RT for 3 minutes.
Centrifuge for 15 minutes @ 12,000 x g, 4 oC. Optional: Remove about 10% of lowest phase.
Add another 0.2 volumes CHCl3. Vortex for 15 seconds. Incubate at RTfor 3 minutes.
Centrifuge for 15 minutes @ 12,000 x g, 4 OC.
Transfer aqueous phase to fresh tubes.
5. Add one volume Ambion Acid Phenol:CHC13 and vortex. Incubate on ice, 10 minutes.
Centrifuge at 15,000 x g, 15 minutes. Added back 100-200 pl1 dH2O/tube and back extract.
Transferred aqueous phase to fresh tubes. Repeat extractions with one volume
Phenol:CHC13:Isoamyl (25:24:1). Chill on ice 10 minutes. Centrifuge at 15,000 x g, 15
minutes, remove aqueous phase. Finally, extract aqueous phase with one volume CHC13, vortex
briefly, and transfer to pre-spun Phase Lock Gel (Heavy, 2.0 ml) tubes. Centrifuge at 15,000 x g,
5 minutes. Remove upper aqueous phase. Determine final volume of the aqueous phase. Use
this value for determining how much RNA binding buffer to add. Per sample, add 4 volumes
Zymo Research RNA Binding Buffer.
6. Per sample, use one Zymo Research spin column/sample. Note: Binding capacity of columns are
~ 5 gtg of total RNA (this is a minimum). Load each column with up to 700 p1 of each sample in
RNA Binding buffer (700 ýtl is max volume per load). Centrifuge 11,000 x g, 15 seconds.
Discard flow through. Reload the column with more sample. Centrifuge 11,000 x g, 15 seconds.
Discard flow through. Repeat if necessary. Remove flowthrough. Add 200 •l wash buffer.
Spin at top speed, 15-30 seconds. Add another 200 p1 wash buffer. Spin at top speed, 30-60
seconds. Discard collection tube. Switch to supplied 1.5 ml eppendorf tube for collection. Add
8 •1 dH 20. Spin at 11,000 x g, 15 seconds. Add another 8 pl dH20. Spin at 11,000 x g, 15
seconds. Volume is now 16 p1. Run out 1 pl/sample on the Agilent Bioanalyzer using the Nano
kit. May want to also take OD's. Store remainder of samples at -80 oC.
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Notes: For RNA amplification, DNase treatment is usually not required. If DNasing is
deemed necessary, can do so prior to Zymo RNA spin column step.
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A.3 Extracted RNA Measurements
Materials:
* Ice bucket
* Samples (with extracted RNA)
* DNase/RNase-free deionized water
* P2, with pipette tips
Procedure:
1. Place a maximum of 12 samples in the ice bucket and go to the Nanodrop instrument
(located in the lab next door).
2. Lift the lever of the Nanodrop and spray eye with ethanol. Clean gently with a kimwipe.
3. Open the Nanodrop software and choose Nucleic Acids.
4. The software will ask you for a calibration measurement. Place lul of the DNase free
water on the eye. Lower lever and click OK.
5. Change the DNA tab to RNA and change the wavelength from 230 to 260.
6. Place another drop of water on the eye and re-calibrate. Measure the sample (water) to
check if the measurement is actually zeroed. Repeat re-calibrating until the measurement
is zeroed with the water sample.
7. Clean the eye with a kimwipe and place lul of the sample on the eye and lower lever.
8. Enter the sample name and click Measure.
9. Repeat steps 6 and 7 until samples are done. The Nanodrop should be re-calibrated about
every six samples.
10. After the samples are all measured, close the program. Save the excel file to a flash drive.
(Desktop -> Shortcut to Yusuke, go up one directory -> Nucleic Acids -> Default ->
Excel file, ordered by date)
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A.4 Reverse Transcription of RNA to cDNA
0) Before commencing ethanol all surfaces, use alcohol wipes on pipettes, pens & trays.
This is done to avoid contamination with proteins, RNAs, RNase and DNase, crucial! Also
calculate the appropriate volume needed for 1 tg of RNA. This should not be larger than
251l.
1) If proceeding straight from a RNA extraction ensure that RNA is kept cold (but not
frozen) by placing vials in an ice bucket and then placing in the 4°C fridge as calculation of
RNA volumes can take some time. If RNA has been frozen and stored in the -800 C freezer
then thaw it immediately before use, and then mix by pipetting.
2) Make a RT master mix using the following guide. Total reaction volume will be 401l once
RNA and H20 have been added.
Mix thoroughly
Keep cold, remove from freezer only when
needed, mix thoroughly by pipetting, (do
not vortex as enzymes are fragile).
3) Generally multiply all the above equations by the number of cartilage samples you have to
create a master mix. A total volume of 40•l was chosen here, but this can be scaled up or
down depending on the total needed volume.
4) Aliquot 15l of the mastermix into X different tubes. Then add the appropriate amount of
H20 (25[pl- volume of 1 tg RNA). Last step, add the RNA, immediately put on thermocycler
block, and run 40 program. This will ensure the mix does not degrade.
5) Load tubes into the thermocycler and follow these steps: GoldRT2
250 C 20 minutes (hybridization)
420 C 30 minutes (reverse transcription)
Hold 40 C (wait for removal)
6) Although cDNA is significantly more stable than RNA and thus doesn't degrade as fast as
RNA, quantitative RT-PCR aims to avoid degradation as much as possible. Hence, move
cDNA into the -200 C as soon as possible after the thermocycler reaches 40 C.
240
RT Reagents
10x PCR buffer
MgC12
dNTP(5mM)
Random Hexamers
Rnase Inhibitor
Multiscribe Reverse
Transcriptase
A.5 Standard Curve Measurements for qPCR Primers
1. Make primer stock by adding H20 to lyophilized primers. Make up 100 ýpmolar of
Primer. Add (10*(nmole)) ýtL of H20 to stock.
2. Make up Aloquats by diluting primer stock by 20:1
a. Use 200 gL eppindorf tubes, add 180 gtL of H20
b. Add 10 gtL of for and 10 tL of rev.
3. Amplify stock cDNA by adding new primer, SGMM, H20, and cDNA
a. For 20g1L, 10L SGMM, 1.5 gIL cDNA, 2 gL Primer, and 6.5 jL H20
4. Use RealPCR protocol on PCR machine
5. Purify the product- Centri-Spin Column
a. Tap column to insure powder is at the bottom
b. Add 650 gl of H20
c. Pipette vigorously till mixed.
d. Vortex, both top and bottom
e. Let sit at room temp for at least 2 hrs.
f. Take off Top and Bottom cap
g. Spin columns in throw away tubes provided for 2 min at 3000rpms
h. Empty flow through, dab bottom membrane with gauze.
i. Carefully pipette 20-50gL of cDNA into center of column, avoid the edges!
j. Place in labeled 1.5 mL eppindorf tube, and position the column in previous
orientation in centrifuge.
k. Spin Columns for 2 min a 3000rpms
6. Dilute purified cDNA amplification.
a. Make a series of 5 10:1 dilutions, this will dilute the cDNA -~10^6 times.
b. Then make a series of 5, 2:1 dilutions.
7. Plate these 5 2:1 dilution along with No Template Controls (NTC)
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A.6 Finding/Designing Primers for qPCR
Finding
http://www.ncbi.nlm.nih.gov/Genomes/index.html
search under locuslink
search under nucleotide
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide&itool=toolbar
Bovine [orgn] IL-1
Click on gene ID = #####
Look at CDS coding region
Making
Primer3: http://frodo.wi.mit.edu/cgi-bin/primer3/primer3 www.cgi
Paste sequence in window
Change Product size ranges to 80-120
Primer GC% 40 to 60;
Click Pick Primers
Check primer3 results, look at any, and 3'. Want low any and low 3'
Want low pair any comp, and low pair 3' comp.
Blast
http://www.ncbi.nlm.nih.gov/blast/Blast.cgi?CMD=Web&LAYOUT=TwoWindo
ws&AUTO FORMAT=Semiauto&PAGE=Nucleotides&NCBI GI=ves&FILTER
=L&HITLIST SIZE=100&SHOW OVERVIEW=yes&AUTO FORMAT=yes&S
HOW LINKOUT=yes
Check forward Sequence given by Primer3
Check reverse transcribed reverse seq. given by Primer3
Check to see if other genes are coded by primer given
Alternatively, use Primer Express (Applied Biosystems) to design primers. With
sequences obtained, ensure proper design through Blast.
Ordering
Use Integrated DNA Technologies, http://www.idtdna.com/Home/Home.aspx
Create User/Password
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A.7 Primer Inventory
Gene
1 AGGRECAN
2 COLLAGEN 1 *
3 COLLAGEN 2
4 COLLAGEN 9
5 COLLAGEN 11
6 FIBROMODULIN
7 FIBRONECTIN
8 DECORIN
9 LINK PROTEIN
10 CD44
11 HAS2
12 OSTEOCALCIN**
13 COMP
14 MMP-1
15 MMP-3
16 MMP-9
17 MMP-13
18 ADAMTS-1
19 ADAMTS-4
20 ADAMTS-5
21 TIMP-1
22 TIMP-2
23 TIMP-3
24 SOX-9
25 C-FOS
26 C-JUN
27 INOS
28 18S
29 6S*
30 G3PDH
31 B-ACTIN
32 IGF-1**
33 IGF-2
34 OP-1
35 BFGF
36 TGFB
37 VEGF
38 LIF
39 IL-1B
40 IL-4
41 IL-6**
42 TNFA
43 IL-6R**
44 COX-2
45 TXNIP
46 LUBRICIN*
47 HSP90
48 CASPASE-3
49 ALPL
50 SOD1
51 SOD2
52 GPX-3**
* These primers were not used in this work
** These primers could be redesigned to improve efficiency
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Forward Sequence
CCTGAACGACAAGACCATCGA
AATTCCAAGGCCAAGAAGCATG
AAGAAGGCTCTGCTCATCCAGG
AATTTGCCCTCCTTGTTCGA
CTGATGTGGCCTACCGAGTGT
ACAACCAGCTGCAGAAGATCC
ACTGCCCACTCCTACAACCA
GCTCCTTTGGTGAAATTGGA
AAGCTGACCTACGACGAAGCG
GTCCTATGCGGAAACCTCAA
GCACATCTGGAAGGAAAACC
AGGGGTGAGTCTCATGCCAGTG
GTGCCAGGGCGACTTTGAT
GGACTGTCCGGAAATGAGGATCT
CACTCAACCGAACGTGAAGCT
TCCCTTCCTTGTCAAGAGCAA
TCTTGTTGCTGCCCATGAGT
CGACACAAGAGAGGAAAGATGG
CTGGGCCATGTCTTCAGCAT
CTCCCATGACGATTCCAA
TCCCTGGAACAGCATGAGTTC
CCAGAAGAAGAGCCTGAACCA
TTTGGCACGATGGTCTACACC
TGAAGAAGGAGAGCGAGGAG
CTCCACTTCATCCTAGCGGC
AGCTGGAGCGCCTAATCATACA
AGGAGATAGAAACAACAGGAACC
TCGAGGCCCTGTAATTGGAA
TCGTGACTCCACGAGTTCTG
ATCAAGAAGGTGGTGAAGCAGG
GATGAGATTGGCATGGCTTT
CAGCAGTCTTCCAACCCAAT
TTCTACTTCAGCCGACCATCC
GGGCTTTTCCTACCCCTA
GCCATAATCGGAACAGCACT
CACGTGGAGCTGTACCAGAA
TCCCTGTGGGCCTTGCT
CAACATCACGAGAGACCAGAAG
GAAGAGCTGCATCCAACACC
GCGGACTTGACAGGAATCTC
TGAGTGTGAAAGCAGCAAGG
ACGGTGTGAAGCTGGAAGAC
GCACACCCGTCGTATTCTTT
AAAAGCTGGGAAGCCTTTTC
CAAGTTCGGCTTTGAGCTTC
AGGAATGCACTGTGGAGCTT
AAACTGTATGTCCGCCGTGT
GAAGTCTGACTGGAAAACCC
CCATGGTGAGTGACACAGACAA
TGGAGACCTGGGCAATGTG
AGGTCGGTTCACTCGGAAAGA
AGGGGTGAGTCTCATGCCAGTG
Reverse Sequence
TGGCAAAGAAGTTGTCAGGCT
GGTAGCCATTTCCTTGGTGGTT
TAGTCTTGCCCCACTTACCGGT
CCTTTCCACGCCAATCAT
AGCAGAGAGAAATCTTTGGGAAAA
TTCATGACATCCACCACGGT
CAAAGGCATGAAGCACTCAA
ACACGCAGCTCCTGAAGAGT
CGCAACGGTCATATCCCAGA
CTGCCCACACCTTCTCCTAC
AAAATCACACCACCCAGGAG
CCAAGGCAGATGTGAGAGCAGG
TCTCCGGACACACATCGATCT
TTGGAATGCTCAAGGCCCA
CGTACAGGAACTGAATGCCGT
TACTTGGCGCCCAGAGAAGAA
GGCTTTTGCCAGTGTAGGTGTA
CATCACTTTACCCGCTGCTAT
GGCGGGAGGTGCTCTCA
AATGCTGGTGAGGATGGAAG
TGTCGCTCTGCAGTTTGCA
TGATGTTCTTCTCCGTGACCC
CCTCAAGCTTAAGGCCACAGA
GTCCAGTCGTAGCCCTTGAG
GCCCCCACTCAGATCAAGAG
CCTCCTGCTCATCTGTCACGTT
TGCCATCTGGCATCTGGTAGC
GCTATTGGAGCTGGAATTACCG
TGGCCTCCTTCATTCTCTTG
TGAGTGTCGCTGTTGAAGTCG
GTCACCTTCACCGTTCCAGT
GAAGAGATGCGAGGAGGATG
TGGCACAGTAAGTCTCCAGCA
CACGAGATTGACGAAGCTCA
AGGAATGCACTGTGGAGCTT
ACGTCAAAGGACAGCCACTC
CGTCTGCGGATCTTGTACAAAC
TCTAGTTGGCACCACGTATAGG
ATGCAGAACACCACTTCTCG
TTCAGCGTACTTGTGCTCGT
AGCAAATCGCCTGATTGAAC
CCCTGAAGAGGACCTGTGAG
TGTCAGATTCAAGGCTGCTG
GCTCTTTCCTCCCTTTCACA
GCTGGGACGATCAAGAAAAG
GCCATAATCGGAACAGCACT
AGATGTTCAGGGGGAGGTCT
GAAGTCTGCCTCAACTGGTA
GGCCCGTTGCCGTACA
ACAATATCCACGATGGCAACAC
GGCGGTCCCTCTCCAACTA
CCAAGGCAGATGTGAGAGCAGG
Slope
-0.912
-1.151
-0.912
-1.018
-1.253
-1.222
-1.051
-1.025
-1.005
-0.998
-0.930
-0.910
-0.852
-1.057
-1.130
-1.439
-1.068
-0.961
-1.041
-1.110
-1.237
-1.210
-1.028
-1.127
-0.755
-1.063
-1.354
-1.104
-1.111
-1.073
-0.800
-0.986
-1.089
-0.909
-0.730
-0.859
-0.889
-1.135
-1.037
-0.862
-1.257
-1.237
-0.887
-1.127
-0.930
-1.090
-0.999
-1.010
-0.794
-0.871
-1.130
Offset
27.560
27.880
23.960
20.284
27.969
30.260
32.001
19.340
27.840
21.830
20.446
21.594
14.635
35.590
30.540
33.279
33.369
17.019
25.001
31.777
30.966
32.170
35.753
25.149
35.500
33.810
23.676
22.970
31.614
27.173
25.000
31.063
23.144
21.984
15.857
31.834
20.857
28.752
24.609
21.817
31.807
30.316
15.482
25.149
22.290
26.400
18.891
15.511
19.215
18.620
14.267
A.8 Bovine DNA Standard and Assay using Hoechst 33258 Dye
Material:
10x TEN Buffer located in 40 stock
lmg/mL Hoechst 33258 Dye (10,000x) located in 40 stock
Stock DNA solution at 10ýlg/ml located in -20' stock
Tris buffer at 50mM located in 40 stock
DNA Dye Solution Mixing Procedure:
* Add 45mL of DI H20 and 5mL of 10x TEN buffer into a 50mL test tube
* Mix well and add 5l of lmg/mL of Hoechst 33258 dye into the lx TEN buffer
* Mix well and wrap the test tube with aluminum foil to protect the dye from light. The
dye will have a final concentration of 0.1 ýtg/mL Hoechst 33258.
Procedure:
* Digest cartilage plugs in proteinase K solution
* Make up standard solutions using following chart:
Tube DNA conc. ig/mL Tris Buffer DNA stock 10ýpg/mL
1 10 0 tl 200 ld
2 5 100 ýl 100 ýl
3 4 120 pl 80 l
4 3 140 pl 60 gl
5 2 160 gl 40 gl
6 1 180 gl 20 tl
7 0 200 pl 0 gl
* Plate 20pl of
plate making
below. Plate
each standard and 20gl of each sample into a microflour 2 black 96 well
sure to duplicate all samples including the standards using the template
standards in descending order of concentration.
Standards Repeat 1 0
Standards Repeat 2 •
Samples #1-12 Repeat 1
Samples #1-12 Repeat 2
Samples #13-24 Repeat 1
Samples #13-24 Repeat 2
Samples #25-36 Repeat 1
Samples #25-36 Repeat 2
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* Use 12-channel pipette to add 180ptl of 0.1g pg/mL Hoechst dye to each well
* Put plate in the Victor machine and select the DNA quantification protocol in the Victor
software. Follow the on screen instructions to read plate.
Post Processing:
In order to process the raw data produced by this assay, a DNA standard curve must be made.
DNA concentrations can then be calculated.
* Open the Microsoft Excel Template called 'MIT_Bovine_DNA_assay_template'
* Paste the raw data obtained from the Victor plate reader into the highlighted area in the
'Data Columns' tab
* Click on the 'DNA standard template' tab to view the standard curve
* Click on the 'DNA analysis' tab to view the concentration of DNA in each well as well
as the average DNA concentration of the two repeats for each sample
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A.9 GAG Standard and the GAG Assay with Maxy Machine
This is the general assay for sulfated GAGs (CS6, CS4, HS, KS). Chondroitin-6-sulfate is used
as the standard because of its prevalence in articular cartilage.
Objective: DMMB Assay for GAG content
Material:
Tris buffer at 50mM located in 40 stock
GAG dye solution (DMMB Dye) located under bench 5
Stock GAG solution at 2mg/ml located in -20' stock
Procedure:
* Digest cartilage plugs in proteinase K solution
* Dilute samples so that GAG concentrations fall in the range of the standards
o For digested bovine cartilage samples, dilute 1:40 in Tris buffer
o For bovine media samples, dilute to 1:20 in Tris buffer
* Make up standard solutions using following chart:
Tube Tris Buffer Transfer GAG conc. [g/ml
1 900gl 100 ptl of 2mg/ml 200 ýtg/ml
stock solution
2 100tl 100 jil from tube 1 100 ýtg/ml
3 100gl 100 gl from tube 2 50 pg/ml
4 100tl 100 gl from tube 3 25 tg/ml
5 100gl 100 pl from tube 4 12.5 gg/ml
6 100gl 100 gl from tube 5 6.25 pg/ml
7 100tl 100 gl from tube 6 3.125 ýig/ml
8 100gl 100 gl from tube 7 1.5625 kg/ml
9 100[l 0 0 gg/ml
* Plate 20pl of each standard and 20pl of each sample into each well making sure to
duplicate all samples including the standards using the template below. Plate standards in
descending order:
246
Standards Repeat 1
Standards Repeat 2
Samples #1-12 Repeat 1
Samples #1-12 Repeat 2
Samples #13-24 Repeat 1
Samples #13-24 Repeat 2
Samples #25-36 Repeat 1
Samples #25-36 Repeat 2
* Use 12-channel pipette to add 180l of DMMB dye to each well
* Turn on the Molecular Devices Kinetic Microplate Reader machine
* Select 520nm wavelength for reading
* Load plate and click "Read Plate"
Post Processing:
In order to process the raw data produced by this assay, a GAG standard curve must be made.
GAG concentrations can then be calculated.
* Open the Microsoft Excel Template called 'MIT_GAG_assay_template'
* Paste the raw data obtained from the Kinetic Microplate Reader into the highlighted area
in the 'Data Columns' tab
* Click on the 'GAG standard template' tab to view the standard curve
* Click on the 'GAG analysis' tab to view the concentration of GAG in each well as well
as the average GAG concentration of the two repeats for each sample
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A.10 Human DNA Standard and Assay using CyQUANT Dye
Material:
Molecular Probes CyQUANT Cell Proliferation Assay Kit located in -20' stock which
contains:
* CyQUANT GR Dye (Component A) at 400x
* Cell-lysis buffer (Component B) at 20x
* k DNA standard (Component C) at 100tg/mL
DNAse free H20 located in 40
DNAse located in -20' stock
DNAse Pretreatment
In order to correct for the presence of RNA in the cell, samples that have been treated with
DNAse will also be analyzed.
* Remove 50tl of each sample into 2ml 12-tube strips
* Add 3gl of DNAse to each sample
* Incubate at room temperature for one hour
DNA Dye Solution Mixing and X DNA Preparation Procedure:
* Calculate the volume of CyQUANT GR/Lysis Buffer that will be needed by multiplying
the number of samples to be tested by 800ptl, then adding 3mL for standards. 800itl of
the buffer/dye solution is allotted for each sample because each sample must be tested 4
times: 2 repeats of the sample treated with DNAse, and two repeats of untreated sample.
* Using this volume, dilute the cell-lysis buffer (Component B) 20-fold in DNAse free H20
* Make a 400 to 1 dilution of the CyQUANT GR Dye (Component A) in the lx cell-lysis
Buffer
* 1.5mL of 1p g/mL k DNA will be needed for the standard curve. Place 1.485mL of lx
CyQUANT GR/Lysis Buffer solution into a 2mL tube.
* Add 15itl of k DNA standard (Component C) at 100ptg/mL. The final concentration of
DNA will be 1 ýtg/mL
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DNA Standard Curve and Assay Procedure:
* Make up standard solutions in the first two rows
using following chart:
of a microflour 2 black 96 well plate
* Use 12-channel pipette to add 180tl of lx CyQUANT GR/Lysis Buffer solution to each
well
* Put plate in the Victor machine and select the CyQUANT protocol in the Victor software.
Follow the on screen instructions to read plate.
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Standards Repeat 1 -
Standards Repeat 2
Samples #1-12 Repeat 1
Samples #1-12 Repeat 2
Samples #1-12 DNAse treated Repeat 1
Samples #1-12 DNAse treated Repeat 2
Wel 1.tg/mL DNACyQUANT in CyQUANT Final DNA
Num GR/Lysis Buffer in CyQUANT ConcentrationNum (l) GR/Lysis (ng/mL)
Buffer (gl)
1 0 200 1000
2 40 160 800
3 80 120 600
4 120 80 400
5 160 40 200
6 180 20 100
7 190 10 50
8 198 2 10
9 200 0 0
Duplicate all standards using the template below.
Once the DNAse treated samples have been incubation for one hour, plate 20[l of each
sample into the microflour 2 black 96 well plate making sure to duplicate all samples,
using the template below. More samples can be added to additional plates using the same
pattern.
A.11 Radiolabel Scintillation Counting Using Microbeta Plate
Reader
Material:
Perkin Elmer Optiphase Supermix Scintillation fluid located under bench 5
Optically clear plastic film located under Microbeta machine
Disposable 24 well flexible plates located above Microbeta Machine
Procedure:
Preparing Samples
* Use clear 24 well disposable flexible plates. Plates are in boxes on the shelf above the
Microbeta machine
* Pipette 50-100p1l of each sample and standard into wells. The amount of sample plated is
dependant on the volume of proteinases K solution used to digest the samples. If lmL
was used, plate 100ul of each sample. If 500uL of proteinases K was used, plate 50ul. A
volume of 50uL should always be used for standards. Duplicate each sample and
standard in alternating rows, e.g., plate one set of samples in rows A and C and the next
set in rows B and D like in the following figure:
Samples #1-6 Repeat 1
Samples #7-12 Repeat 1
Samples #1-6 Repeat 2
Samples #7-12 Repeat 2
* Pipette lmL scintillation fluid into each well using a repeating pipette. Be sure not to
spill fluid on the black part of the plate.
* Cover plate with optically clear plastic film and seal with the roller. Run over the
boarders of each well with a spatula to ensure the wells are sealed.
* Shake all plates on the orbital shaker for 5-10 minutes, or until scintillation fluid is
homogenous
* Load flexible plates into white plate cassettes. These can be found in the drawer under
the Microbeta machine
* Place cassettes into the machine. The Microbeta machine can hold a maximum of 15
plates. Place a "STOP" cassette above the last plate if reading fewer than 15 plates.
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Reading Plates
* Start Microbeta Windows Workstation
* Choose protocol group "General" and click "Open"
* Choose the protocol you wish to use, e.g., "n Adjusted Dual Label"
* Click "Protocol" under the "Edit" heading to edit the count time
* Click "Plate map..." to view and edit the order the wells will be reported
* Click "Output" to change what will be included in the output file and to create a new
output file
* Click "Start..." A window will appear that will let you select which shelf to start
counting on. The machine will start at this shelf and continue until it hits the "STOP"
plate.
* Click on "Live Display" to view the counting progress
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Appendix B: Nitric Oxide Project
Nitric oxide enhances aggrecan degradation by aggrecanase
in response to TNF-a but not IL-1p treatment at a post-
transcriptional level in bovine cartilage explants. *
* This chapter has appeared as a paper in Osteoarthritis and Cartilage (Stevens AL, Wheeler
CA, Tannenbaum SR, Grodzinsky AJ. Nitric oxide enhances aggrecan degradation by
aggrecanase in response to TNF-alpha but not IL- beta treatment at a post-transcriptional level
in bovine cartilage explants. Osteoarthritis Cartilage. 2007 Oct 9)
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Abstract
Objective: The objective of this study was to determine the role of NO in TNF-ca-induced
matrix damage, compared to IL-1 , in bovine cartilage explant cultures.
Methods: Cartilage explants were subjected to treatment with TNF-a (100 ng/ml), IL-1 I3 (10
ng/ml) and to the nitric oxide synthase inhibitor, N-methylarginine (L-NMA; 1.25 mM) for 26,
50 or 120 hours (5 days). The collected medium was analyzed for sGAG, nitrate and nitrite,
MMP activity by zymography, and aggrecan degradation by immunoblotting of aggrecan G 1 and
aggrecan-G 1-NITEGE fragments. RNA was extracted from the 26 and 50 hour treated explants
for real-time PCR analyses.
Results: TNF-oa and IL-I3 treatment caused a 3-5 fold increase in sGAG release with an
increase in aggrecanase specific aggrecan breakdown and an increase in nitrate and nitrite
production. L-NMA treatment inhibited almost 50% of the sGAG release caused by TNF-a
treatment, with concomitant decrease in the aggrecanase-specific-NITEGE neo-epitope of
aggrecan released into the medium. No L-NMA effect was identified with IL-1 3. TNF-a and
IL-i1 both increased ADAMTS4 and ADAMTS5 transcription with no effect by L-NMA,
suggesting that nitric oxide regulates aggrecanase activity at a post-transcriptional level in
response to TNF-c. TNF-a and IL-1 3 both caused an increase in protease transcription (MMP3,
MMP13, ADAMTS4 and ADAMTS5) and in pro-inflammatory enzymes iNOS and COX2, as
well as a decrease in matrix protein transcription, including collagen II, aggrecan, fibromodulin
and link, protein (IL-1 3 only), and an increase MMP-3 and MMP-9 secretion. L-NMA had no
effect on gene transcription or MMP secretion.
Conclusion: Nitric oxide regulates aggrecanase activity at a post-transcriptional level in
response to TNF-c treatment while having no effect on IL-1 3 treated cartilage explants.
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Introduction
Nitric oxide (NO) is a neutral free radical product of nitric oxide synthase (NOS) with
potent biological effects through its actions on cGMP production as well as through various
oxidative and nitrosative chemistries that have been shown to modulate gene expression and to
alter protein structure and function (I). NO production by chondrocytes was first discovered by
Stadler et al. who showed that, in vitro, chondrocytes produce substantial amounts of NO in
response to interleukin 1 beta (IL-Ip) and to lipopolysaccharide (LPS) (2). Since these first
reports, numerous studies have shown that chondrocytes or cartilage explant cultures from most
species produce NO via inducible nitric oxide synthase (iNOS) in response to IL-13P, IL-lac, LPS,
and tumor necrosis factor alpha (TNF-a) (3, 4), as well as IL-17, IL- 18, interleukin I converting
enzyme (ICE), and fibronectin fragments (5-7
The inflammatory cytokines TNF-a and IL-1 contribute to disease processes in
rheumatoid arthritis (RA) and likely in osteoarthritis (OA). TNF-oa was identified in synovial
exudates of RA and OA joints (8, 9). In RA patients, TNF-ca may contribute to IL-1 production as
determined by anti-TNF-ca therapy (10), and TNF-oa alone or in combination with IL-i may cause
cartilage breakdown and a decrease in new matrix synthesis by chondrocytes in vitro ("). TNF-a
production by OA synovial cells and in synovial fluid and serum may be elevated in OA (10, 12, 13)
and OA cartilage explants may be more sensitive to IL-1 and TNF-a treatment (14-16). TNF-oa
receptor, TNF-R p55, is elevated in chondrocytes near OA lesions, and this expression correlates
with sGAG depletion (17). These data together suggest that TNF-ca as well as IL-1 may play a
role in cartilage breakdown in OA.
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To determine whether NO production plays a role in mediating the pro-catabolic and
anti-anabolic effects of inflammatory mediators, in vitro studies have used the NOS inhibitors,
L-NMA (L-N-methyl-arginine), N.-nitro-L-arginine methyl ester (L-NAME), aminoguanidine,
and L-NIO (N-iminoethyl-L-ornithine), to evaluate the role of NO in IL-1-induced changes in
chondrocyte metabolism and matrix degradation in explant, hydrogel, and monolayer culture.
With the exception of bovine explant studies (18), inhibiting NOS partially reversed IL-i-induced
inhibition of proteoglycan synthesis in cartilage explants or chondrocyte cultures (4,1920). TNF-a
can decrease proteoglycan synthesis in a NO dependent manner (21), and the exogenous NO
donor, SNAP, may also decrease proteoglycan synthesis. Cao et al. found that NO decreased
collagen synthesis (22 ). Studies on matrix degradation have shown that inhibiting NO production
may enhance (18,23,24) or have no effect (25) on IL-l13-induced aggrecan degradation as measured
by sGAG release. IL-1-induced NO was also found to enhance gelatinase (2, 26, 27) and alter
stromelysin (MMP-3) (18,26) expression or activity. While most studies on inhibition of NOS are
associated with IL-i treatment, other inflammatory cytokines, such as TNF-ca, are capable of
mediating cartilage damage and enhancing NO production. Thus, understanding the
contributions of NO with other cytokines may be important in determining their role in cartilage
degradation.
The purpose of this study was to characterize the role of NO in matrix degradation in
response to TNF-a and compare it to the effects of NO following IL-i 1 treatment using a non-
specific NOS inhibitor, N-methylarginine (L-NMA). We found that inhibition of NOS by L-
NMA decreased sGAG release in response to TNF-Ca by almost 50%, with a concomitant
decrease in release of aggrecan-Gi-NITEGE fragments specific for aggrecanase-mediated
aggrecan degradation. No L-NMA effect was seen with IL- 13 treatment. L-NMA did not alter
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ADAMTS4 or ADAMTS5 transcription in response to cytokine treatment. Gene transcription
profiling of a panel of inflammatory molecules, proteases, and matrix proteins showed that
TNF-ca and IL-1 3 both inhibited transcription of matrix proteins including collagen II, aggrecan,
link protein, and fibromodulin, while enhancing matrix proteases and inflammatory factors such
as MMP-3, MMP-13, iNOS, and COX2, all with no effect of L-NMA. Overall these data
suggest that NO plays a role in TNF-a-induced aggrecan release at a post-transcriptional level
by altering ADAMTS4 or ADAMTS5 protein expression or post-translational modification, and
that TNF-oa and IL-1 3 appear to promote aggrecan degradation through different mechanisms of
aggrecanase regulation.
Methods
Reagents: ITS medium supplement and NOS inhibitor, N-methyl-arginine, were from
Sigma (St Louis, MI). Recombinant human IL-1 I and TNF-ca were from R&D systems
(Minneapolis, MN), PAGE gels were from BioRad (Hercules, CA). Protease-free chondroitinase
and keratanase II were from Seikagaku (Japan). Common chemicals were purchased from ICN,
Mallenkrodt, or Sigma.
Cartilage explant harvest and culture: Articular cartilage disks were obtained from the
patello-femoral groove of 1-2 week old bovine calves as described previously (28). Cartilage-bone
cylinders (9-mm-diameter) were cored from the patello-femoral groove, perpendicular to the
joint surface. Two 1-mm-thick slices were then microtomed from the middle zone and a 6-mm
diameter dermal punch was then used to core a 6-mm diameter by 1-mm thick disk from the
center of each of the 9-mm slice. The explants were cultured in high glucose DMEM with 1%
ITS as described previously with medium change every other day prior to treatment (29)
Explants were weighed two days prior to the start of cytokine treatment.
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TNF-a IL- lfi, and L-NMA treatments: Cartilage explants were allowed to rest 7 days in
culture, and were then treated with 10 ng/ml IL-1 IP or 100 ng/ml TNF-ot or left untreated in 2 ml
of medium without 1% ITS. After 2 hours, half the explants were further treated with 1.25 mM
L-NMA. Experiments utilized 5-8 different joints (5-8 different animals) with at least two
explants per joint per condition. Every 24 hours over 5 days, cultures underwent a 10% (200 PIl)
medium removal and supplementation. After day 5 of treatment, medium and explants were
collected, pooled to each treatment group, and stored at -80 'C. For real time PCR analyses
explants were cultured for 24 or 48 hours after the addition of L-NMA and snap frozen in liquid
nitrogen.
Sulfated Glycosaminoglycan (sGAG) Assay: sGAG released to the medium was measured
as an indicator of aggrecan degradation and assessed via the dimethylmethylene blue (DMMB)
assay using shark chondroitin C as a standard, as described previously (30)
Nitrate/Nitrite Analysis: Medium samples were diluted 1:2 in water prior to nitrate and
nitrite analysis by Griess assay (31). Total nitrogen oxides were determined by cadmium column
reduction of nitrate to nitrite followed by direct nitrite detection by Griess reaction. Nitrite was
assayed directly, and nitrate was calculated as the difference between the total nitrogen oxides
and nitrite.
Gelatin and Casein Zymography for MMPs.: Zymograms were performed as described
(32). Briefly, conditioned medium from day 5 was mixed with 4X non-reducing SDS-sample
buffer and electrophoresed in 10%/12% gelatin or casein zymogram gels. Proteases were
renatured in 2.5% triton X-100 solution, and placed in solution of 50 mM Tris and 5 mM CaCl2
for 18 hours at 370C. Gels were then fixed and stained with Coomassie brilliant blue and
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destained until bands became visible and distinct. EDTA was added to the incubation buffer to
verify MMP activity. MMP-3 and MMP-9 were verified by immunoblot.
Desalting and deglycosylation: Samples were desalted by ethanol precipitation or by
dialysis with deglycosylation. The medium equivalent of 10-20 gg sGAG was precipitated by the
addition of 3 volumes of ice-cold ethanol. The samples were resuspended (50 mM Tris-Acetate,
10mM EDTA) and sequentially deglycosylated beginning with 5 mU of protease-free
chondroitinase ABC for three hours followed by 0.1 mU of keratanase II and 0.1 mU of endo-p-
galactosidase for an additional four hours. Equal amounts of sGAG were loaded for aggrecan
western blots.
Western blot analysis. Concentrated samples (10-15 pl) were subjected to denaturing
SDS-PAGE on a 4-15% gradient gel run at 15 mA for 2 hours. Proteins were then transferred to
Immobilon (PVDF) membrane, and proteins were detected using a monoclonal antibody to the
aggrecan-NITEGE neoepitope in the interglobular domain of aggrecan associated with
aggrecanase degradation (from C. Flannery, Wyeth Pharmaceuticals).
RNA extraction and real time PCR: For each condition (untreated, L-NMA, TNF-•_ +, L-
NMA, IL- I ± L-NMA), 2-3 cartilage explants per condition per joint, from a total of 8 joints (8
animals) were taken at 26 and 50 hours of culture, pulverized under liquid nitrogen and
homogenized in Trizol (Invitrogen, San Diego,CA). As described previously (33), homogenates
were transferred to Phase Gel tubes according to the manufacturer's instructions (Eppendorf,
Hamburg, Germany) and spun at 10,000 rpm for 10 minutes at 40 C. The clear RNA containing
supernatant was removed from Phase Gel tubes and subjected to RNAeasy mini-kit clean-up
(Qiagen, Chatsworth, CA) according to manufacturer's instructions. RNA quantification was
determined by nano-drop method measuring absorbance at 260 nm and 280 nm, which gave the
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concentration of RNA extracted from the tissue and the purity of the extract; the average 260/280
absorbance ratio for all samples was 2.12 ± 0.1. Equal amounts of RNA were subjected to
reverse transcription using AmpliTaq-Gold reverse transcription kit (ABI, Foster City, CA) to
generate cDNA for real time PCR analysis. Real time PCR analysis was performed with Applied
Biosystems SYBR-Green master mix in combination with cDNA and primers, using the ABI
prism 7900HT real time 384-well plate PCR instrument. Both forward and reverse primers were
designed using Primer3 software based on the bovine genomic sequence (33). Primers from 32
genes relevant to cartilage homeostasis were used: 18S-RNA, aggrecan, collagen II,
fibromodulin, fibronectin, proteoglycan link protein, MMP1, MMP3, MMP9, MMP13,
ADAMTS4, ADAMTS5, TIMP1, TIMP2, TIMP3, COX2, iNOS, G3PDH, 3-actin, IGF-1, IGF2,
TGF-P, TNF-o, IL-13, IL-4, IL-6, TXNIP, HSP90, CD44, HAS2, bFGF, and OP-1. Standard
curve analysis was performed on each primer to determine the efficiency of amplification and
proper primer concentration. The measured cycle threshold (CT) was determined and converted
to relative copy number using information from standard curves for comparisons.
Data analysis and statistics: Real time PCR data for each gene were first normalized to
18S-RNA; data from each sample were then normalized to the untreated control sample within
each sample set (animal), and these normalized data were pooled across all animals and are
reported as the mean +/- SEM (n=8) for each condition. Principal component analysis and k-
means clustering were performed on the PCR data using components of the Matlab Statistics
toolbox (33). Cluster analysis was performed(33) on a (31 x 5 x 2) matrix of data derived from the
set of 31 genes (i.e., all genes but 18S), 5 treatment conditions (each normalized to untreated
control), and 2 time points (26 or 50 hrs). Each time point was also clustered individually to test
the robustness of the co-expressed gene groupings. The Kruskal-Wallis test and Wilcoxon sign-
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rank test with Bonferroni correction for multiple comparisons were used to determine statistical
significance of the L-NMA effect and of pair-wise comparisons between treatments,
respectively. For the sGAG and nitrate/nitrite assays, multi-way ANOVA followed by a post-hoc
Student's t-test with Bonferroni correction for multiple comparisons were used to determine
statistical significance defined as p < 0.05. All statistical analyses were performed using Matlab
(Natick, MA) or Systat 11 (Richmond, CA).
Results
Nitrate/Nitrite: Nitrite and total nitrate plus nitrite were determined by the Griess assay
as described by Green et al. (31). IL-1 3 and TNF-oa both increased accumulated nitrate and nitrite
compared to the untreated control (p < 0.001) (Figure 1). The relative amounts of nitrite and
nitrate were similar between the two cytokine treatments by day 5 (data not shown). Treatment
of samples with L-NMA inhibited NO production to levels at or near untreated controls.
Sulfated glycosaminoglycan release: sGAG loss, which is known to be predominantly
the result of aggrecan degradation in cartilage explants, was measured by DMMB assay. TNF-oa
and IL-1 caused 3-4 fold increase in sGAG release to the medium compared to control samples
(Figure 2; p<0.001 for TNF-ca and IL-1I3 compared to controls at all time points). Treatment with
L-NMA partially inhibited TNF-ax induced sGAG release (p<0.003, all time points). However
with the exception of the 24-hour time point, L-NMA had no effect on IL- 1 -induced sGAG
release (p = 0.015 first 24 hours; p > 0.745 for all other points). No L-NMA effect was seen in
the absence of cytokine treatment. These results suggest that NO was partially responsible for
sGAG release in response to TNF-ca treatment, but had little or no effect on IL-1 I3 treatment.
Western analysis for aggrecanase generated aggrecan-G1 neo-epitope: To investigate
whether L-NMA was able to decrease sGAG release by decreasing aggrecanase mediated
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proteolysis of aggrecan, immunoblots were performed to probe for the aggrecan-NITEGE-
COOH neoepitope generated by aggrecanase activity (Figure 3). A 60-80 kDa band was visible
in the TNF-a and IL- 10 treated lanes but not in the untreated (control) lanes of the immunoblot.
While the addition of L-NMA to IL- 1 treatment had no effect on the anti-NITEGE-stained
band, samples treated with TNF-a and L-NMA showed a marked decrease compared to the
sample treated with TNF-a alone. This result suggests that the decrease in sGAG release seen
with the addition of L-NMA to TNF-a treatment was related to decreased aggrecanase-specific
proteolysis of aggrecan.
Zymographyfor Metalloproteinase Measurements: To examine MMP expression and
activity, zymography was performed on medium samples at the end of the experiment. Samples
subjected to IL-1 3 treatment and, to a lesser extent, TNF-a treatment showed a diffuse clearing
containing a doublet between 50 kDa and 75 kDa (with the lower band most prominent) by
casein zymography (Figure 4A), representing secreted pro-MMP-3. No activated MMP-3 band
(at 45 kDa) was visible in any of the samples. Gelatin zymography (Figure 4B) demonstrated
two bands running in between 75 kDa and 50 kDa in all samples, which represent the pro- and
the active forms of MMP-2. In addition, a -90 kDa band indicative of pro-MMP-9 was present
only in the cytokine treated samples. No differences in MMP-2, MMP-3, or MMP-9 were seen
with L-NMA treatment, as assessed by zymography.
Real time PCR analyses: To determined whether cytokine ± L-NMA treatments altered
transcription of aggrecanases, other proteases, matrix molecules, cytokines, and growth factors,
real time PCR analysis of a 32-gene set was performed on explants from 8 different animals
subjected to 26 and 50 hours of IL-i1 or TNF-a treatment ± L-NMA, or L-NMA alone. Relative
copy numbers were normalized to 18S-RNA and expressed in terms of the fold increase or
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decrease compared to untreated control samples within each set. Expression of both ADAMTS4
and ADAMTS5 was elevated in response to TNF-oa and IL-1 3 treatment (though little increase at
50 hours for ADAMTS5), with no statistically significant effect of added L-NMA at either the 26
hour or the 50 hour time point (Figure 5A). To elucidate the main expression patterns and
identify groups of genes co-expressed under different treatment conditions, gene clustering was
performed. The results are shown in principal component space (Figure 6); the first three
principal components accounted for -95% of the variance in the data. K-means clustering (31
genes, 5 normalized conditions, 2 time points) showed that the genes segregated well into two
spatially distinct groups with group centroids as indicated (Figure 6). The centroid profiles
(showing each condition for each group) are represented in Figure 5B,C as the mean ± SEM of
each centroid. Group 1 genes (Figure 5B) had little response or were slightly down regulated by
IL-1 3 and TNF-a treatment, while Group 2 genes were up regulated by IL-I1 and TNF-a
(Figure 5C). For each individual gene in Groups 1 and 2, the average-fold-change ± SEM is
listed in Table 1 (with TNF-a and IL-1 3 each compared to control, TNF-aX compared to TNF-
a + L-NMA, and IL-1I3 compared to IL-1I3 + L-NMA); asterisks represent statistical significance
for the comparison (p<0.05). While addition of L-NMA often slightly decreased gene
transcription compared to IL-1i or TNF-a alone, this decrease was not statistically significant
for any individual gene.
Discussion
IL-1 P and, to a lesser extent, TNF-ca, can induce chondrocyte-mediated matrix
degradation, with loss of aggrecan typically preceding collagen degradation (34). Previous studies
explored the role of NO in IL- 1 -induced aggrecan degradation; however, to our knowledge,
this is the first study to test the effect of NO on TNF-a-induced sGAG release and to explore its
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underlying mechanism. Cartilage explants treated with the NOS inhibitor, L-NMA, showed
marked inhibition of TNF-ax-induced sGAG release and concomitant production of aggrecan
Gl-NITEGE fragments, indicating a decrease in aggrecan proteolysis by aggrecanase. In
contrast, L-NMA did not alter IL- 1 -induced sGAG release or the generation of aggrecan-G 1-
NITEGE fragments. Real time PCR analyses showed no significant effect of L-NMA alone on
expression of ADAMTS4 or ADAMTS5 or a panel of 30 other matrix genes, proteases and
cytokines. Together, these results suggest that NO plays a role in the post-transcriptional
regulation of aggrecanases in response to TNF-a, while NO has no effect on IL-i I3 induced
aggrecan degradation. Thus, TNF-ca and IL-1 3 utilize different pathways of expression or
activation of aggrecanases to mediate aggrecanolysis, with that of TNF-oa being regulated in part
by an NO mediated post-transcriptional processing of ADAMTS4 and ADAMTS5.
NO can mediate its effects through enhancing cGMP, increasing protein nitrosation or
protein nitration which may serve as an important regulatory mechanism at the level of the cell
or individual proteins. NO concentration and chemistry, which depends in part of oxygen free
radicals, may determine its role as a second signal mediator. Treatment of cartilage with
cytokines caused an increase in NO production (Figure 1, p<0.001 for IL-1 I3 and TNF-a vs.
control for both nitrate and nitrite). In addition, TNF-ca or IL-1 P resulted in similar amounts of
nitrate and nitrite, each corresponding to approximately half of the NO production, suggesting
that NO chemistry was similar for both cytokine treatments. L-NMA decreased NO to control
levels for both cytokines (cytokine + L-NMA vs. control not significant). Equal nitrate and
nitrite production with both TNF-a and IL-1 3 treatment suggests that the effects of NO likely
depend on cellular processes induced with each cytokine treatment and not NO chemistry.
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The role of NO in matrix degradation associated with TNF-a may be quite different than
that with IL-1P. In this study, L-NMA treatment inhibited TNF-a-induced sGAG loss by -50%
(Figure 2). While we know of no previous reports of the effects of NO treatment with TNF-a
alone, van Bezooijen et al. (35) showed no measurable effect of L-NMA on cartilage damage
induced by the combination of TNF-oa and IL- 17, compared to the cytokine combination alone as
assessed by Alcian blue staining for sGAG. We found that L-NMA had no effect on sGAG loss
following IL-1 3 treatment (Figure 2), similar to the findings of Bird et al.(25) using equine
cartilage explants. In contrast, Stefanovic-Racic found that L-NMA in the presence of IL-1
significantly increased sGAG release compared to IL-1 I3 alone, using bovine, human, and rabbit
explants(18 .23). Regarding other matrix degrading signals, Pichika et al. (36) showed that inhibiting
NO resulted in a matrix protective effect when cartilage was treated with fibronectin fragments,
similar to the effect seen with TNF-a (Figure 2). The effects of NO appear to depend on the
cytokines or other signals with which it is produced and with which it signals. NO appears to
play a distinctly degradative role in TNF-a (but not in IL-1 3) treated cartilage.
Because aggrecanases are known to mediate aggrecan degradation in response IL-1 3 and
TNF-a (37, 38), we hypothesized that the mechanism of L-NMA inhibition of TNF-ax-induced
sGAG release was through a decrease in aggrecanase cleavage of aggrecan at the Glu 373-Ala 374
site in the interglobular domain (37, 39). Immunoblot analysis of the medium using an antibody to
the aggrecan-NITEGE 373 fragment showed that L-NMA + TNF-a resulted in less fragment
release than TNF-a alone (Figure 3), consistent with decreased sGAG release (Figure 2). And
while L-NMA did not alter sGAG release induced by IL-1 3, there was no decrease in aggrecan-
NITEGE 373 fragment release either. These results suggest that NO is partially responsible for
TNF-a-induced aggrecanase activity in cartilage explants.
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While aggrecanases are the main mediator of aggrecanolysis early in response to IL-10
and TNF-a treatment, NO has also been implicated in activation of MMPs through the disruption
of the cysteine switch present in the zymogens (40). Therefore, zymography was used to evaluate
the effects of L-NMA on expression and activation of selected MMPs in response to cytokine
treatment. IL-1 3 (and to a lesser extent, TNF-x) increased pro-MMP-3 secretion to the medium
with no effect of L-NMA on activation or secretion (Figure 4A). Pro-MMP-9 was expressed in
response to cytokine treatment, while MMP-2 was present under all conditions. L-NMA had no
effect on MMP-2 or MMP-9 secretion or activation. MMP-3 and MMP-9 protein in the medium
correlated well with the gene expression data (Figure 5,6; Table 1). These zymography results
were also similar to those of Dozin et al. (41), who saw no effect of NOS inhibition on MMPs with
chondrocyte monolayers treated with IL-lax and TNF-a in combination. Zymography failed to
show evidence of an active MMP-3 band and no effect of L-NMA was observed, suggesting NO
mediates aggrecan degradation in response to TNF-a by enhancing aggrecanase and not MMP-3
activity.
While ADAMTS 1, 8, 9, 15, 16, and 18 have aggrecanase activity (42, 43), only ADAMTS4
and 5 are known to potently cleave the Glu 373-Ala374 site forming the aggrecan-NITEGE
fragment(44 ). We thus focused on ADAMTS4 and ADAMTS5 to explore the possible mechanism
by which NO may be mediating an increase in aggrecanase activity. Because ADAMTS4 and
ADAMTS5 proteins could not be reliably identified in tissue or medium samples (data not
shown), we examined the effects of NO inhibition on gene expression of ADAMTS4 and 5 as
well as a panel of genes associated with cartilage homeostasis (Table 1). We hypothesized that
changes in expression of aggrecanases in response to cytokine and L-NMA treatments would
likely occur approximately 24 hours before sGAG release to the medium, allowing time for
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protein expression and diffusion of aggrecan fragments out of the tissue. Since the rate of sGAG
release was maximal between days 2 and 4 of treatment (Figure 2), real time PCR analysis was
performed on explants at 26 and 50 hours after treatment with IL- 1 3 or TNF-a ± L-NMA. While
IL- I and TNF-ax treatment caused significant changes in gene expression of many of the genes
tested including ADAMTS4 and ADAMTS5 (Figure 5, Table 1), L-NMA treatment did not alter
transcription of any genes evaluated in this study at either 26 or 50 hours.
Previous studies using young bovine explants showed significant increases in
transcription of ADAMTS4 after 24 hours of treatment with IL-1 a (45) and IL-1 p (46), while
ADAMTS5 was up-regulated by TNF-a (46). Here, we observed a strong increase in ADAMTS5
expression with TNF-a and IL-1 3 at 26 hours but little increase at 50 hours (Figure 5A). In
contrast, ADAMTS4 showed a sustained increase in expression at 26 and 50 hours with both IL-
1 and TNF-a (Figure 5A). Interestingly, while TNF-ax caused a greater average increase in
ADAMTS4 and 5 transcription than IL-1 3 (Table 1), IL-i1 3 treatment resulted in greater sGAG
release. In addition, L-NMA did not significantly alter transcription of either ADAMTS4 or 5 in
response to either cytokine treatment. Thus, the NO mediated regulation of ADAMTS4 and/or 5
activity in response to TNF-a is likely post-transcriptional and may be at the level of either
translation or post-translational modification such as proteolysis( 45). ADAMTS4 and 5 do
undergo proteolysis, which is known to change its binding affinity and proteolytic specificity of
aggrecan cleavage sites (44, 45, 47). Although less is known about ADAMTS5, some work on
ADAMTS4 suggests that its activity may be regulated in part through a combination of
proteolysis and/or protein-protein interactions rather than by protein expression (4 5, 48, 49). Further
work to explore the role of NO in modulating possible ADAMTS4 activators or inhibitors may
be warranted. While it is possible that NO could play a more direct role in ADAMTS4 and/or 5
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activity through direct chemical modification, this would still require a difference in ADAMTS4
and 5 protein expression between TNF-ca and IL- 1 3 in order to explain a TNF-a specific NO
effect. But based on our findings, changes in aggrecanase transcription cannot account for the
effects of L-NMA on TNF-oa induced aggrecan degradation or the differential effects of L-NMA
between IL-1 3 and TNF-oa.
While previous studies have not reported changes in expression via qPCR for the broad
panel of genes examined here (Table 1), we note several useful comparisons. Sasaki et al.
reported a NO dependent increase in bFGF and MMP-9 gene expression by rabbit chondrocytes
in monolayer in response to IL-1 p(SO). While we did find an increase in the mean transcription
level of bFGF and MMP-9 at 26 and 50 hours with TNF-a and IL- IP (not statistically
significant), no L-NMA effect was observed. In the present study, inducible nitric oxide
synthase (iNOS), responsible for chondrocyte production of NO, was elevated in response to
both IL-1I3 and TNF-c (p<0.05), as was COX-2, MMP-3, and MMP-13 but not IL-6 or MMP-1.
With the exception of IL-6 and MMP-1, these findings were consistent with the reported effects
of IL-1 3 on human chondrocytes (5 1 ) and effects on MMPs in human OA cartilage using TNF-a
and IL- 13 receptor inhibitors(52) as well as equine cartilage in response to TNF-o( 53). Decreases
in matrix geme expression (e.g., collagen II, aggrecan, fibromodulin, and link protein) were more
pronounced at 50 hours than 26 hours suggesting that effects of IL-1 3 and TNF-a on matrix
gene expression may occur later compared to the up regulation of matrix degrading enzymes (54)
(p<0.05 TNF-a and IL-1 3 compared to control for collagen alpha 1(II), aggrecan, fibromodulin,
and link protein (IL-i only) at 50 hrs). The inhibitory effect of IL-i I3 and TNF-a on aggrecan
and collagen synthesis is well characterized.
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In summary, NO plays an enhancing role in TNF-a (but not IL-I1 ) induced aggrecanase-
mediated aggrecan degradation. Inhibiting NO production with L-NMA caused no changes in
ADAMTS4 or ADAMTS5 gene transcription; however, L-NMA partially inhibited aggrecanase-
mediated aggrecan degradation in response to TNF-oa suggesting that NO must play a role in
regulating aggrecanases at a post-transcriptional level. At the same time, inhibiting NOS had no
detectable effects on IL- IP or TNF-oa induced MMP expression, activation, or the gene
expression of various other matrix proteins, cytokines or growth factors after 26 or 50 hours of
cytokine treatment. IL-1 3 and TNF-a-enhanced transcription of inflammatory genes such as
iNOS and COX2 as well as matrix degrading enzymes MMP-3 and MMP-13 at 26 hours, and
both cytokines decreased collagen II, aggrecan, link protein and fibromodulin at 50 hours,
consistent with known effects of these cytokines and with no effect of L-NMA. These findings
support the hypothesis of a post-transcriptional role for NO in regulating aggrecanase activity in
response to TNF-a treatment, and the hypothesis that TNF-a and IL- 10 regulate aggrecanase
activity though different mechanisms.
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Figure Legends
Figure 1: Five-day accumulated total nitrate and nitrite release to the medium
(nmol/mg wet weight) as a measure of NO production plotted as mean +/- SEM from
greater than 3 explants per joint pooled from from 5 different joints (animals) (* p<0.001
cytokine compared to control and ** p<0.01 cytokine compared to cytokine + NMA)
Figure 2: Accumulated sGAG release to medium over five day cytokine treatment in the
presence or absence of L-NMA plotted as mean +/- SEM. IL-1 3 and TNF-a alone cause a 3-5
fold increase in sGAG release compared to untreated controls (p<0.001 for all points). L-NMA
inhibited roughly half the sGAG release caused by treatment with TNF-ca (p<0.01 for all time
points).
Figure 3: Anti-Aggrecan-G 1-NITEGE-COOH Western blot to probe mechanism of
sGAG loss in response to IL-1 3 and TNF-ca treatment with and without NOS inhibitor, L-NMA.
A band is visualized in all cytokine-treated conditions; however, the TNF-aX + L-NMA band is
significantly lighter than that with TNF-a alone or with IL- 1 + L-NMA. This immunoblot is
representative of five different experiments and corresponding blots.
Figure 4. Casein (4A) and Gelatin (4B) zymograms of 5 day culture medium. (A) The
casein zymogram for both IL-1 3 and IL-1 3 - L-NMA contains a 54 kDa band, corresponding to
pro-MMP-3 that appears as a doublet, with a lighter upper band and a brighter lower band. A
faint doublet is seen for TNF-ca treatment and, in addition, a 90 kDa band is seen with all
cytokine treatments. (B) The gelatin zymogram contained a 72 kDa band (arrow) and a lower 65
kDa band in all samples, corresponding to the pro- and active forms of MMP-2, respectively.
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Only cytokine treated samples had a 92 kDa band corresponding to MMP-9. L-NMA had no
effect on MMP-3, MMP-9 or MMP-2 expression or activation as seen in medium samples.
Figure 5: Relative gene expression by real-time PCR and clustering analyses.
(5A) Expression of ADAMTS4 and ADAMTS5 at 26 and 50 hour time points, relative to
controls, in response to treatment with L-NMA alone, IL-i1 P L-NMA and TNF-a ± L-NMA.
(5B) Centroid profile for gene cluster 1 (group-1 genes) which showed decreased expression or
were unchanged in response to cytokine treatment. Centroids represent 26 and 50 hour time
points clustered together. (5C) Centroid profile for gene cluster 2, showing genes that were
upregulated in response to cytokine treatment. (Groups produced from clustering 26 hours alone
(see Table 1) vs. 26 and 50 hours together were identical, except IGF-2 and TIMP-3 in Table 1
swapped groups. The * indicates statistical significance compared to the untreated control
sample by pair-wise comparison (Wilcoxan Sign Rank test with Bonferroni correction for
multiple comparison; p<0.05)
Figure 6: Projection plot of gene behavior represented by the first three principal
components. The genes readily separated into 2 clusters which correspond to genes that respond
positively to IL- 1I3 and TNF-a treatment (triangles = Group 2 of Table 1) and those genes that
either did not respond or responded negatively to the cytokine treatment (squares; Group 1). The
black circles indicate the group centroids which are significantly different from each other
(p<0.001; Student's t-Test).
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Table Caption
Table 1: Genes probed by real time PCR, represented as the mean fold change over
control +/-SEM at 26 hours. Groups were determined using clustering analysis of data from the
26 hour time point. The expression data for the individual genes show similar trends at the 50
hour time point. The * indicates statistical significance compared to the untreated control sample
by pair-wise comparison (Wilcoxan Sign Rank test with Bonferroni correction for multiple
comparison; p<0.05). Data represent experiments from eight animals with 2 or 3 explants pooled
per animal for RNA extraction.
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Table 1
NMA
0.98+/-0.06
0.98+/-0.13
1.18+/-0.12
1.0+/-0.10
0.99+/-0.12
0.61+/-0.11
0.88+/-0.09
0.90+/-0.12
0.95+/-0.08
1.0+/-0.13
0.82+/-0.11
0.77+/-0.13
0.92+/-0.09
1.0+/-0.12
GENE
Group 1
Aggrecan
Collagen II
Fibromodulin
Link protein
TIMP-2
TIMP-3
MMP-1
G3DPH
b-actin
IGF-1
IL-4
IL-6
TXNIP
HAS2
Group 2
Fibronectin
MMP-3
MMP-9
MMP-13
ADAMTS4
ADAMTS5
TIMP- 1
COX2
NOS2
IGF-2
TGF-beta
TNF-alpha
IL- beta
HSP90
CD44
bFGF
OP-1
TNF- a
0.74+/-0.07*
0.73+/-0.11
0.59+/-0.06*
0.46+/-0.06*
0.53+/-0.03*
1.1+/-0.37
0.92+/-0.08
0.72+/-0.15
0.81+/-0.06
0.50+/-0.12*
0.78+/-0.11
0.82+/-0.15
0.55+/-0.05*
0.49+/-0.03*
1.60+/-0.15*
11+/-2.7*
115+/-60
12+/-4.4*
8.0+/-1.1*
68+/-9.1*
4.6+/-1.3*
11.4+/-2.7*
4513+/-1495*
0.92+/-0.08
2.3+/-0.20
2.5+/-1.6
4.4+/-2.8
2.2+/-0.27*
20+/-3.0*
1722+/-1109
80+/-16*
TNF- a/
TNF+NMA
1.17+/-0.14
1.14+/-0.27
0.98+/-0.08
0.95+/-0.07
1.12+/-0.16
4.07+/-3.18
1.02+/-0.10
0.93+/-0.21
0.92+/-0.05
1.05+/-0.21
1.10+/-0.26
1.56+/-0.38
0.87+/-0.09
0.95+/-0.11
1.16+/-0.10
1.75+/-0.43
1.11+/-0.24
1.87+/-0.66
1.24+/-0.16
1.28+/-0.24
1.40+/-0.38
1.13+/-0.20
1.04+/-0.31
0.94+/-0.17
0.91+/-0.06
0.91+/-0.13
1.35+/-0.25
1.21+/-0.11
1.06+/-0.09
10.56+/-5.86
1.32+/-0.28
IL-l f
0.91+/-0.05
0.81+/-0.10
0.86+/-0.06
0.81+/-0.08
0.50+/-0.08*
0.97+/-0.27
0.98+/-0.09
0.89+/-0.19
0.86+/-0.07
0.64+/-0.10
0.91+/-0.13
1.1+/-0.16
0.66+/-0.05*
0.47+/-0.04*
1.41+/-0.15*
34+/-9.1*
74+/-54
76+/-23*
5.9+/-1.4*
17.4+/-6.9*
3.4+/-0.64*
17.6+/-5.0*
894/-183*
1.1+/-0.11
1.7+/-0.18*
3.7+/-2.6
4.3+/-2.4
1.3+/-0.14
11+/-2.1*
61+/-48
26+/-10*
IL-l f/
IL-1 b+NMA
1.12+/-0.24
1.31+/-0.19
0.91+/-0.05
1.09+/-0.15
0.76+/-0.12
1.52+/-0.53
1.15+/-0.08
0.82+/-0.16
1.03+/-0.07
1.33+/-0.27
1.27+/-0.23
1.33+/-0.30
0.91+/-0.06
1.01+/-0.12
1.20+/-0.16
1.80+/-0.53
0.79+/-0.17
1.31+/-0.17
1.26+/-0.14
1.15+/-0.17
1.24+/-0.19
1.28+/-0.27
1.94+/-0.70
0.96+/-0.11
1.10+/-0.08
1.27+/-0.22
1.33+/-0.34
1.06+/-0.08
1.27+/-0.16
8.66+/-4.91
1.42+/-0.31
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U
0.96+/-0.08
1.0+/-0.18
1.1+/-0.24
0.83+/-0.17
0.98+/-0.09
1.26+/-0.23
10.1+/-0.16
1.2+/-0.11
1.5+/-0.57
0.99+/-0.10
0.92+/-0.07
2.0+/-0.98
0.95+/-0.12
0.85+/-0.07
1.0+/-0.17
9.0+/-7.0
1.6+/-0.41
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